EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2025

 

7-10 May Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  LBP-001 Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D Marc P. Windisch Received Received
  TOP-001 Community-based screening of viral hepatitis infections among high risk migrant and refugee populations in Greece, Italy and Spain: 2-year results of the VH-COMSAVAC project Camila A Picchio Received Received
  TOP-002 Disparities in hepatocellular carcinoma screening and in its detection rates in individuals with hepatitis B or C and cirrhosis in Canada Jean Damascene Makuza Received Received
  LBP-2 High-throughput combinatorial CRISPR screening in hepatic progenitor cell-derived organoids reveals genetic determinants of response to standard-of-care chemotherapy in cholangiocarcinoma Michael Girma Mamo Received Received
  SAT-003 A global survey of practice patterns in the management of hepatitis C virus (HCV)-related fibrosis Ira Jacobson Received Received
  FRI-003 Changing prevalence and risk factors of metabolic dysfunction associated steatotic liver disease in Taiwan Jee-Fu Huang Received Received
  THU-3 One-stop shop: a bespoke single-point-of-referral clinic enhances linkage to care for ultrasound surveillance of hepatoma in patients diagnosed with advanced fibrosis and cirrhosis via targeted community screening Basil Ahmad Received Received
  THU-004 Hospital-based and individual disparities in liver transplantation access in France: a national health data system analysis José URSIC BEDOYA Received Received
  LBP-004 Primary analysis of a phase 2b open-label study demonstrates VTP-300 administered with low-dose nivolumab is associated with meaningful reductions of HBsAg in chronic hepatitis B participants with HBsAg less than 200 IU/mL Man-Fung Yuen Received Received
  WED-004 Global burden of liver cancer related to viral hepatitis attributable to high body mass index from 1990 to 2021 Sitao Ye Received Received
  SAT-004 Emergency department opt-out testing for hepatitis B: a 2-year multicentre study of outcomes across 7 sites Jennifer Plunkett Received Received
  LBP-005 DA-1241, a GPR119 agonist, demonstrates hepatoprotective and glucose-regulating effects in a 16-week randomized placebo-controlled trial in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients Ji Eun Lee Received Received
  SAT-005 From screening to treatment: the impact of opportunistic hepatitis screening in emergency departments on hepatitis C prevalence Juan Carlos Ruiz Cobo Received Received
  WED-005 Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across Europe Anders Boyd Received Received
  FRI-005 Metabolic dysfunction-associated steatotic liver disease as the leading cause of hepatocellular carcinoma in mexican cirrhotic patients: a perspective consistent with trends observed in europe Nahum Méndez-Sánchez Received Received
  THU-005 The largest, exhaustive in-depth analysis and concerning report on 386 complementary and alternative medicinal products belonging to the Indian-systems of medicine (AYUSH) retrieved from patients that caused liver-related harm at the consumer level Cyriac Philips Received Received
  WED-006 Liver stiffness and AST-to-platelet ratio index (APRI) predict all-cause mortality in untreated people living with hepatitis B across Africa: a multi-centre cohort analysis in the hepatitis B in Africa collaborative network (HEPSANET) Alexander Stockdale Received Received
  FRI-006 Reference blood-based biomarkers SteatoTest-2 (ST2) and NashTest-2 (NT2) permit assessment of the prevalence of steatosis and MASH in large general population of UK-Biobank (UKB), stratified by cardiometabolic risk factors (CRF) and alcohol consumption (A Olivier Deckmyn Received Received
  THU-006 Bridging the gap between primary care physicians and hepatology with electronic consultations Aviel Hankin Received Received
  LBP-006 MELD 3.i: a bayesian approach for consecutive updates to model for end-stage liver disease Tomohiro Tanaka Received Received
  SAT-006 Emergency department blood-borne virus screening and the revealed burden of hepatitis B-driven liver disease Kartikeya Khanna Received Received
  FRI-007 An algorithm based on the liver risk score to identify subjects at-risk for advanced liver disease in the general population Patrick Ingiliz Received Received
  LBP-007 Macrophage Nrf1-Foxo1 axis controls liver fibrosis by modulation of mitochondrial reprogramming Qiong Wu Received Received
  WED-007 Implementation of a multicenter reflex testing program for hepatitis D detection of and registration of positive cases in Catalonia Adriana Palom Received Received
  THU-007 Real-world experience using serial transient elastography by FibroScan in a community outreach service for the earlier detection of liver disease Ann Archer Received Received
  SAT-007 National hepatitis C virus (HCV) screening pilot using rapid HCV antibody tests in Kazakhstan Kulpash Kaliaskarova Received Received
  LBP-008 Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507 Zhuo Chang Received Received
  FRI-008 Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers Pietro Guerra Received Received
  THU-008 The placebo project - comprehensive analysis of 134 commonly prescribed homeopathic remedies in India uncovers potential for severe hepatotoxicity Arif Theruvath Received Received
  SAT-008 Population-based hepatitis C screening and elimination program in Lithuania: 26-month results Limas Kupcinskas Received Received
  WED-008 Micro-elimination of hepatitis C utilizing hepatitis C virus self-testing in a district prison of northern India: a demonstration project AJEET SINGH BHADORIA Received Received
  SAT-009 Risk of advanced liver disease among individuals with hepatitis B virus infection with low-level viremia compared to individuals with no evidence of hepatitis B virus infection Olivia Harwood Received Received
  WED-009 Return to Care (R2C) - the missing link in hepatitis C elimination Alistair Story Received Received
  FRI-009 External validation of Dallas steatosis index (DSI) in the diagnosis of steatotic liver disease (SLD) in thai population Pimsiri Sripongpun Received Received
  LBP-009 Globally derived and externally validated cut offs for liver failure and inclusion of infections improve prognostication for inpatient death: towards ACLF harmonization Jasmohan Bajaj Received Received
  WED-010 Complex multiple morbidity and social vulnerability among hep C patients with delays accessing care Alistair Story Received Received
  THU-10 Leave no one behind: an examination of how the hepatitis C elimination programme in England is reducing healthcare inequalities Mark Gillyon-Powell Received Received
  SAT-10 Peer-led mass testing in prisons to support hepatitis C elimination Leila Reid Received Received
  FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis Pisit Tangkijvanich Received Received
  LBP-010 Short-term intravenous albumin administration increases serum sodium levels in hospitalized patients with decompensated cirrhosis and dilutional hyponatremia. A randomized, multicenter, controlled trial (ALBUCAT) Adriŕ Juanola Received Received
  WED-011 Treatment for chronic hepatitis C infection in Pakistan – in a high prevalence country treatment initiation is sub-optimal and may impact elimination programs Aliya Hasnain Received Received
  FRI-011 What is known about the relationship between food insecurity and metabolic dysfunction-associated steatotic liver disease? A systematic review Patricia Treseder-Griffin Received Received
  LBP-011 Modeling the epidemic of metabolic dysfunction associated steatohepatitis in Europe shows a growing clinical and economic burden in France, Italy and United Kingdom Carey Escheik Received Received
  THU-011 Incidence-based mortality trends of primary liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in Scotland between 2000 and 2021 Berkay Yanik Received Received
  SAT-011 Survival and inactivation of hepatitis A virus on inanimate surfaces Lilli Pottkämper Received Received
  LBP-012 Multicenter, open-Label, randomized non-inferiority study comparing 8-week vs 12-week Sofosbuvir/Ravidasvir treatment for non-cirrhotic chronic hepatitis C patients (EASE trial) Muhammad Radzi bin Abu Hassan Received Received
  WED-012 A comparative analysis of carbon footprints: nucleic acid test vs. rapid antigen test for preventing mother-to-child transmission of hepatitis B in the gambia Alassane NDIAYE Received Received
  SAT-012 Evaluating and aiding hepatitis C elimination efforts through natural language processing (Cogstack): analysis of electronic health records including diagnosis, demographics and outcomes Mahd Siddiqi Received Received
  FRI-012 Unveiling the burden of cirrhosis among Ontario, Canada´s refugee population Saloni Aggarwal Received Received
  THU-012 Circulating metabolites, gallstones, and gallbladder cancer Felix Boekstegers Received Received
  WED-13 Clearing the road for viral hepatitis microelimination in croatian prisons: the Hepatos project Tatjana Reic Received Received
  LBP-013 Novel hepatitis B virus biomarkers-guided nucleos(t)ide analogues withdrawal strategy promotes hepatitis B surface antigen clearance in chronic hepatitis B patients: results from a randomized controlled trial (BIO-STOP study) Rui Deng Received Received
  FRI-013 Age-related trends in FIB-4 scores among MASLD risk groups: insights from primary care data Hiroko Setoyama Received Received
  THU-013 First nations australians with cirrhosis have higher and premature mortality and multiple cofactors Catherine Brown Received Received
  SAT-013 Knowledge and perception of chronic hepatitis B infection and attitude towards point-of-care testing among the general population in primary care settings in Hong Kong Marco Tsun Lee Received Received
  LBP-014 HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb study Junqi Niu Received Received
  FRI-14 Impact of COVID-19 pandemic on racial/ethnic disparities in liver transplant waitlist outcomes among U.S. adults with end-stage liver disease Shyam Patel Received Received
  THU-014 Chronic liver diseases are often diagnosed at an advanced stage despite identification of risk factors: insights from a french national study Charlotte Costentin Received Received
  WED-014 Evaluation of Belgium´s progress towards HBV elimination: results from a national serosurvey Arno Furquim dAlmeida Received Received
  SAT-014 Setting the record straight: utility and outcomes in patients with HCV related HCC Maria Guerra Received Received
  LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements Irina Dragomir Received Received
  TOP-15 Emergency department opt out testing for HBV and HCV in London with integrated linkage to care: an effective initiative to diagnose hepatitis or work in progress? Rachel Hill-Tout Received Received
  TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan´s vaccinated generations: a genome-wide association study CHUN-YI CHANG Received Received
  LBP-016 Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study David Margolis Received Received
  LBP-017 SCG101 HBV-specific TCR-T cell therapy demonstrates dual antiviral and antitumor activities, achieving HBV clearance in liver biopsies and functional cure in HBV-related hepatocellular carcinoma patients Shunda Du Received Received
  TOP-017 Global association between metabolic dysfunction policies and the burden of metabolic dysfunction-associated steatotic liver disease (MASLD) Luis Antonio Diaz Received Received
  LBP-018 Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus peginterferon-alfa: end of treatment data from ENSURE study Grace Lai-Hung Wong Received Received
  TOP-018 Examining the causal link between alcohol consumption and fatty liver disease using Mendelian randomization Yun-Chen Wu Received Received
  LBP-019 Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo Mary E. Rinella Received Received
  THU-19 Gaps in palliative care for liver cirrhosis in Singapore: an analysis on disease burden, timing and utilization of palliative services Charlene Yeo Li Xin Received Received
  FRI-019 Patient safety, cross-sectoral quality of care, cost efficiency, and interprofessional competence: a comparison of the interprofessional training wards A-STAR with conventional hepatology-focused wards at Regensburg university hospital Schlosser Sophie Received Received
  SAT-019 Knowledge of hepatitis D epidemiology and access to hepatitis D diagnostic testing among healthcare providers in Africa: a multi-country survey Maria Buti Received Received
  WED-19 Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England Beatrice Emmanouil Received Received
  SAT-020 Patient perspectives on barriers and enablers to a treatment for all approach for hepatitis B Marvad Ahad Received Received
  THU-020 Assessing awareness of fatty liver disease among people in Scotland: a cross-sectional survey study (ADIPOSE) Damien Leith Received Received
  WED-20 Mind the gap - addressing inequitable hepatitis D testing in Wales Bazga Ali Received Received
  LBP-020 Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB) Grace Wong Received Received
  THU-21 Advanced care planning (ACP) for liver cirrhosis patients in Singapore: barriers to ACP and influence of hepatocellular carcinoma diagnosis on ACP preferences Danelle Lai Received Received
  LBP-21 Prolonged reduction of hepatitis B surface antigen in virologically suppressed participants treated with concurrent or sequential use of pegylated interferon alpha with xalnesiran-based therapy: results after 120 weeks of follow-up of an observational stu xieer liang Received Received
  FRI-021 Differential liver-related mortality among native hawaiian / pacific islander (NHPI) and asian subpopulations: a national cohort study Tiange Zhang Received Received
  WED-021 Emergency department screening and linkage to care for undiagnosed hepatitis C infection: an effective initiative to reach elimination targets Kartikeya Khanna Received Received
  SAT-021 Initiation of direct acting viral therapy in prison is associated with a significant loss to follow-up: relevance to WHO elimination metrics? Matthew Foxton Received Received
  FRI-022 Ultra-processed foods significantly increase liver and metabolic injury among younger adults, lessons from the liver screening program SIRIUS Tomas Koller Received Received
  WED-022 Automated universal testing for hepatitis B in the emergency department improves screening and characterises the undiagnosed and untreated cohort in an australian setting Bonita Gu Received Received
  LBP-022 Treatment options to support the elimination of hepatitis C: an open label, factorial randomised controlled trial Graham Cooke Received Received
  SAT-022 Screening for risk factors for hepatitis C infection with a large metropolitan primary care population - The size of the problem Matthew Foxton Received Received
  FRI-023 Prevalence of MASLD and its association with the consumption of sugar sweetened beverages among a non-communicable disease cohort in the rural district of Iringa, Tanzania Valentin Calvez Received Received
  LBP-023 Validation of quantitative magnetic resonance cholangiopancreatography metrics in the prediction of event-free survival in primary sclerosing cholangitis: an International PSC study group collaboration Tim Middelburg Received Received
  WED-23 Three-year evaluation of retention in specialist care among migrants and refugees living with HBV in Catalonia following a community-based intervention Camila Picchio Received Received
  SAT-023 Treatment of Hepatitis C in the over-80s in the direct anti-viral therapy era: age is no barrier! Matthew Foxton Received Received
  THU-023 Health behaviors significantly modify the sex-specific alcohol-attributable liver-related mortality in the United States. A population-based study Eduardo Vilar Gomez Received Received
  LBP-24 Metabolic dysfunction- and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort Carey Escheik Received Received
  FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom Vanessa Hebditch Received Received
  WED-024 Linking community-based organizations and specialized prescribing pharmacist teams to improve testing and treatment in hard-to-reach hepatitis C-infected groups: the LiveRx experience in Alberta, Canada Cari Egan Received Received
  SAT-024 Semi-qualitative feedback from individuals living with HBV newly diagnosed in the emergency department ED opt-out testing program – high acceptability but better platforms of advocacy and support required Mia Olsen Received Received
  LBP-25 Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial Costello Medical Received Received
  WED-025 Engaging hard-to-reach individuals through community-based holistic care health and wellness fairs linked to HCV testing and treatment in Alberta, Canada Cari Egan Received Received
  FRI-025 Readily available indices of liver fibrosis and insulin resistance associated with cancer and cardiovascular disease outcomes Xuehong Zhang Received Received
  SAT-025 Epidemiological, economic and budgetary implications of expanding screening strategies for hepatitis C virus in Brazil: a modelling study Everton Macdo Received Received
  THU-025 Prevalence of and outcomes related to metabolic dysfunction-associated steatotic liver disease (MASLD) in a nationwide cohort: insights from over 23 million individuals in Taiwan´s national health insurance research database Huei-Tyng Huang Received Received
  FRI-026 Metabolic dysfunction-associated steatohepatitis (MASH) prevalence in germany – results from a claims analysis Thomas Ramezani Received Received
  THU-026 Population study of hepatocellular carcinoma survival in northest region of Spain ISABEL SERRA MATAMALA Received Received
  WED-026 Development of a predictive model using artificial intelligence (AI) for the detection of hepatitis C based on real-world data from the population health database (BPS) of Andalusia, Spain Carmen Lara Romero Received Received
  SAT-026 Delta in Denmark: prevalence of hepatitis delta virus infection Hugh Watson Received Received
  LBP-027 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis, with limited correlation with pruritus: analyses from the phase III ELATIVE® trial Costello Medical Received Received
  FRI-027 Metabolic dysfunction-associated steatohepatitis as a risk factor for hepatocellular carcinoma mortality Gish Robert Received Received
  SAT-027 Therapy of HCV infections among patients of ukrainian origin during the influx of war refugees to Poland Robert Flisiak Received Received
  THU-027 Vibration-controlled transient elastography dynamics in the general population: longitudinal results from the LiverScreen consortium Jesse Pustjens Received Received
  WED-027 Changes in hepatitis C virus screening and treatment rates in pregnant individuals before and after implementation of universal screening guidelines compared to hepatitis B virus screening during the same time frame Chandler Shapiro Received Received
  LBP-028 Variceal hemorrhage outcomes are worse in patients with prior decompensating events. Systematic review with individual patient data meta-analysis Vincenzo La Mura Received Received
  SAT-028 The impact of peers on sustaining hepatitis C elimination in people who inject drugs - a network based model Ryan Buchanan Received Received
  FRI-28 Shortfalls and obstacles in sexual function assessment by healthcare providers in patients with liver disease and liver transplantation Yooyun Chung Received Received
  THU-028 Hospital wide approach to limiting and treating alcohol use disorder Rohit Gupta Received Received
  WED-29 Patient-reported outcomes measuring an individual´s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial Marvin Rock Received Received
  SAT-029 Hepatitis C incidence in Pakistan – large scale test and recall analysis shows that infection rates can be reduced by pro-active ´find and treat´ programs Saad Niaz Received Received
  LBP-29 Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC Marta Piqué-Gili Received Received
  THU-029 Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in four cities in the United States, including among people with diabetes and primary care providers Jeffrey Lazarus Received Received
  FRI-29 The global prevalence and mortality of metabolic dysfunction associated steatotic liver disease-related cirrhosis Carey Escheik Received Received
  THU-030 Risk factor awareness for liver disease in four United States cities Jeffrey Lazarus Received Received
  WED-030 Trends in the effect of direct acting antivirals on mortality in people diagnosed with hepatitis C in England using routine surveillance data David Etoori Received Received
  SAT-030 Eliminating hepatitis C in Nouvelle Aquitaine, the largest region of France: the SCANVIR® project Sandrine Francois Received Received
  LBP-030 Pitfalls in creatinine measurement and their impact on model for end stage liver disease score Eda Kaya Received Received
  FRI-030 In patients with metabolic dysfunction-associated steatotic liver disease, sleep disturbance is highly prevalent and associated with a profound impairment of health-related quality of life Carey Escheik Received Received
  FRI-031 Performance of chronic liver disease questionnaire – metabolic dysfunction-associated steatohepatitis (CLDQ-MASH) against non-invasive tests Carey Escheik Received Received
  SAT-031 The cost of HCV elimination in Kazakhstan based on the current disease burden Samantha Hall Received Received
  THU-031 MASLD impacts quality of life and work productivity Leen Heyens Received Received
  LBP-032 Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline Raji Nair Received Received
  TOP-32 Prevalence of the spectrum of steatotic liver disease and associated fibrosis and cirrhosis among adults in the United States Carey Escheik Received Received
  LBP-033 Rapid HBsAg declines and HBsAb seroconversion observed with a single dose of VRON-0200 plus Tobevibart and Elebsiran: preliminary results of a VRON-0200 combination treatment from a phase 1b study for functional cure in chronically HBV-infected patients Edward J. Gane Received Received
  SAT-033 Using community partnerships to achieve micro-elimination of HCV and HIV in inner-city Vancouver Shana Yi Received Received
  FRI-033 TIGIT blockade on CD8+T cells induces hepatocyte apoptosis Amber Bozward Received Received
  THU-033 The "Traffic Light System" - a radiology-led pathway for hepatocellular carcinoma surveillance in patients with liver cirrhosis Lusyan Dayalan Received Received
  SAT-034 Early diagnosis of HCV in people who inject drugs in the Czech Republic: preliminary results of a pilot project Sona Franková Received Received
  FRI-034 Crohn´s associated invariant T (CAIT) cell subphenotype analysis for inflammatory bowel disease and primary sclerosing cholangitis Aya Mahdy Received Received
  WED-34 Prevalence of HBV and HCV among migrants in EU-27: the impact of the ukrainian refugee crisis Devin Razavi-Shearer Received Received
  LBP-034 Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients Filippo Gabrielli Received Received
  WED-035 A National web self-testing portal for hepatitis C: an empowering solution with good uptake and linkage to care - preliminary data Ewan Glassey Received Received
  FRI-35 The role of FOXP3+ regulatory T (Treg) cells in mouse models of liver disease Caitlin Abbott Received Received
  THU-035 Bortezomib improves advanced fibrosis by selectively inducing stellate cell apoptosis via downregulation of LGALS2 and CDH3 expression Ling Wu Received Received
  SAT-035 Results of the national program for the elimination of viral hepatitis in Uzbekistan Shakhlo Sadirova Received Received
  WED-036 The impact of cardio-metabolic risk factors on liver-related diseases and mortality after hepatitis C virus eradication: insights from a multi-center taiwanese cohort Ming-Lung Yu Received Received
  FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure Alina Bauschen Received Received
  SAT-036 Physician perspectives on hepatitis C treatment for women of childbearing age and during pregnancy: results from a global multispecialty survey Tatyana Kushner Received Received
  LBP-036 Suboptimal performances of Baveno VII and AASLD 2024 criteria for detecting clinically significant portal hypertension with varices in untreated patients with HDV cirrhosis Maria Paola Anolli Received Received
  THU-036 Integrating spatial lipidomics with imaging mass cytometry: a novel approach for metabolic profiling of liver fibrosis Aleksandra Gruevska Received Received
  WED-037 Hepatitis C knowledge and perceptions among Singapore´s LGBTQ+ Individuals: barriers and opportunities for outreach Garrett Kang Received Received
  THU-037 Lycorine reduces liver fibrosis by inactivating hepatic stellate cells (HSCs) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) Alma Diaz Ruiz de Zarate Received Received
  FRI-037 miRNA/mRNA signature of mouse Kupffer cells during the progression of chronic liver disease from fibrosis to hepatocellular carcinoma Ananya Ajith Received Received
  LBP-038 Initial safety data from ELIMINATE-B, the first clinical trial of a gene editing treatment for chronic hepatitis B Alina Jucov Received Received
  FRI-038 Unraveling the liver immune rheostat: How contact-dependent regulation causes dysfunction of antigen-specific CD8 T cells over the course of chronic hepatitis B Anna Fürst Received Received
  THU-038 Patients with chronic liver disease present elevated plasma levels of peptidylprolyl isomerase C associated with the degree of fibrosis Ana Blas-García Received Received
  SAT-038 Atherosclerotic cardiovascular disease risk in chronic hepatitis C patients with metabolic dysfunction-associated steatotic liver disease after viral eradication: a multi-center cohort study Wan-Long Chuang Received Received
  WED-038 The impact of COVID-19 outbreak from February to June 2022 on chronic hepatitis B patient management in Shanghai: a cross-sectional study Simin Guo Received Received
  THU-039 Sex differences in aging rates and superoxide dismutase activity in patients with metabolic dysfunction-associated steatotic liver disease: implications for fibrosis risk Anastasiia Radchenko Received Received
  WED-039 A comparative study on liver disease severity and comorbidity profile in patients with chronic hepatitis B virus infection and hepatitis B virus/hepatitis D virus co-infection: a korean nationwide study Hoyoung Na Received Received
  FRI-039 Single-cell profiling of hepatic dendritic cells in metabolic-associated steatotic liver disease Camilla Klaimi Received Received
  SAT-039 Revisiting hepatitis B and delta viral infections in the brazilian Amazon: current epidemiological, clinical and molecular characteristics Maria Mendes-Correa Received Received
  THU-040 Efficacy of CRV431 and Semaglutide on liver fibrosis in a mouse model of MASH Asha Goodman Received Received
  FRI-040 Transcriptional and functional profiling of HBV-specific CD8 T cells in chronic HBV infection for the design of novel targeted T cell correction strategies for HBV cure Carolina Boni Received Received
  WED-040 Trends and cross-country inequalities in the global burden of acute hepatitis A, 1990–2021: a population-based study Deliang Huang Received Received
  SAT-40 Identifying people who are HBV positive but undiagnosed : a model-based approach informed by health administrative data William WL Wong Received Received
  THU-041 Investigating the role of Fn14 in metabolic associated steatohepatitis: effects on fibrosis, inflammation, and proliferation in a mouse model Anouk Oldenburger Received Received
  THU-042 Targeting metabolic dysfunction-associated steatohepatitis with microRNA therapeutics Cinzia Chinnici Received Received
  SAT-042 Rapid multiplex liver gene editing in mice using adeno-associated virus 8 or lipid nanoparticles Dandan Wu Received Received
  FRI-042 Defining the role of tissue-resident Kupffer cells in the pathogenesis of chronic liver disease Fabio Colella Received Received
  SAT-43 rhTPO promotes hepatocyte proliferation in rats with acute liver failure through the MAPK and PI3K AKT signaling pathways JING LIANG Received Received
  WED-043 Targeting the gut-liver crosstalk: the role of Gardenin A in alleviating alcohol-associated liver disease Prashsti Chadha Received Received
  THU-043 Nuclear factor I-B delays liver fibrosis by inhibiting chemokine ligand 5 transcription Qianwen Zhao Received Received
  FRI-043 Safety and efficacy of everolimus in autoimmune hepatitis – a single center retrospective analysis Florian Seltsam Received Received
  FRI-044 Dynamic adaptations of CD8+?d T cells in acute and chronic hepatitis E virus infection Erich Freyer Received Received
  SAT-044 Dynamic hepatocyte adaptations in acute biliary hypertension: role of canalicular remodeling, mechanosensors activation and alternate bile transport Himanshi Himanshi Received Received
  THU-044 CCN5 promotes fibrogenic activation of hepatic stellate cells and serves as a biomarker for liver fibrosis Yunhao Duan Received Received
  WED-044 Microbial changes resulting from vertical sleeve gastrectomy attenuate obesity by modulating bile acid metabolism and the intestinal farnesoid X receptor?fibroblast growth factor 15/19 axis Yi Xia Received Received
  SAT-45 10 year analysis and trends in liver biopsy; a single centre experience Jennifer Cathcart Received Received
  THU-045 Neo-epitope biomarkers for fibrogenesis and neutrophil activity predict liver-related events in advanced chronic hepatitis C infection Emilie Skovgaard Received Received
  WED-45 PPAR a is a key molecule mwdiating the diurnal variation of sepsis in mice Junzhou Zhao Received Received
  FRI-045 Hepatic stellate cells orchestrate the retention and functional impairment of tissue-resident CD8+ T-cells in the fibrotic human liver George Finney Received Received
  THU-046 Engineering liver fibrosis in a three-dimensional, extracellular matrix-hydrogel, ex-vivo disease model Frederik Hbjerg Svejs Received Received
  FRI-046 Fine needle aspiration reveals immunotherapy biomarkers and targets compartmentalised within hepatocellular carcinoma Gloryanne Aidoo-Micah Received Received
  WED-046 The intestinal virome related clinical outcomes, systemic inflammation and immune functions in hospitalized cirrhosis patients – the foremost work in an indian patient cohort Cyriac Philips Received Received
  FRI-047 Low-dose lipopolysaccharide administration improves the survival rate of septic shock by enhancing the bactericidal activity of Kupffer cells and reducing hepatic infiltration of pro-inflammatory monocyte-derived macrophages in mice Hiroyuki Nakashima Received Received
  WED-047 A single center experience from India on associations of fungal microbiota (mycobiome) in cirrhosis - orally-predominant fungal dysbiosis in the gut and immune-escaping Candida species drive outcomes in hospitalized patients Cyriac Philips Received Received
  THU-047 Inhibition of Adipocyte triglyceride lipase (ATGL) reduces fibrosis and portal hypertension in murine CCl4 liver fibrosis Henriette Horstmeier Received Received
  FRI-048 Establishing an optimised method for single-cell RNA-seq based immunophenotyping from cryopreserved human liver needle biopsies Juliet Luft Received Received
  THU-048 Cell-type specific roles of TGF-ß2 signaling in cholestatic liver disease progression and therapeutic targeting Ida Harst Received Received
  WED-048 Deep insights on gut bacterial associations with long-term clinical events, host immunology, and inflammatory cytokines in hospitalized Indian cohort of patients with cirrhosis Cyriac Philips Received Received
  SAT-048 Regulation of thyroid hormone metabolism by HNF4A via modulation of deiodinase activity in hepatocytes Xinru Zhang Received Received
  FRI-049 Influence of T cell exhaustion versus senescence in the development of spontaneous operational tolerance following liver transplantation Jorge P. Torres-Yaguana Received Received
  WED-49 Dietary bacterial D-lactate modulates liver steatosis and ameliorate experimental MASLD André Santos Received Received
  THU-049 Extracellular vesicle-dependent crosstalk between hepatic stellate cells and Kupffer cells promotes their mutual activation Junyu Wang Received Received
  SAT-049 Harnessing antioxidant nano-chimeras for combining targeted transforming growth factor ß receptor I degradation and transforming growth factor ß reduction to attenuate liver fibrosis Hanshu Liu Received Received
  THU-050 Dual inhibition of glutaminolysis and de novo amino acid synthesis underpins Pirfenidone´s suppression of hepatic stellate cell activation Jia Li Received Received
  WED-50 Fecal microbiota transplant activates hepatic PPAR-alpha resulting in remission of alcohol-related liver disease in murine model Ashi Mittal Received Received
  FRI-050 CD155 blockade modulates monocyte responses in acute-on-chronic liver failure Joseph Delo Received Received
  TOP-052 Baseline oral microbiome composition in liver transplant recipients can help predict graft dysfunction Rosmy Babu Received Received
  TOP-053 The mechanisms of transcription factor ZEB2 in regulating hepatic stellate cell activation and liver fibrosis Qianwen Zhao Received Received
  TOP-054 Single cell fixed RNA-seq revealed HSCLMCD1+LIMK2+ is a driver of liver fibrosis by modulating SMAD3-AKT-PRAS40-4EBP1 Minh Duc Pham Received Received
  FRI-055 Inhibition of the lysophatidylcholine-autotaxin-lysophosphatidic acid axis restores monocytic pro-inflammatory cytokine production in patients with acute-on-chronic liver failure Joseph Wilson Received Received
  THU-055 Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis Johnny Amer Received Received
  SAT-055 Echinococcus multilocularis infection induces pathological angiogenesis in mouse liver via PDGFR/PI3K/AKT/FAK signaling pathway Xiaojuan Bi Received Received
  WED-055 Microbiota-derived S-equol ameliolates inflammatory pathway in metabolic dysfunction-associated fatty liver disease Goo Hyun Kwon Received Received
  FRI-056 Investigating macrophage- phenotype and organ injury in acute-on-chronic liver failure Juan Wang Received Received
  SAT-56 Regulation of interleukin-6- and epidermal growth factor receptor-dependent pathways by augmenter of liver regeneration is mediated by activation of ADAM17 Christoph Voigt Received Received
  WED-056 Absence of cholesterol gallstone formation in male C57BL/6 mice by abrogation of hepatic thyroid hormone action Denise Zwanziger Received Received
  SAT-057 Time-restricted feeding modulates genes involved in liver regeneration and damage regression processes in a rat model treated with diethylnitrosamine Christian Molina-Aguilar Received Received
  THU-057 Disease-specific human ECM composition and bioactivity in MASH liver fibrosis Lisa Longato Received Received
  WED-057 Microbially conjugated bile salts undergo hepatobiliary secretion in humans and mice Frank Schaap Received Received
  FRI-057 Mucosal-associated invariant T (MAIT) cells possess direct cytotoxic potential against HCC, but are rendered dysfunctional within the tumour microenvironment Junika Pohl-Topcu Received Received
  SAT-058 MAIT cells mediate liver tissue repair via VEGF and VIM secretion Katia Sayaf Received Received
  WED-058 An integrative multi-omics and machine learning framework for diagnostic biomarker identification in patients with liver cirrhosis In Gyu Park Received Received
  THU-058 Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease Maximilian Joseph Brol Received Received
  FRI-058 Time-resolved liver fibrosis regression at single-cell resolution in a murine CCl4-cessation model Katharina Bonitz Received Received
  THU-059 Use of the LiverRisk score for prediction of moderate to advanced liver fibrosis in United States adults Mary E. Rinella Received Received
  SAT-059 A comprehensive study on acute and chronic liver injury response in Acomys (Spiny mice): insights into the role of p21 in liver regeneration Karen Ching Received Received
  FRI-059 Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma Luc Magre Received Received
  WED-059 The role of the gut microbiota in high-fat diet-induced hepatic steatosis in juvenile and adult mice Milos Vrataric Received Received
  SAT-060 Extending the lifespan of human chemically derived hepatic progenitors by treating with Drug A Seunghee Kim Received Received
  FRI-060 Lnk/Sh2b3 regulates the development of hepatic memory CD8+ T cells via IL-15 signaling and suppresses the pathogenesis of MASLD Taizo Mori Received Received
  WED-060 Gut microbial antibiotic resistance genes in clinicians taking care of cirrhosis patients shows wide variation according to country income and could be a risk factor for bidirectional transmission Jasmohan Bajaj Received Received
  THU-061 The study of pathogenesis of the progression of liver cirrhosis Oksana Shapoval Received Received
  FRI-061 Glucocorticoid receptor inhibits Th2 immune responses by down-regulating Pparg and Gata3 in schistosomiasis Xiaojuan Bi Received Received
  WED-061 Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis Jasmohan Bajaj Received Received
  SAT-061 Impact of NEDDylation on aging and liver senescence: key insights Leidy Estefanía Zapata-Pavas Received Received
  SAT-062 Generation and functional profiling of injury-resistant ductal organoids with biliary tree networks optimized by genipin Shiwen Ma Received Received
  FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure Bingqi Li Received Received
  THU-062 Human umbilical cord mesenchymal stem cells attenuate liver fibrosis in mice and inhibit hepatic stellate cell activation via secreting soluble factors QI ZHOU Received Received
  FRI-063 Understanding the impact of the liver microenvironment on regulatory T cells Maegen Fleming Received Received
  WED-063 Gut fungi in liver cirrhosis: characterizing mycobiota alterations and links to disease stages Juozas Kupcinskas Received Received
  WED-064 Targeting gut-liver axis crosstalk with probiotic Lactobacillus rhamnosus attenuates ductular reaction in Mcpip1-deficient mice Katarzyna Trzos Received Received
  THU-064 GPC3-based mRNA cancer vaccine for hepatocellular carcinoma immunotherapy Yifan Jiang Received Received
  SAT-064 Expression and role of trefoil factor 3 (TFF3) in hepatoblastoma Maite G Fernandez-Barrena Received Received
  WED-065 Myricetin alleviates steatotic liver disease through gut microbiota modulation and Wnt-signaling inhibition Min Ju Kim Received Received
  SAT-065 Engineered extracellular vesicles derived from mesenchymal stem cell carrying insulin-like growth factor I to promote liver regeneration after partial hepatectomy Mailín Casadei Received Received
  FRI-065 Non-neuronal role of immune cells in liver regeneration Nastaran Fazel Modares Received Received
  WED-066 Bacteroides caccae alleviates hepatic fibrosis by suppressing inflammation kyeongjin Lee Received Received
  SAT-066 A 3D human liver organoid model to study the impact of ischemia-reperfusion injury on liver regeneration during transplantation maura cimino Received Received
  THU-66 Femoral vs hepatic vein plasma levels of collagen biomarkers confirm Pro-C3 as true marker of collagen synthesis in the fibrotic/cirrhotic liver RAMBABU SURABATTULA Received Received
  SAT-067 3D assembloid model as a useful in vitro tool to study acute and chronic liver diseases Riccardo Perriera Received Received
  WED-067 Akkermansia muciniphila inhibits serotonin-induced fibrosis progression in liver injury mouse model Sung-Min Won Received Received
  THU-067 A simple lab based machine learning model (FAET) predicts advanced Liver Fibrosis more accurately in MASLD patients Shobha Sharma Received Received
  THU-068 EmTPx promotes liver fibrosis via enhancing IL-33 secretion from macrophage Tuerhongjiang Tuxun Received Received
  SAT-068 Room for improvement in female authorships across leading medical journals Sara Tnder Hauskov Received Received
  FRI-068 The role of T-cell immunoglobulin and mucin domain 3 (TIM-3) in immune dysregulation and infection in patients with decompensated cirrhosis and liver failure syndromes Roosey Sheth Received Received
  WED-068 Enterohepatic circulation of microbial bile acid conjugates Alvaro Temprano Received Received
  SAT-069 Cathepsin L inhibitor enhances liver regeneration in fibrotic liver SHUNHEI Yamashina Received Received
  FRI-069 Scar-associated macrophages demonstrate phenotypic plasticity during the progression and regression of liver fibrosis Ravi Parhar Received Received
  WED-069 Gut microbiota composition of obesity resistant mice protects from high fat diet-induced steatosis Milos Vrataric Received Received
  THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C Thomas Wiggers Received Received
  FRI-70 p120 catenin expression by CD8+ T cells correlates with their frequency of invasion into cholangiocytes in autoimmune liver disease Scott Davies Received Received
  SAT-070 Extracellular matrix protein 1 (ECM1) as a dual regulator of liver regeneration via HGF/c-MET and TGF-ß signaling pathways Ye Yao Received Received
  WED-070 Fecal microbiota transplantation results in increased caproic acid which alleviates steatosis and reduces ethanol-induced hepatotoxicity (in vivo and in vitro) Nishu Choudhary Received Received
  THU-070 Characterizing the differentiation and cellular heterogeneity of hepatic stellate cells derived from induced pluripotent stem cells Zhengqing Xu Received Received
  TOP-071 Integrated single-cell transcriptome and protein analysis unveils long-lasting liver NK cell dysfunction in NUC-treated chronic HBV Andre Boonstra Received Received
  TOP-072 Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance Erich Freyer Received Received
  TOP-073 Disruption of mitochondrial dynamics and stasis leads to liver injury, innate immune response and tumorigenesis Wen-Xing Ding Received Received
  TOP-074 The reelin signaling pathway in lymphatic endothelial cells is a key driver of ductular reaction during liver injury Aarti Sharma Received Received
  THU-075 A naturally derived monoterpene potentiates sorafenib´s anticancer efficacy in drug-induced-hepatocellular carcinoma animal model Amr Amin Received Received
  WED-075 Restoration of gut microbiome-nitrogen metabolism post oral administration of black carrot extracellular vesicles in hepatic encephalopathy P Debishree Subudhi Received Received
  SAT-075 Prediction of hepatocellular carcinoma using AI-driven MRI radiomics: development of the AI-HCC prediction model Maureen Guichelaar Received Received
  FRI-075 Differential granzyme-mediated immune responses in CXCR6+PD-1+ CD8 T cells in acute versus chronic ALT flares Roni Souleiman Received Received
  WED-076 Association between gut fungal microbiota and subclinical coronary atherosclerosis in patients with MASLD Pisit Tangkijvanich Received Received
  THU-076 RIPK3 is a metabolic regulator impacting mitochondrial dysfunction, endoplasmic reticulum stress and tumour development during murine chemical-induced hepatocarcinogenesis André F. L. Cardador Received Received
  SAT-076 Therapeutic potential of Human antigen R inhibition in chronic liver disease and hepatocellular carcinoma Mickaël Jouve Received Received
  SAT-077 OGT and c-Myc promote non-canonical activation of gene expression by EZH2 in hepatocellular carcinoma Mirjam Zeisel Received Received
  FRI-077 T-cell receptor analysis of circulating T cells reveals non-epitope-driven clonal expansion in metabolic-associated steatotic liver disease Xinlei Zhao Received Received
  WED-077 Next-generation beneficial bacteria combined with fructo-oligosaccharides and fecal microbiota transplantation attenuates diet-induced metabolic dysfunction-associated steatohepatitis in mice Quinten Augustijn Received Received
  THU-077 E7386 enhances lenvatinib´s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma Agavni Mesropian Received Received
  FRI-078 Inflammation-educated macrophages drive exacerbated re-injury patterns via innate immune memory Yuting Wang Received Received
  SAT-078 Immunoregulation and T cell paralysis mediated by MDSC induction in hepatocellular carcinoma following rVSV-NDV therapy Mirta Jimenez Received Received
  THU-078 Artificial intelligence-driven prediction of biology-related poor outcome and presence of vascular invasion in hepatocellular carcinoma Agavni Mesropian Badalian Received Received
  WED-078 Sex-specific effects of beta-blockers on the gut microbiome and metabolome in liver cirrhosis Rosa Haller Received Received
  FRI-079 Prognostic value of early change in neutrophil to lymphocyte ratio after atezolizumab plus bevacizumab treatment for hepatocellular carcinoma Young Mi Hong Received Received
  SAT-079 Metabolic and functional characterization of CD8+ T-cell subpopulations in hepatocellular carcinoma: implications of tumor microenvironment on T-cell dysfunction Gabriele Missale Received Received
  THU-079 Beta klotho as a regulator of liver cancer cell proliferation and liver cancer development Alexandra Aaldijk Received Received
  WED-079 Quantification of genes encoding bacterial sialidases and enzymes of the nan cluster in combination with cutaneous T cell-attracting chemokine (CTACK) in bile for the early detection of cholangiocellular carcinoma in patients with primary sclerosing chola Antonia Triefenbach Received Received
  FRI-080 TACE combined with ICIs plus MTT after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY ?) Mei Junhao Received Received
  THU-080 Platelet-derived extracellular vesicles (PEVs) in hepatocellular carcinoma. Emerging diagnostic biomarkers Ángela Rojas Received Received
  SAT-080 The NLRP3 inflammasome and its downstream target Il1R, but not IL18R drive hepatocarcinogenesis Mona Peltzer Received Received
  SAT-081 Development and performance of AI in supporting the diagnosis of liver tumors using B-mode ultrasound Naoshi Nishida Received Received
  THU-081 Association of T cell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC Anthony Tan Received Received
  WED-081 Role of alcohol-associated gut microbiota in driving liver fibrosis via tgfbr1 kinase alterations in alcohol associated liver disease MANISHA YADAV Received Received
  FRI-082 Conversion ability of systemic therapy in patients with hepatocellular carcinoma: a multicenter international study. On behalf of the converse survey collaborative study group Alessandro Vitale Received Received
  WED-082 Gut-oral microbial translocation promotes ammonia metabolism in liver cirrhosis Yi Jin Received Received
  SAT-082 The metabolic heterogeneity induced by different genetic mutations in hepatocellular carcinoma leads to a particular response to feeding a lipid-enriched diet Natalia Sainz Received Received
  SAT-083 Clinical potential and non-canonical roles of the cytosolic aspartyl-tRNA synthetase (DARS1) in hepatocellular carcinoma Natalia Herman-Sánchez Received Received
  WED-083 Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma Abelina Kreuter Received Received
  FRI-083 Histologic predictors of response to atezolizumab and bevacizumab in hepatocellular carcinoma biopsies Alexandre Sayadi Received Received
  WED-084 Added-value of PET imaging to AFP score in predicting HCC recurrence after liver transplantation Alina Pascale Received Received
  THU-084 Comprehensive characterization of the peripheral immune landscape through single-cell transcriptomics in hepatocellular carcinoma patients undergoing immunotherapy Beatriz Minguez Received Received
  FRI-084 Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry Andrea Mospan Received Received
  SAT-084 Microscale detection of selenium in liver tissue using laser ablation-inductively coupled plasma time-of-flight mass spectrometry Nataliya Rohr-Udilova Received Received
  SAT-085 The role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential Naroa Goikoetxea-Usandizaga Received Received
  THU-85 SMG7 as a potential driver of chronic liver disease progression to hepatocellular carcinoma Betsaida Ojeda-Perez Received Received
  WED-085 Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis Aline Mähringer-Kunz Received Received
  WED-86 Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients Aliya Sarmanova Received Received
  THU-86 Translational approaches to evaluating novel antifibrotic and anticancer drugs for hepatocellular carcinoma: strategies for prevention and treatment Caecilia Sukowati Received Received
  SAT-086 Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma Niloufar Safinia Received Received
  FRI-086 Long-term survival outcomes in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: an update of the AB-real study Bernardo Stefanini Received Received
  THU-087 TIGAR SUMOylation: a key modulator of metabolic balance in hepatocellular carcinoma Carolina Conter Received Received
  SAT-087 MiR-485-3p as a predictor of therapeutic response and its role of the PIAS3/STAT3/VEGF signal in Atezolizumab plus Bevacizumab therapy for hepatocellular carcinoma Kyoko Oura Received Received
  WED-087 Prognosis after resection or ablation of hepatocellular carcinoma: a danish population-based multi-state cohort study Clara Stenderup Received Received
  WED-088 Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study Antonio Guerrero Received Received
  THU-088 MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4 Chaiyaboot Ariyachet Received Received
  SAT-088 Integrated multi-omics profiling of pan heat shock proteins in hepatocellular carcinoma identifies CCT3 and CCT7 as druggable oncogenes in hepatocytes Manju Nidagodu Jayakumar Received Received
  WED-089 Development and validation of PSU´s AI-assisted ultrasound (AI-US) algorithm for focal liver lesion detection Apichat Kaewdech Received Received
  THU-089 Tumor microenvironment differences in liver cancer are lineage-dependent when controlled for oncogenic pathway activation Chun-Shan Liu Received Received
  FRI-089 Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis Ciro Celsa Received Received
  SAT-089 mRNA-based vaccination for tumor neoantigens to induce a therapeutic T cell response in HCC Paul Schneider Received Received
  THU-090 Glutaminolysis-driven iron accumulation in the liver: a mechanism for aging through Lysosomal dysfunction Claudia M. Rejano-Gordillo Received Received
  WED-090 The mind and monitoring: The psychological impact of hepatocellular carcinoma surveillance Azzra Maricar Received Received
  SAT-090 MFAP-5 siRNA nanohydrogels for antiangiogenic stromal-targeting HCC therapy Paul Schneider Received Received
  FRI-090 Incidence of radiation pneumonitis following resin-based yttrium-90 selective internal radiation therapy Kaina Chen Received Received
  FRI-091 The "A-B-C" cluster-based classification reveals distinct outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab Claudia Campani Received Received
  WED-091 Delta hepatitis versus HBV monoinfection associated hepatocellular carcinoma: spot the difference Mirela Chitul Received Received
  SAT-091 Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma Paula Olaizola Received Received
  FRI-092 Patterns and outcomes of recurrence after thermal ablation for hepatocellular carcinoma CHI-PING TAN Received Received
  WED-092 Lower allele frequency of the TERT-rs2242652 in sub-saharan african than american populations and hepatocellular carcinoma risk Perapa Chotiprasidhi Received Received
  SAT-092 Brown adipose tissue activation: a novel strategy to prevent/treat the hepatocarcinogenesis promoted by metabolic lipotoxicity Marion Peyrou Received Received
  TOP-093 Development and external validation of preoperative prediction model for early recurrence of intrahepatic cholangiocarcinoma Sang Hyun Choi Received Received
  TOP-094 Breaking barriers: intensive care admission in patients with advanced HCC on immunotherapy Marta Fortuny Received Received
  FRI-096 Effects of pre-transplant locoregional therapies on dropout rates and survival outcomes in patients with hepatocellular carcinoma: a propensity-matched analysis of the United Network for Organ Sharing (UNOS) database Nariman Nezami Received Received
  THU-096 FSP1 inhibitor icFSP1 enhances lenvatinib sensitivity for hepatocellular carcinoma treatment by promoting ferroptosis through the FSP1/MIR4435-2HG pathway Congyue Zhang Received Received
  SAT-096 Reduction in lipid accumulation, inflammation and hepatocellular carcinoma development after protease-activated receptor 2 inhibition through 1-Piperidinepropionic acid Pietro Guerra Received Received
  WED-097 Identification of diagnostic markers based on spectral infrared fingerprints of bile samples from endoscopic drainage of patients with biliary stenosis due to extrahepatic cholangiocarcinoma or pancreatic adenocarcinoma Elia Gigante Received Received
  FRI-097 Bridging and long-term impact of pre-orthotopic liver transplant transjugular intrahepatic portosystemic shunt (TIPS) creation: a propensity-matched analysis using the united network for organ sharing (UNOS) database Nariman Nezami Received Received
  THU-097 A syngeneic and orthotopic HCC mouse model demonstrating the high efficacy of combination therapies targeting the ECM and immune microenvironment Emma Eichler Received Received
  SAT-097 Protein kinase R-like endoplasmic reticulum kinase in hepatic stellate cells promotes hepatocellular carcinoma progression via the p38delta mitogen-activated protein kinase/interleukin-1beta axis Makoto Morita Received Received
  THU-98 miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment Elisa Monti Received Received
  WED-098 Predictive microRNA panel of hepatocellular carcinoma occurrence in patients with chronic hepatitis C achieving sustained virological response after direct-acting antiviral therapy Emanuela De Santis Received Received
  SAT-099 The liver artificial intelligence (lai) consortium: a benchmark dataset and optimised machine learning methods for MRI-based diagnosis of solid-appearing liver lesions Ruben Niemantsverdriet Received Received
  THU-099 Atorvastatin and gene expression signatures in hepatocarcinogenesis Ezequiel Ridruejo Received Received
  FRI-099 Systematic review of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma with tumor thrombus extension to the inferior vena cava or right atrium Divya Khosla Received Received
  WED-099 Insights into the GALAD Score: a new optimal cut-off for hepatocellular carcinoma Endrit Shahini Received Received
  THU-100 Functional properties of unannotated, small RNA clusters during hepatocarcinogenesis Francesca Pagani Received Received
  FRI-100 Laparoscopic liver resection as a treatment for early-stage hepatocellular carcinoma in patients with and without portal hypertension: a case-control study Alvaro Urzua Received Received
  SAT-100 Multiomic insights into bile acid dysregulation, microbiome dysbiosis, and epigenetic modifications in metabolically associated non-B, non-C hepatocellular carcinoma: findings from multi-cohort studies and implications for early detection and therapeutic Royston Liew Received Received
  SAT-101 Defective liver endothelial autophagy occurring in metabolic dysfunction-associated steatotic liver disease promotes hepatocellular carcinoma SAMIRA LAOUIREM Received Received
  WED-101 Hepatocellular carcinoma in the MENA region differs in presentation and outcomes: an analysis of 2736 patients from Saudi Arabia, Oman, Egypt and Turkiye Faisal M Sanai Received Received
  FRI-101 Viral etiology of hepatocellular carcinoma as an independent determinant of survival for patients receiving tyrosine kinase inhibitor treatment Lu Li Received Received
  THU-101 Selective targeting of class I histone deacetylases with new derivatives of ursodeoxycholic acid as a novel treatment strategy for bile duct cancer Francisco Javier Caballero-Camino Received Received
  FRI-102 Selective internal radiation therapy (SIRT) for HCC: real-world experience from a tertiary care center Ilkay Ergenc Received Received
  SAT-102 The role of Activating Factor 4 (ATF4) in the immunosuppressive phenotype of beta-catenin mutant hepatocellular carcinoma Stefany Infante Received Received
  WED-103 Impact of statin therapy on survival in hepatocellular carcinoma: a single-center study Christos Triantos Received Received
  FRI-103 Prognosis of patients undergoing curative surgery for combined hepatocellular-choloangiocarcinoma Eung-Ho Cho Received Received
  THU-103 Impact of PNPLA3 and TM6SF2 single nucleotide polymorphisms in metabolic dysfunction-associated steatohepatitis-linked hepatocellular carcinoma development in 3D extracellular matrix models Giulia Lupo Received Received
  SAT-104 Impact of environmental pollution and the aryl hydrocarbon receptor signaling pathway on hepatic carcinogenesis Sri-Kamini SOOCHETA Received Received
  WED-104 Surrogate survival endpoint in hepatocellular carcinoma patients on first-line Atezolizumab-Bevacizumab: RECIST 1.1 vs modified RECIST Hyo Jung Park Received Received
  FRI-104 Sorafenib plus transarterial chemoembolization versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial Guohong Han Received Received
  THU-104 A large-scale genetic analysis of hepatocellular carcinoma reveals novel mutational patterns and ancestry-linked mutations Christoph Gerdes Received Received
  THU-105 Liver-derived mesenchymal stem cells promote epithelial-mesenchymal transition in a hepatocellular carcinoma spheroid coculture model Grégory de Bodt Received Received
  SAT-105 Spatiogenomic characterization of malignant transformation in dysplastic nodules Jihyun An Received Received
  FRI-105 Evolutionary learning-derived multimodal models integrating comprehensive imaging features to predict early recurrence of hepatocellular carcinoma after curative resection I-Cheng Lee Received Received
  THU-106 Macrophage-targeted biodegradable polymer nanocarriers loaded with a cytokine pathway activator effectively suppress orthotopic HCC growth in immune-competent mice Hicham El Mard Received Received
  FRI-106 Real-world treatment patterns and survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC): the OREIOS - Middle East and North Africa (MENA) cohort Imam Waked Received Received
  WED-106 Impact of metformin on the prevention of hepatocarcinoma in chronic hepatitis C with advanced fibrosis after sustained virologic response Henar Calvo Sánchez Received Received
  SAT-106 CD40–Integrin a5ß1 and CD27-CD70 axes: novel mechanisms driving HCC progression in chronic hepatitis C Le Thi Thanh Thuy Received Received
  TOP-107 Machine learning approaches for hepatocellular carcinoma risk stratification across various aetiologies Pierre Nahon Received Received
  TOP-108 Prevalence and impact of clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database Rusi Chen Received Received
  TOP-109 Treatment of cholangiocarcinoma with Claudin-1 antibodies reprograms the tumor microenvironment to improve survival in an orthotopic mouse model Romain Desert Received Received
  TOP-110 Longitudinal analyses of Innate Lymphoid Cells in patients with HCC identifies patterns associated with disease stage and response to therapy with atezolizumab and bevacizumab Tijana Ristic Received Received
  FRI-111 The role of immune cell composition potentially predicts response to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma Jana Knorr-Klocke Received Received
  SAT-111 Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab Takahiro Kodama Received Received
  THU-111 Cryptochrome proteins as key regulators in circadian rhythm-enhanced photodynamic therapy for cholangiocarcinoma Tianxiao Huang Received Received
  THU-112 Proinflammatory cytokines drive peripheral Foxp3high Tregs into tumor sites: a reliable and accessible prognostic biomarker for HCC patients Chien-Hao Huang Received Received
  FRI-112 Local control and survival after stereotactic body radiotherapy for hepatocellular carcinoma without macrovascular invasion Jose Paul Received Received
  WED-112 Tumor burden score as a surrogate prediction marker in patients with hepatocellular carcinoma: prognostic role of performance status Hung-Ting Tseng Received Received
  SAT-112 Role of hypoxia on the progression and survival of hepatocellular carcinoma in hypoxia-inducible factor 1 alpha knockout bi- and tri-dimensional in vitro models Tania Payo-Serafín Received Received
  THU-113 Distinct roles of SOS1 and SOS2 in lipid metabolism and tumorigenesis: implications for therapeutic targeting in cancer and metabolic disorders Andrea Olarte Received Received
  FRI-113 Clinical outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with macrovascular invasion in a predominantly non-viral cohort Jose Paul Received Received
  WED-113 Targeted immunotherapy combined with TACE for conversion therapy of unresectable hepatocellular carcinoma: metabolomic biomarker insights YUHAI HU Received Received
  SAT-113 The intratumoral microbiome in HCC and its impact on treatment response Ugne Balaseviciute Received Received
  SAT-114 Modulation of mitotic stress-induced activation of the cGAS/STING signaling pathway by DNA demethylation Umar Mukhamedaliev Received Received
  THU-114 Liposomal doxorubicin and atezolizumab promote EMT regression by acting on the tumor microenvironment: preclinical in vitro and in vivo studies Ilaria Zanotto Received Received
  WED-114 Outcome in patients with liver cirrhosis and hepatocellular carcinoma : comparing MRI and ultrasound for HCC surveillance Jasper van Leengoed Received Received
  FRI-114 Liver resection versus trans-arterial chemoembolization for huge hepatocellular carcinoma (>10cm): a nationwide propensity score adjusted analysis Jai Young Cho Received Received
  THU-115 Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk Irene Olaizola Received Received
  FRI-115 Improving outcomes in unresectable hepatocellular carcinoma through proactive adverse event management with Atezolizumab-Bevacizumab therapy Jeayeon Park Received Received
  SAT-115 A novel panel of Methylated DNA markers for hepatocellular carcinoma William Chung Received Received
  WED-115 Differential gene expression in hepatocellular carcinoma: a bioinformatic approach to correlate with HIF1A Jennifer Martínez-Geijo Received Received
  WED-116 Statin and its effects on hepatocellular carcinoma risk and liver fibrosis in chronic liver disease Jonggi Choi Received Received
  THU-116 Novel chemotherapy selectively induces double-strand DNA breaks and death in naďve and Cisplatin-resistant cholangiocarcinoma tumours Irene Olaizola Received Received
  WED-117 Challenges and adherence to hepatocellular carcinoma screening program in patients with advanced chronic liver disease José Presa Received Received
  FRI-118 Statins in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an italian prospective multicentric dataset Marco Vicardi Received Received
  WED-118 Shifting etiologies and emerging metabolic factors of hepatocellular carcinoma from 2005 to 2020: a german nationwide population-based study Josune Cabello Calleja Received Received
  FRI-119 Evaluation of the intratumoral immune microenvironment in hepatocellular carcinoma treated with liver surgery after selective internal radiation therapy Maria Stella Franzč Received Received
  WED-119 Increasing prevalence of hepatocellular carcinoma in the Netherlands: changing etiologies, tumor characteristics and survival rates Koen van Son Received Received
  SAT-119 Detection of Candida species via shotgun sequencing in patients with decompensated cirrhosis is associated with impaired survival and higher risk of acute-on-chronic liver failure Sarah Lisa Schütte Received Received
  SAT-120 DOACs offer superior safety and survival over traditional agents in anticoagulant therapy for cirrhosis Eun Young Cho Received Received
  FRI-120 Recompensation before first-line systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis Manuel Mendizabal Received Received
  WED-120 Machine learning-based survival analysis and risk stratification for patients with cholangiocarcinoma CHUN-TING HO Received Received
  WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection CHUN-TING HO Received Received
  THU-121 Claudin-1 modulates cell plasticity, carcinogenic signaling and proliferation in patient-derived cholangiocarcinoma organoids in vivo Jade Brochon Received Received
  SAT-121 Hybrid care models in liver disease management: lessons from telemedicine during the COVID-19 pandemic Nada Abedin Received Received
  FRI-122 Impact of hepatocellular carcinoma multidisciplinary team on treatment outcomes: an analysis from the Middle East and North Africa region Al Naamani Khalid Received Received
  THU-122 Can fractal descriptors distinguish vascular organization within the tumor microenvironment? Jake Penney Received Received
  SAT-122 Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes Alberto Calleri Received Received
  FRI-123 The dose of radiation absorbed by the tumor and the non-tumoral compartments does not impact peripheral immune markers after SIRT Elisa Pinto Received Received
  SAT-123 5-year outcomes of a dedicated, multidisciplinary clinic for decompensated cirrhosis Alexander Mitropoulos Received Received
  WED-123 Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicentre study on overall survival following hepatectomy or orthotopic liver transplantation Konstantinos Arvanitakis Received Received
  THU-123 YAP activity in cancer-associated fibroblasts is relevant for immune escape in cholangiocarcinoma Kieu Trinh Dinh Received Received
  FRI-124 Sub-symptomatic Child-Pugh score 7 shows comparable survival outcomes to Child-Pugh score 6 in hepatocellular carcinoma patients treated with Atezolizumab and Bevacizumab Jung Hyun Kwon Received Received
  WED-124 National burden of MASH-related liver cancer in the United States 1990 – 2021: a systematic analysis for trends and patterns of geographic variations of the global burden of disease study Seung Up Kim Received Received
  SAT-124 Harnessing human immune system mouse models to validate NADPH oxidase 1 inhibition as a treatment for hepatocellular carcinoma Zenzi De Vos Received Received
  THU-124 3,4-dihydroxyphenylpropionic acid deficiency in chronic hepatitis B promotes hepatocellular carcinoma Zhixian Lan Received Received
  FRI-125 Real-world treatment patterns and outcomes among patients with hepatocellular carcinoma managed at a single centre in Switzerland Iuliana Pompilia Radu Received Received
  THU-125 Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma Luca Fabris Received Received
  SAT-125 Targeting Annexin A1 improves immunotherapy efficacy by remodeling the macrophage-related immunosuppression for hepatocellular carcinoma Zhenghui Song Received Received
  WED-125 The Liver Frailty Index predicts survival in hepatocellular carcinoma: an australian multicentre prospective cohort study (APriCa study) Leo Ye Received Received
  WED-126 Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study Lorenzo Canova Received Received
  THU-126 So hot, yet so cold: bacterial lipopolysaccharides hinder tumor adaptive immunity by producing inflammatory and suppressive innate immunity in non- or poorly-infiltrated hepatocellular carcinoma Lugien AL ASADI Received Received
  FRI-126 Predictors for postembolization syndrome in a cohort of patients with hepatocellular carcinoma Letitia Toma Received Received
  TOP-127 Primary cilia loss promotes neoplastic outgrowth in intrahepatic cholangiocarcinoma through suppression of neutrophilic immune surveillance Sara Teles Received Received
  TOP-128 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma Ugne Balaseviciute Received Received
  TOP-129 Perineural invasion drives hilar cholangiocarcinoma progression via epithelial-mesenchymal transition augmented by cancer-associated Schwann cell-derived nerve growth factor inducible (VGF) Honghua Zhang Received Received
  TOP-130 Deep learning derived radiomics with advanced machine learning outperforms clinical biomarkers in predicting outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma Mathew Vithayathil Received Received
  FRI-131 Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE Jihyun An Received Received
  THU-131 Expression signatures of IL-18 and IL-18BP characterize stages of cirrhotic decompensation Aenne Harberts Received Received
  WED-131 Low FIB-4 in multinational hepatocellular carcinoma cohort Margaret Teng Received Received
  SAT-131 Physical frailty is associated with myosteatosis and physical frailty assessment tools may predict the presence of myosteatosis in liver cirrhosis ALEXANDRA ALEXOPOULOU Received Received
  SAT-132 Loculated ascites in the setting of spontaneous bacterial peritonitis is associated with increased morbidity and mortality Anita Mahadevan Received Received
  WED-132 Serologic and immunologic biomarkers for the identification of patients with hepatocellular carcinoma with high tumour burden and poor survival Marta Guariglia Received Received
  THU-132 Hepatocyte derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p – pyroptosis axis Anabel Fernández-Iglesias Received Received
  WED-133 A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma incorporating computed tomogram-derived imaging biomarkers Moon Haeng Hur Received Received
  SAT-133 Adherence to a remote monitoring platform for the liver cirrhosis population, a multicenter feasibility study Britt van Ruijven Received Received
  FRI-133 Immunoprofiling-based machine learning model predicts outcomes to pembrolizumab plus lenvatinib in patients with unresectable hepatocellular carcinoma Pei-Chang Lee Received Received
  THU-133 Risk of hypoglycemia in people with cirrhosis without diabetes Alan Hutchison Received Received
  WED-134 Age differences in the association between alcohol consumption and risk of hepatocellular carcinoma: a nationwide cohort study Mi Na Kim Received Received
  THU-134 Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of circulatory and renal failure in animal models of acute-on-chronic liver failure (ACLF) Alexandra Phillips Received Received
  SAT-134 Impact of parenteral nutrition on the risk of infections and the disease course of malnourished patients with decompensated liver cirrhosis Laura Buttler Received Received
  FRI-134 Impact of radiation dose on treatment response and survival outcomes in solitary hepatocellular carcinoma treated withY90 selective internal radiation therapy: a retrospective single-center study Lu Yang Received Received
  FRI-135 Pre-treatment serum IgG levels predict immune-related adverse events in HCC patients treated with atezolizumab plus bevacizumab Yutaka Yasui Received Received
  SAT-135 SHiNE-UK: a national evaluation of hepatocellular carcinoma surveillance and treatment pathways Christopher Mysko Received Received
  WED-135 Metabolic response to locoregional treatment for hepatocellular carcinoma measured by 18F-FDGal PET/CT Mona Kristiansen Received Received
  THU-135 Associations between cardiorespiratory fitness and physical frailty in patients with cirrhosis Alexis Couret Received Received
  SAT-136 Identification of prognosis determining risk factors in outpatients with cirrhosis Clara Guntlisbergen Received Received
  WED-136 Proton-pump inhibitors and gut microbiome are associated with survival in patients with hepatocellular carcinoma under immunotherapy Marco Sanduzzi Zamparelli Received Received
  THU-136 Clinical relevance of the evaluation of cardiorespiratory fitness in patients with cirrhosis: a systematic review with meta-analysis Alexis Couret Received Received
  FRI-137 Flavin-containing monooxygenase 3 (Fmo3) knockout mouse reveals the role of Fmo3 in female tolerance to acetaminophen-induced liver injury Chibuisi Alimba Received Received
  SAT-137 Community-acquired infections requiring hospitalization in patients with alcohol-related cirrhosis Clara Stenderup Received Received
  WED-137 Hepatocellular carcinoma after liver transplantation: development of a machine learning-based risk score for safely ruling out recurrence Pedro Passos Received Received
  THU-137 The metabolome of patients with cirrhosis hospitalized with overt hepatic encephalopathy and association with clinical course Anindro Bhattacharya Received Received
  WED-138 Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study Elisa Pinto Received Received
  THU-138 Albumin infusion improves albumin binding capacity in patients with cirrhosis and MHE on gut-specific therapy Anna Mestre Received Received
  FRI-138 Enhanced prediction of drug-induced liver injury in keratinocyte-based high-content single-cell screening integrating machine learning ANGELA REMESAL DOBLADO Received Received
  SAT-138 Functional and structural evaluation of patients with cirrhosis to consider recompensation JOSE LUIS PEREZ-HERNANDEZ Received Received
  FRI-139 Lipid metabolites in acute and chronic liver damage: Do N-acyl taurines protect the liver? Anna Hassing Received Received
  THU-139 Glycated albumin is increased in patients with cirrhosis and hepatic encephalopathy already on gut-directed therapy and links with cognitive and quality of life impairment Anna Mestre Received Received
  SAT-139 Prevalence and determinants of reduced muscle status among adults with cirrhosis attending liver clinics Damian Harding Received Received
  WED-139 Evaluating the performance of large language models at hepatobiliary tumor boards: a prospective study Robert Oehring Received Received
  THU-140 The in vitro immune response of mononuclear cells to Escherichia coli is not dependent on antibiotic multidrug resistance Berta Cuyŕs Received Received
  SAT-140 Predictive value of systemic inflammation biomarkers towards recompensation versus progression to further decompensation in patients with decompensated cirrhosis Dalila Costa Received Received
  WED-140 Liver function and tumor stage determines adherence to tumor board recommendation in HCC Fabian Jänick Received Received
  FRI-140 Drug-induced hepatic sinusoidal obstruction syndrome: clinical characteristics analysis and preliminary exploration of mechanisms Mingyan Ji Received Received
  WED-141 MicroRNA profiling of hepatocellular carcinoma can improve the prediction of tumor recurrence after liver resection Per Stl Received Received
  SAT-141 Chronic Liver Disease and Autoimmune Haemolytic Anaemia: A Case Series Dorien Pint Received Received
  FRI-141 A comparison of the protective effects of Rimtoregtide (HTD4010) and DUR-928 on acute liver failure in mice Kjersti Swearingen Received Received
  SAT-142 Liver frailty index: a prognostic tool for predicting mortality in cirrhotic patients Burcu Gurbuz Received Received
  WED-142 Impact of hepatocellular carcinoma surveillance on survival in a contemporary international cohort Ryan YanZhe Lim Received Received
  THU-142 Early detection of hepatic encephalopathy using wearable sensors: preliminary data Clelia Asero Received Received
  SAT-143 Cirrhotic cardiomyopathy: diagnostic challenges and debating role in mortality prediction in cirrhosis Burcu Gurbuz Received Received
  FRI-143 Metabolomic profiling to differentiate drug-induced liver injury from other liver diseases using machine learning models Daniel E. Di Zeo-Sánchez Received Received
  WED-143 Ki-67 and CK19 as predictors of hepatocellular carcinoma recurrence after liver transplantation Saur Hajiev Received Received
  WED-144 Clinicopathological features of liver tumors in Guilin: a region with significant Aflatoxin contamination in food crops in China Wenhua Shao Received Received
  THU-144 Epigenetic regulation of LSECtin in hepatic antigen presenting cells during experimental cirrhosis Angel Gomis Enrique Received Received
  FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury Denise Zwanziger Received Received
  SAT-144 FastPHES offers a rapid but valid alternative for the detection of cognitive impairment in patients with liver cirrhosis Julius Egge Received Received
  SAT-145 Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience Giacomo Zaccherini Received Received
  THU-145 Propranolol reverses splanchnic ß-adrenergic induced small intestinal barrier disruption stabilizing gut-liver axis in experimental cirrhosis Alejandro Miranda González Received Received
  WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study Spyridon Pantzios Received Received
  FRI-146 Genetic polymorphisms associated with idiosyncratic drug-induced liver injury: a systematic review and bioinformatic analysis Gonzalo Matilla-Cabello Received Received
  SAT-146 A novel non-invasive diagnostic model for high-risk varices in cirrhosis: a multicenter retrospective and prospective study Wang Yanhu Received Received
  THU-146 Global trends in antimicrobial resistance in chronic liver disease patients with bacteremia: a systematic review and meta-analysis of observational studies Ellis Paintsil Received Received
  WED-146 HCC detection using LI-RADS ultrasound surveillance algorithms: a comparative analysis of v2024 and v2017 Subin Heo Received Received
  TOP-148 Microwave ablation versus single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized control trial SHUNSUKE NAKAMURA Received Received
  THU-149 Sex-specific estradiol signaling in liver cirrhosis and portal hypertension Fabian Schachteli Received Received
  SAT-149 Hospital acquired infection is associated with higher mortality in patients hospitalised with acute decompensation of liver cirrhosis and infection Gemma Wells Received Received
  WED-149 Machine learning-based decision tree model for predicting survival in patients with single-large hepatocellular carcinoma Yi-Chen Lin Received Received
  FRI-149 Serum levels of immune checkpoints in drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease Juan Pedro Toro Ortiz Received Received
  SAT-150 Highly variable antibiotic prescribing practices in a real world cohort of patients in the United Kingdom with decompensated cirrhosis Gemma Wells Received Received
  FRI-150 Dynamic transition of hepatocyte subtypes highlights novel repair pathways in acute liver failure after hBMSC transplantation Jun Li Received Received
  THU-150 Comparative analysis of surrogate markers of intestinal permeability, bacterial translocation, and gut vascular barrier damage across different stages of cirrhosis Frederic Haedge Received Received
  WED-150 Cost-effectiveness of ultrasound plus alpha-fetoprotein and biomarker-based strategies for hepatocellular carcinoma surveillance in patients with chronic hepatitis B Tanat Saeoui Received Received
  WED-151 Development and external validation of a weakly supervised deep learning algorithm for the diagnosis of focal liver lesions on contrast-enhanced ultrasound Tobias Seraphin Received Received
  SAT-151 Mortality in patients hospitalised with decompensated cirrhosis and infection is associated with higher baseline measures of infection and organ dysfunction Gemma Wells Received Received
  THU-151 Aberrant monocyte function promotes systemic inflammation in decompensated advanced chronic liver disease and can be therapeutically targeted Malgorzata Grzelka Received Received
  FRI-151 Drug-induced liver injury in biopsy-scaled precision-cut liver slices Milan Lobo Received Received
  THU-152 CLM-022, a dual inhibitor of priming and activation steps of NLRP3 inflammasome, as a potential treatment for acute and chronic inflammatory late-stage liver diseases guillaume vidal Received Received
  FRI-152 Validation of markers of hepatocyte senescence for the prognosis of patients with severe acute hepatitis MohammadMahdi Saeidinejad Received Received
  SAT-152 Optimising management of patients discharged from hospital following an acute decompensation of cirrhosis – a multicentre UK perspective Giovanna McGinty Received Received
  WED-152 An arti?cial intelligence-based risk prediction model for early-onset hepatocellular carcinoma Won Kim Received Received
  WED-153 A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care Diane Langenbacher Received Received
  FRI-153 Prognostic significance of very high and towering peak alanine aminotransferase (ALT) values with normal or near normal total bilirubin in patients with idiosyncratic drug-induced liver injury Naga Chalasani Received Received
  THU-153 Immunometabolism of mononuclear cells from blood and ascites in patients with decompensated cirrhosis: compartment-specific features of metabolic dysfunction Hasan Tarik Cosgun Received Received
  SAT-153 COVID-19 pandemic significantly increased anxiety and depression in patients with cirrhosis, but not in patients without liver disease Greta Priebe Received Received
  WED-154 Artificial intelligence foundation models for histological diagnosis of hepatocellular carcinoma based on 121,344 digitalized whole slide image patches Yan Miao Received Received
  FRI-154 Gadoxetate-enhanced MRI detects acute rifampicin-induced inhibition of hepatocellular transporter function in rats and normalization of function after chronic dosing Paul Hockings Received Received
  SAT-154 A metagenomics approach to frailty in patients with cirrhosis undergoing a multifactorial intervention German Soriano Received Received
  THU-154 Downregulation of interleukine-6 receptors on ascitic T cells may shape the immune compartment in the peritoneal cavity Helena Stadler Received Received
  FRI-155 The PPAR agonists Saroglitazar and Rosiglitazone provide hepatoprotection after APAP-induced liver injury in E2f1-/- mice Paul Gómez Received Received
  THU-155 Cyclooxygenase-2 promote hepatic microvascular thrombosis and portal hypertension via AKT/mTOR-Thbs1 pathway in partial inferior vena cava ligation mice Jisen Xu Received Received
  WED-155 Validation of hepatocellular carcinoma risk scoring tools in patients with chronic hepatitis B virus and hepatitis C virus infection– results from a large multicentre cohort study Yun Jung Kim Received Received
  FRI-156 Coordinated liver tissue regeneration becomes ineffective with increasing injury in patients with acute indeterminate liver failure Richard Sittner Received Received
  SAT-156 Role of renal biomarkers on sarcopenia and frailty in patients with cirrhosis Won Sohn Received Received
  THU-156 An antimicrobial peptide, melittin attenuates gut urease activity and ammonia production in experimental model of cirrhosis DEEPIKA JAKHAR Received Received
  WED-156 Evaluation of elevated tumor markers in the absence of detectable hepatocellular carcinoma during post-curative ablation follow-up Makoto Moriyama Received Received
  FRI-157 Longitudinal assessment of liver stiffness for up to 96 weeks by magnetic resonance elastography and correlation with fibrosis markers in alpha-1 antitrypsin deficiency-associated liver disease: results from phase 2 studies of fazirsiran Zehrah Nanji Received Received
  WED-157 A prospective multicenter study for comparison of standard-dose repeated bolus injection vs. low-dose continuous intravenous infusion of terlipressin for acute esophageal variceal bleeding in patients with liver cirrhosis Hyung Joon Yim Received Received
  SAT-157 Identification of sarcopenia in patients with liver cirrhosis by combining anthropometry and ultrasound of thigh and psoas Isabel Campos Varela Received Received
  THU-157 Novel potential metabolomic mechanisms for albumin-related improvement in cognitive function in patients with patients with hepatic encephalopathy Jasmohan Bajaj Received Received
  WED-158 A metabolomic model based on portal venous functional metabolites for predicting post-TIPS overt hepatic encephalopathy using machine learning methods Xiaoze Wang Received Received
  SAT-158 Factors predicting response to long-term albumin administration and impact on survival in patients with decompensated cirrhosis. A single-centre real-world experience Isabel Payeras Received Received
  SAT-159 Increasing ´Liver Frailty Index´ scores are associated with increased mortality and unplanned hospital admission in patients with cirrhosis: a retrospective cohort study Isobel Phillips Received Received
  FRI-159 Adrenomedullin as an immunomodulator of CD14+MerTK+ circulating monocytes in liver failure syndromes Francesca Maria Trovato Received Received
  WED-159 The role of hepatic venous pressure gradient in patients with porto-sinusoidal vascular disease Xiaofeng Zhang Received Received
  THU-159 Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre european cohorts Kohilan Gananandan Received Received
  WED-160 Long-term outcome of interventional radiological management of Budd-Chiari syndrome: a retrospective, multicenter survey of 10 years Guohong Han Received Received
  THU-160 Characterization of the muscle-liver axis in a murine model of liver injury Karen Rischmüller Received Received
  SAT-160 Phase angle as a predictive factor for mortality in hospitalized patients with cirrhosis Javier Fajardo Received Received
  THU-161 Proximity extension assay-based proteomics: a reliable tool for prediction of major adverse liver outcomes Katharina Remih Received Received
  FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure Yang Zhi Received Received
  SAT-161 Prevalence and prognosis of cirrhotic cardiomyopathy in hospitalized patients with decompensated cirrhosis cristina Solé Received Received
  SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition Jeanette Pei Xuan Ng Received Received
  THU-162 Profiling of intestinal blood vessel-associated macrophages in cirrhosis Lena Smets Received Received
  SAT-163 Factors associated with AKI development and external validation of the AKI prediction score Jeanette Pei Xuan Ng Received Received
  THU-163 Attenuation of inflammatory bystander CD8+ T cell activation in decompensated cirrhosis via non-selective beta-blockers Christian Niehaus Received Received
  FRI-163 Human cytomegalovirus reactivation in cirrhotic individuals with acute decompensation Changze Hong Received Received
  WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results Jia jia He Received Received
  THU-164 Mitochondrial transfer from mesenchymal stem cells to hematopoietic stem cells mitigates bone marrow failure and promotes liver regeneration in pre-clinical model of cirrhosis Manisha Bhardwaj Received Received
  SAT-164 Periodontal diseases in cirrhosis: prevalence, microbiome profile and dental assessment safety and tolerability Ji Jade King Received Received
  FRI-164 Efficacy of Granulocyte Colony-stimulating factor in hepatitis B virus-associated acute-on-chronic liver failure patients: a multicenter study Jinhua Hu Received Received
  FRI-165 Prevalence and characteristics of bacterial and fungal infections in end-stage liver disease: a multi-center, cross-sectional study from central China Wei Liu Received Received
  THU-165 Spleen Area affects the predictive performance of the platelet count-based non-invasive tools in MASLD Carmine Napolitano Received Received
  SAT-165 Oral health and microbiome: do they influence cirrhosis outcomes? A comparison of cirrhotic patients with periodontitis versus those with good oral health Ji Jade King Received Received
  WED-165 Baveno VII algorithm was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis Haiyu Wang Received Received
  SAT-166 Use of light-EEG to rule out covert hepatic encephalopathy in advanced chronic liver disease Juliana Goediker Received Received
  THU-166 NTZ alleviates stress-induced hepatocyte cell death through modulation of oxidative stress and DNA damage signaling pathways in ACLF models Marie Gerard Received Received
  FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decompensations in alcohol-related end-stage liver disease Cyriac Philips Received Received
  WED-166 Prophylactic antibiotics cannot prevent infection in patients undergoing trans jugular intrahepatic portosystemic shunt or plug assisted retrograde transvenous obliteration electively for portal hypertension complications- a double-blind pilot randomized Aashika Bhashyakarla Received Received
  FRI-167 AI-AD score: a novel machine learning-based model for predicting acute liver decompensation progression – a prospective observational study Dalbeni Andrea Received Received
  WED-167 The efficacy of HCP407 in reducing dysphagia and chest pain following esophageal variceal ligation in patients with cirrhosis. Preliminary results of a prospective randomized study Alejandro Fernandez-Simon Received Received
  THU-167 Recombinant ADAMTS13 attenuates LPS-induced acute kidney injury and renal microangiopathy in mice with liver cirrhosis by cleaving vWF Hiroyuki Masuda Received Received
  SAT-167 Obesity decreases liver-related death in patients with cirrhosis: a retrospective, propensity score-matched study Kei Endo Received Received
  TOP-168 Endoscopic ultrasound-guided portal pressure gradient predicts hepatic decompensation in compensated cirrhosis Michael Yu Received Received
  TOP-169 Impact of physical exercise and protein-enriched nutritional support on the development of post-TIPS hepatic encephalopathy Anna Baiges Received Received
  SAT-170 Variables associated with postoperative mortality in advanced chronic liver disease patients undergoing urgent or elective surgery. a multicentre spanish cohort Lidia Canillas Alavés Received Received
  THU-170 HBV-specific metabolic footprints and impact on mortality in patients with HBV reactivation and acute-on-chronic liver failure Mirco Glitscher Received Received
  FRI-170 Acute-on-chronic liver failure in Australia: a non-transplant centre experience Annie Zhou Received Received
  WED-170 Descriptive study of the impact of using non-cardioselective beta-blockers in cirrhotic patients after a first episode of ascites Alejandro Fernandez Soro Received Received
  WED-171 Safety of seladelpar in primary biliary cholangitis patients with cirrhosis and clinical signs of portal hypertension: data from the ENHANCE and RESPONSE studies Sefa Basci Received Received
  SAT-171 The novel classification as acute vs. non-acute decompensation provides prognostic value in cirrhosis patients developing ascites Lucie Simonis Received Received
  THU-171 Statins as an alternative therapy to improve the cardiac chronotropic dysfunction in cirrhotic cardiomyopathy in cirrhotic rats Muhammad Shafique Received Received
  FRI-171 Oral anticoagulants are safe and may reduce risk of hepatic decompensation in patients with cirrhosis and atrial fibrillation Axel Wester Received Received
  FRI-172 Intraperitoneal administration of VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosis Berenice Alard Received Received
  SAT-172 Branched-chain amino acids in liver cirrhosis and hepatic encephalopathy: a meta-analysis of clinical evidence Luise Aamann Received Received
  WED-172 Outcomes following transjugular intrahepatic portosystemic shunt in patients with hepatorenal syndrome and acute-on-chronic liver failure ANAND KULKARNI Received Received
  THU-172 A disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 and von Willebrand factor axis regulates acute kidney injury in mice with liver cirrhosis Norihisa Nishimura Received Received
  WED-173 Machine and deep learning for non-invasive detection of esophageal varices in hepatocellular carcinoma patients Asier Rabasco Meneghetti Received Received
  THU-173 A biliary organoid model to investigate the malignant transformation of primary sclerosing cholangitis to cholangiocarcinoma Noah Sendtner Received Received
  FRI-173 Severe liver disease patients had dysfunctional platelets hypoergic to adenosine diphosphate Xiuhua Jiang Received Received
  SAT-173 History of overt hepatic encephalopathy is associated with worsen cognitive tests and cerebral atrophy in a prospective cohort of outpatients with cirrhosis with multimodal evaluation and brain magnetic resonance imaging with diffusion tensor imaging Lyčs Kheloufi Received Received
  SAT-174 The impact of anticoagulant therapy on safety of variceal ligation in cirrhotic patients: a systematic review and meta-analysis Madeleine Corkery-Hayward Received Received
  WED-174 Utility of spleen elastography in predicting transjugular intrahepatic porto-systemic shunt dysfunction in patients with liver cirrhosis Asunción Ojeda Gómez Received Received
  THU-174 Activated intestinal fibroblasts induce inflammatory Th17 differentiation in experimental cirrhosis Oriol Juanola Received Received
  THU-175 Characterising renal dysfunction in chronic liver disease rodent models Olivia Greenham Received Received
  WED-175 Anemia following portal hypertension-related bleeding in liver cirrhosis: incidence and impact on prognosis Asunción Ojeda Received Received
  FRI-175 Loss of hepatic leptin clearance is associated with development of acute-on-chronic liver failure Frederike Krus Received Received
  SAT-175 Natural history of overt hepatic encephalopathy defining factors associated with progression, resolution and mortality Maria Pilar Ballester Received Received
  FRI-176 Elevated lipase levels during acute-on-chronic liver failure are linked to increased mortality Georg Kramer Received Received
  WED-176 Role of splenic stiffness in predicting outcomes in decompensated cirrhosis: an ambispective cohort study Ayush Agarwal Received Received
  SAT-176 Minimal serum creatinine fluctuations impact on prognosis in acutely decompensated cirrhosis Marco Tizzani Received Received
  THU-176 Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension Peio Aristu Received Received
  SAT-177 Specialist palliative care is under-utilized at end of life in chronic liver disease, especially in patients without liver cancer Maria Valjus Received Received
  THU-177 Albumin as a therapeutic target for endothelial dysfunction in patients with decompensated cirrhosis Susan Fischer Received Received
  FRI-177 HDL-C, Cholesterol and the ALT/HDL-C ratio are predictors of survival in patients with acute-on-chronic liver failure Georg Kramer Received Received
  WED-177 Cirrhotic cardiomyopathy in patients underwent transjugular intrahepatic portosystemic shunt (TIPS): clinical impact of the updated diagnostic criteria for diastolic dysfunction CHIARA BECCHETTI Received Received
  THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis Sachiyo Yoshio Received Received
  SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study Markus Maagaard Received Received
  WED-178 Dynamics in hepatic venous pressure gradient (HVPG) during the course of recompensated alcohol-related cirrhosis Benedikt Hofer Received Received
  FRI-178 Development of an AI-driven predictive model and decision support system for managing acute-on-chronic liver failure: insights from the KACLiF cohort Hyung Joon Yim Received Received
  THU-179 Comparison of hepatocellular carcinoma risk scores in people with cirrhosis: concordance analysis of four prediction tools Sude Yarar Received Received
  SAT-179 The prognostic role of LiverRisk score in patients with compensated cirrhosis Marta Tonon Received Received
  FRI-179 Integrated analyses of cytokine and metabolomics profiles uncover pathways regulating acute-on-chronic liver failure induced mortality Hai Li Received Received
  WED-179 CT-based imaging indices predict hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients Xinyu Chen Received Received
  FRI-180 Establishment of a sarcopenia decline curve for patients with liver cirrhosis to develop hepatic rehabilitation medicine Hiroteru Kamimura Received Received
  WED-180 Rate of recurrent gastrointestinal bleeding and outcomes in patients undergoing balloon-occluded retrograde obliteration (BRTO) versus transjugular intrahepatic portosystemic shunt (TIPS) for gastric variceal bleeding Cristina Angelo Received Received
  SAT-180 Determinants of muscle mass in patients with liver cirrhosis Martin Philipp Received Received
  THU-180 Toll-like receptor 4 inhibition restores cytochrome C oxidase mitigating hyperammonemia-induced hepatocyte mitochondrial dysfunction Supachaya Sriphoosanaphan Received Received
  FRI-181 Plasma interleukin-33 as a novel diagnostic marker for invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure: a prospective study Lanyue Huang Received Received
  WED-181 Role of spleen stiffness measurement by vibration-controlled transient elastography at 100Hz in guiding invasive hemodynamic reassessments after underdilated TIPS Dario Saltini Received Received
  SAT-181 Attitudes towards exercise among patients with advanced chronic liver disease: a survey Matthew McKenna-Barry Received Received
  THU-181 Plasma-induced neutrophil dysfunction is a novel approach to identification of acutely decompensated cirrhosis patients at risk of infection Supachaya Sriphoosanaphan Received Received
  FRI-182 Prediction of circulatory failure in patients with liver cirrhosis and acute-on-chronic liver failure on the intensive care unit Hendrik Matthias Rogge Received Received
  WED-182 Predicting post-TIPS hepatic encephalopathy risk in patients with cirrhosis and refractory ascites: a proof-of-concept study using a 4D MRI perfusional model Dario Saltini Received Received
  THU-182 Transcriptomic and metabolic insights into hyperammonemia: the complementary therapeutic roles of toll-like receptor 4 inhibitor and ornithine phenylacetate Supachaya Sriphoosanaphan Received Received
  SAT-182 Transjugular intrahepatic portosystemic shunt implantation is associated with resolution of hepatopulmonary syndrome Jim Benjamin Mauz Received Received
  WED-183 Cardiopulmonary hemodynamics and liver stiffness changes in predicting cardiac decompensation after TIPS: a prospective study Dario Saltini Received Received
  FRI-183 Supporting unified management for patients with prior or first decompensation: evidence from three ACLF criteria Meiqian Hu Received Received
  THU-183 Mesenchymal stem cells restore gut-liver axis integrity by targeting intestinal barrier dysfunction and MLN inflammation in cirrhotic mice Sandeep Kumar Received Received
  SAT-183 The association between familial mediterranean fever and incidence liver cirrhosis: a population based matched cohort study Michal Carmiel-Haggai Received Received
  THU-184 Synergy between ornithine phenylacetate and strategies targeting endotoxemia with either a toll-like receptor 4 antagonist (TAK-242) or Yaq-001 for the treatment of hyperammonemia in cirrhosis and ACLF Tingting Qi Received Received
  FRI-184 Multidrug-resistant organism colonization and outcomes in critically Ill patients with cirrhosis: evidence from a tertiary care center Iva Kouta Received Received
  SAT-184 Impact of diabetes mellitus on clinical outcomes in patients with acutely decompensated cirrhosis Mimma Bonomo Received Received
  THU-185 Neuropathological basis of brain failure in acute-on-chronic liver failure (ACLF): insights into the roles of hyperammonaemia and neuroinflammation Tingting Qi Received Received
  WED-185 Exploring point-of-care ultrasound for diagnosis of spontaneous bacterial peritonitis in patients of decompensated cirrhosis - proof of concept study Sunil Taneja Received Received
  SAT-185 Impact of PPIs, PCABs, and Rifaximin on SBP risk in cirrhotic patients with moderate-to-severe ascites Satoshi Miuma Received Received
  FRI-185 Outpatient sbp prophylaxis associates with higher sbp reccurence in a global cohort of cirrhosis inpatients with greatest impact in high- income countries Jasmohan Bajaj Received Received
  THU-186 Endotoxin induced Liver sinusoidal endothelial cell metabolic reprogramming promotes vascular dysfunction and contribute to portal hypertension in experimental cirrhosis Vaibhav Tiwari Received Received
  WED-186 TIPS for hydropic decompensation improves short-term outcome: a case-control study Eduardo Cervantes-Alvarez Received Received
  SAT-186 Comparison of the animal naming test 1 minute versus 2 minutes for the screening of covert hepatic encephalopathy in a prospective cohort of outpatients with cirrhosis Clara Modolo Received Received
  FRI-186 Rifaximin use does not significantly affect the rate of 30-day mortality or liver transplant in patients with cirrhosis on Daptomycin in two national US-based cohorts Jasmohan Bajaj Received Received
  WED-187 Shunt cross-sectional area is a better predictor of overt hepatic encephalopathy than minimal hepatic encephalopathy Elise Humerfelt Received Received
  THU-187 Efficacy of the apoptosis-signal-regulating kinase 1 (ASK1) inhibitor SRT-015 in in vivo and in vitro pathogen-associated molecular patterns (PAMPs)-induced disease models Vanessa Legry Received Received
  SAT-187 Rehabilitation classes for sarcopenic cirrhotics, a proof of concept Mariana Verdelho Machado Received Received
  FRI-187 Long term abdominal drains: a five-year study of safety and efficacy of long-term abdominal drains in a tertiary referral centre Jemma Mickleburgh Received Received
  TOP-188 Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis Benedikt Hofer Received Received
  TOP-189 Vibration-controlled transient elastography of the liver and the spleen for hepatic decompensation risk stratification in a european multicentre study of contemporary cACLD patients Mathias Jachs Received Received
  TOP-190 Biomarkers of pathophysiological mechanisms identify stage-specific divers of disease progression in ACLD Georg Semmler Received Received
  WED-191 De novo decompensation and portal vein thrombosis are both linked to similar pathophysiologic alterations associated with advanced liver disease Erica Villa Received Received
  FRI-191 Modification of mortality risk scores with dynamic serum creatinine definition improves survival discrimination in patients with decompensated cirrhosis Julian Allgeier Received Received
  THU-191 Immunocompetence in outpatients and hospitalized chronic liver disease patients: gene expression profiles and cell-type estimation from stimulated whole blood Xiaomian Tan Received Received
  SAT-191 Regulation and prognostic value of Fibroblast Growth Factor 23 in advanced chronic liver disease Clemens Renhardt Received Received
  FRI-192 Loss of paraspinal skeletal muscle tissue is independently associated with increased 90-, but not 28-day mortality in patients with acute-on-chronic liver failure Julian Pohl Received Received
  WED-192 Real-world outcomes and treatment response to terlipressin in patients with hepatorenal syndrome - acute kidney injury: a multicenter study from the German cirrhosis/Terli-CKD study group Eva Maria Schleicher Received Received
  SAT-192 Identifying potential baseline risk factors for further decompensation in patients with cirrhosis and early decompensation: analysis of data from a phase 2 randomized trial Allyson Wagner Received Received
  FRI-193 A machine-learning algorithm using real-world data identified subpopulations at risk for adverse outcomes in patients with acute-on-chronic liver failure Pierbruno Ricci Received Received
  THU-193 Therapeutic plasma exchange improves outcomes in Amanita phalloides induced acute liver failure – results from an interim analysis of the Amanita-PEX study Alejandro Campos Murguía Received Received
  SAT-193 Economic evaluation of LivR Well, a multidisciplinary, multimodal, home-based program for acute hepatic decompensation: interim analysis Natalie Ngu Received Received
  WED-193 Resolution of portal hypertension by transjugular intrahepatic portosystemic shunt (TIPS) implantation reverses markers of gut-barrier dysfunction, systemic inflammation and anti-inflammatory monocyte alterations in patients with decompensated liver cirrh Felix Piecha Received Received
  WED-194 Treatment response to terlipressin in patients with acute kidney injury - hepatorenal syndrome and preexisting chronic kidney disease – the german liver cirrhosis / CKD-Terli study group Frank Erhard Uschner Received Received
  SAT-194 Transcatheter closure of acquired portosystemic shunts for the management of refractory hepatic encephalopathy. A case-series Natalie Ngu Received Received
  FRI-194 Impact of home-based hepatology nurse-led care on disease knowledge in recently hospitalised patients with cirrhosis Leya Nedumannil Received Received
  FRI-195 Single-cell multimodal analysis reveals cellular dynamics underlying divergent immune response trajectories in HBV-ACLF progression Jun Li Received Received
  WED-195 Frequency and impact of early and sustained hepatic recompensation after TIPS Sophia Geielbrecht Received Received
  THU-195 Haemophagocytic lymphohistiocytosis – a rare but deadly cause of acute liver failure Esme Gardiner Received Received
  SAT-195 Daily step count using pedometer for sarcopenia management in patients with cirrhosis: a randomized controlled trial Witchuta Niamsanit Received Received
  WED-196 Validation of the blood-based Vienna 3P/5P portal hypertension risk models in patients with compensated advanced chronic liver disease Georg Kramer Received Received
  FRI-196 Outperformance of the COSSH diagnostic framework for acute-on-chronic liver failure: a global aetiology cohort Jun Li Received Received
  THU-196 Effects of universal early antimicrobial treatment in acute liver failure patients at a large volume transplant centre in the United Kingdom Gladson Thomas Received Received
  SAT-196 Prognostic performance of MELD and MELD 3.0 in 777 patients hospitalized with an acute decompensation of cirrhosis Nikolaj Torp Received Received
  WED-197 Prognostic performance of the enhanced liver fibrosis (ELF) test in patients with advanced chronic liver disease in tertiary care Georg Kramer Received Received
  SAT-197 Smoking aggravates inflammation, fibrogenesis, angiogenesis and cancer risk in patients with cirrhosis Nina Dominik Received Received
  FRI-197 The AMMON-OHE model predicts liver-related complications in outpatients with cirrhosis: a prospective cohort study of the AMMON consortium María Pilar Ballester Received Received
  FRI-198 Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin Michael Curry Received Received
  THU-198 Combination therapy with plasma exchange and continuous renal replacement therapy improves transplant free outcomes in acute liver failure: a tertiary care center experience Manasa Alla Received Received
  SAT-198 Clinical and hemodynamic factors associated with hemoglobin levels in patients with liver cirrhosis Natalia Jimenez-Esquivel Received Received
  WED-198 Incidence and clinical significance of recompensation after HCV-cure Georg Semmler Received Received
  THU-199 Evaluation of different large language models´ performance in answering common questions from drug-induced liver injury patients Yinuo Dong Received Received
  SAT-199 A systematic review and meta-analysis of the ability of novel biomarkers to differentiate subtype of acute kidney injury and predict response to terlipressin treatment Olivia Greenham Received Received
  WED-199 Advanced chronic liver disease in the context of further decompensation & recompensation – a multistate analysis of a contemporary prospective study Georg Semmler Received Received
  FRI-199 Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-on-chronic liver failure Maike Rebecca Pollmanns Received Received
  WED-200 Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of different aetiologies Giulia Francesca Manfredi Received Received
  THU-200 Checkpoint inhibitor-induced liver injury in patients with advanced skin cancer: a single center experience Sebastiano Archilei Received Received
  FRI-200 Interleukin-22 is a predictor for pre-ACLF and short-term mortality in cirrhosis Nikola Mareljic Received Received
  TOP-201 MeCP2 as epigenetic mechanosensor of liver sinusoidal endothelial cells in cirrhosis Manuel Prampolini Received Received
  TOP-202 Matrix remodeling and versican upregulation in mesenteric lymph nodes modulate bacterial phagocytosis and migration of activated CD4+ T cells, fueling systemic bacterial infections in cirrhosis Pinky Juneja Received Received
  TOP-203 Recombinant insulin-like growth factor-1: a novel therapy for patients with cirrhosis and ACLF Wenting Tan Received Received
  WED-205 A pan-elastographic machine learning model for non-invasive diagnosis of clinically significant portal hypertension Mauro Giuffre Received Received
  FRI-205 Non-acute decompensation of cirrhosis is a clinically and biologically distinct phenotype in cirrhosis NIPUN VERMA Received Received
  THU-205 Increased risk of hepatic steatosis in young adults treated for first-episode psychosis; a retrospective study Tristan Rocheleau Received Received
  SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma Paolo Gallo Received Received
  SAT-206 Hepatic perfusion measured with 15Oxygen-water-Positron emission tomography/computed tomography correlates with severity of cirrhosis Paul Runeson Received Received
  FRI-206 Excess ICU mortality in septic patients with cirrhosis compared to a population without cirrhosis in two contemporary prospective cohorts Natalia Jimenez-Esquivel Received Received
  WED-206 Influence of low-dose acetylsalicylic acid on renal function in patients with liver cirrhosis and ascites Henrik Karbannek Received Received
  FRI-207 A retrospective study of puncture counts and diagnostic accuracy in 119 patients undergoing transjugular liver biopsy Asako Nogami Received Received
  WED-207 Effectiveness of carvedilol plus variceal band ligation compared to carvedilol alone in primary prophylaxis of variceal bleed in cirrhosis with high-risk oesophageal varices JATA SHANKAR KUMAR Received Received
  SAT-207 High mortality of further decompensation of liver cirrhosis: validation study Petra Dinjar Kujundic Received Received
  THU-207 Clinical follow up in patients treated for hepatitis C Arron Jones Received Received
  SAT-208 Elevated serum ammonia is a poor prognostic marker for 1 year liver related outcomes and external validation of AMMON-OHE prediction model in stable outpatient cirrhosis Pooi Ling Loi Received Received
  WED-208 The GEMA score predicts mortality in patients undergoing TIPSS for ascites Jemima Finkel Received Received
  THU-208 Post-treatment outcomes for patients with hepatitis C cirrhosis treated through west London operational delivery network Ashley Brown Received Received
  FRI-208 Pre-existing sarcopenia as the 7th organ failure and one of the leading predictors of 90-day mortality in acute decompensated cirrhosis Yan Ling Ong Received Received
  SAT-209 Randomized, open-label, phase 2a comparator study to assess the pharmacodynamics, safety and pharmacokinetics of oral administration of mnk6106 (l-ornithine phenylacetate) vs. rifaximin in subjects with hepatic cirrhosis and a previous history of hepatic Rajiv Jalan Received Received
  FRI-209 Prevalence of advanced liver fibrosis and accuracy of non-invasive tests in primary, secondary and tertiary care in Austria Paul Thöne Received Received
  THU-209 Impact of hepatitis C eradication with direct-acting antivirals on metabolic and liver-related outcomes in diabetic patients Clelia Asero Received Received
  WED-209 Early need for paracentesis after TIPS is linked to further ascitic decompensation and impaired survival Martin Kabelitz Received Received
  SAT-210 Development and validation of the modified hepatic encephalopathy staging tool (mHEST) for grading of hepatic encephalopathy for accurate assessment and regulated clinical trials Rajiv Jalan Received Received
  WED-210 Growth differentiation factor 11 increases after TIPS insertion, correlates with muscle mass and is an independent predictor of survival Martin Kabelitz Received Received
  THU-210 Evaluation of transient elastography and platelets count for predicting hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to direct-acting antivirals Cristiane Villela-Nogueira Received Received
  FRI-210 Impact of blood cell count derived inflammatory markers on the outcome of critically ill cirrhotic patients Paulo Bittencourt Received Received
  WED-211 Non-invasive evaluation of portal hypertension in patients with advanced chronic liver disease undergoing major abdominal surgery Lidia Canillas Alavés Received Received
  FRI-211 Vasopressin is safe and effective as a second vasopressor in patients with cirrhosis and septic shock: results of the VITEL-C trial. NCT05315557 Rakhi Maiwall Received Received
  THU-211 PRO-Link HCV: automated detection and Re-engagement of hepatitis C patients lost to follow-up. A pilot study in southern Spain Federico Garcia Received Received
  SAT-211 Risk of hepatocellular carcinoma and cirrhosis decompensation in a large retrospective cohort of cirrhotic patients with autoimmune hepatitis Rawi Hazzan Received Received
  SAT-212 Lipopolysaccharide-binding protein indicates risk for infections and liver-related death in patients with compensated and decompensated liver cirrhosis Rhea Veelken Received Received
  THU-212 Overweight, but not alcohol is associated with increased risk for advanced liver disease in patients with chronic hepatitis C infection- results from the german hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  WED-212 Determining the optimal portal pressure gradient after small-diameter TIPS for ascites: a cohort study Guofeng Liu Received Received
  WED-213 Right heart function on hemodynamic alterations and survival outcomes after transjugular intrahepatic portosystemic shunt Yaozu Liu Received Received
  SAT-213 Muscle mass assessed by rectus femoris ultrasound predicts clinical outcomes in cirrhosis: a step beyond the "black-and-white" classification of sarcopenia Roberta Gagliardi Received Received
  THU-213 HCC risk stratification scores: insights from large multi-center national cohort study Imam Waked Received Received
  FRI-213 The presence of chronic kidney disease does not worsen 28- or 90-day survival in cirrhotic patients with acute on chronic liver failure Sakktivel Elangovan Received Received
  SAT-214 Micronutrients supplementation in patients with liver cirrhosis: a single-arm prospective cohort study Yiran Wang Received Received
  WED-214 The safety and efficacy of trans-splenic portal vein recanalization-assisted TIPS for the treatment of portal vein obliteration: a multicenter retrospective study Yaozu Liu Received Received
  FRI-214 Predicting the risk of clinically relevant bleeding in patients with acute-on-chronic liver failure and acute decompensated liver cirrhosis Sanna Norén Received Received
  THU-214 An innovative peer-led, smartphone-based intervention to enhance engagement for patients with untreated hepatitis C Jennifer Plunkett Received Received
  FRI-215 An argument for risk-based case-finding in chronic liver disease Sava Handjiev Received Received
  WED-215 Factors associated with clinical deterioration in patients with ascites that may be preventable by TIPS Lorenz Balcar Received Received
  THU-215 Characterising prevalence and unmet needs in the setting of funded hepatitis C therapy - automated hepatitis screening in australian emergency departments can assist Julia Di Girolamo Received Received
  SAT-215 A retrospective review of reduced dose argatroban in liver impairment Sarah Sawieres Received Received
  THU-216 A step toward eliminating recalls and follow-up testing: first australian implementation of hepatitis C RNA reflexive testing utilising a single blood sample collected in the emergency department setting Julia Di Girolamo Received Received
  FRI-216 Interprofessional therapeutic drug monitoring of Piperacillin/Tazobactam enhances care for patients with acute-on-chronic liver failure in the ICU Stephan Schmid Received Received
  WED-216 Inter-assay/inter-laboratory comparison of von Willebrand Factor antigen as diagnostic and prognostic biomarker in advanced chronic liver disease Lorenz Balcar Received Received
  SAT-216 The most common bacterial isolates in spontaneous bacterial peritonitis in a tertiary hospital center in Croatia and their antibiotic resistance Sanja Stojsavljevic Shapeski Received Received
  TOP-217 Pathophysiological basis of acute on chronic liver failure (ACLF) triggered by alcohol-related hepatitis or infection using circulating biomarkers of inflammation, circulatory dysfunction and albumin modifications Julian Pohl Received Received
  TOP-218 Yaq-001 positively impacts gut microbiome composition, virulence, antimicrobial resistance gene profile resulting in significant effects on ammonia, endotoxemia and inflammation in cirrhosis patients Jinxia Liu Received Received
  TOP-220 Prevalence and clinical impact of rectal colonization by multidrug-resistant (MDR) bacteria in patients with acute decompensation of cirrhosis Nicola Zeni Received Received
  SAT-221 High incidence of diuretic derived complications among patients with refractory ascites undergoing either TIPS implantation or insertion of tunneled peritoneal catheter Sarah Lisa Schütte Received Received
  THU-221 Sex-related differences in patients with chronic hepatitis c virus infection treated with direct-acting antiviral drugs Krystyna Dobrowolska Received Received
  WED-221 Copeptin decrease after TIPS is linked to portal pressure and kidney function Lukas Hartl Received Received
  SAT-222 Liver cirrhosis detection by canine olfaction using randomized controlled blinded testing: a proof-of-concept study suwadee Aramwittayanukul Received Received
  THU-222 Development of a hepatitis C infection integrated care model for prisoners in chinese population Lung Yi Mak Received Received
  WED-223 Colonization with multidrug resistant organisms is associated with poor outcomes in patients with decompensated cirrhosis of liver: a tertiary care center experience Manasa Alla Received Received
  FRI-223 Intermediate-term survival in patients with hepatorenal syndrome-acute kidney injury treated with terlipressin R. Todd Frederick Received Received
  SAT-223 Novel sex-specific cut-offs for subcutaneous adipose tissue radiointensity in patients with cirrhosis: a post-hoc analysis Simone Di Cola Received Received
  THU-223 Implementation of a systematic hepatitis C screening program: insights from a regional approach and its impact on diagnosis and treatment outcomes Madalena Pestana Received Received
  SAT-224 Management of ascites in elderly patients with cirrhosis: results of an italian survey Simone Di Cola Received Received
  THU-224 Hepatocellular carcinoma risk scores and incidence during and after hepatitis C therapy with direct antiviral agents - data from the german hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  WED-224 The AMMON-OHE model predicts post-TIPS overt hepatic encephalopathy Maria Pilar Ballester Received Received
  FRI-224 Time-varying effect of acute-on-chronic liver failure on post-liver transplant survival accounting for selection bias Tomohiro Tanaka Received Received
  THU-225 Systematic screening for HBV, HCV and HIV in hospitalised psychiatric patients: a feasible approach on the road towards elimination of viral hepatitis Marie Coessens Received Received
  SAT-225 Current incidence of decompensating events, HCC and their prognostic impact on patients with compensated advanced chronic liver disease Susana G. Rodrigues Received Received
  WED-225 Risk factors of post-banding ulcer bleeding in patients with cirrhosis at a large tertiary center in Switzerland Maria De Brito Nunes Received Received
  SAT-226 Impact of infections on the natural history of compensated advanced chronic liver disease: data from an individual patient data meta-analysis Susana G. Rodrigues Received Received
  WED-226 Unveiling the economic burden of decompensated cirrhosis: a comprehensive cost analysis Mariana Esteves Received Received
  FRI-226 The burden of extrahepatic organ failures in european patients with cirrhosis Wenyi Gu Received Received
  THU-226 Hepatitis C treatment in arterial hypertension is safe and highly effective: real-world study Micha&322; Brzd&281;k Received Received
  THU-227 Relinking lost to follow up patients with hepatitis C: a modeling approach to assess liver-related outcomes Manuel Mendizabal Received Received
  SAT-227 Cirrhotic cardiomyopathy: Prevalence and clinical impact on liver cirrhosis outcomes Takashi Kitagataya Received Received
  FRI-228 CD300A+CD8+T cells promote functional cure in patients with chronic hepatitis B under PEG-IFN-a Wen-Xin Wang Received Received
  SAT-228 L-ornithine-L-aspertate improves quality of life and ammonia levels but not microbiome dysbiosis in cirrhosis: results of a phase 4 study Vanessa Stadlbauer Received Received
  THU-228 Effectiveness of automatic alerts from microbiology laboratories to liver units for linking to hepatitis C treatment Montserrat Garcia-Retortillo Received Received
  WED-228 Frailty, malnutrition, and sarcopenia are prevalent among patients with liver disease and are associated with worse health-related quality of life and complications of cirrhosis Helma Cotrim Received Received
  WED-229 Prognostic performance of MELD 3.0 in patients undergoing transjugular intrahepatic portosystemic shunt placement - a retrospective multicentre study Markus Kimmann Received Received
  THU-229 Increasing risk of hepatic decompensation in patients with HCV related liver cirrhosis during long-term follow up after sustained virological response (SVR) - data from the german hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  SAT-229 Urinary microbiome alterations in patients with cirrhosis: a link to an increased urinary tract infection risk Vanessa Stadlbauer Received Received
  FRI-230 Naďve C57BL/6 mice immunized with CLB-405 and CLB-505 combined with a saponin-based adjuvant TQL-1055 exhibit a dose-dependent humoral and cellular immune Aditi Deshpande Received Received
  THU-230 Predictors of hepatocellular carcinoma risk after hepatitis C viral clearance - data from the german hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  WED-230 A novel MELD-copeptin score accurately predicts ACLF and liver-related death in patients with decompensated cirrhosis Marlene Hintersteininger Received Received
  SAT-230 Biomarker-based profiling of pathomechanisms across distinct clinical stages of cirrhosis Vlad Taru Received Received
  WED-231 Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study Maria Paola Anolli Received Received
  FRI-231 Inflammatory and oncogenic gene signatures in chronic hepatitis delta infection Arshi Khanam Received Received
  THU-231 Microelimination project for HCV in patients with elevated ALT using pooling PCR technique in a health area. Preliminary results Natalia Marcos Carrasco Received Received
  SAT-231 Improved glycaemic control over time in patients with type 2 diabetes mellitus (T2DM), with and without cirrhosis: a territory-wide cohort study of 1.2 million patients in Hong Kong Mary Yue Wang Received Received
  THU-232 Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir saeed hamid Received Received
  FRI-232 Prolonged exposure to HBV suppresses the immunogenicity and antiviral efficacy of therapeutic vaccination Anna D. Kosinska Received Received
  WED-232 Assessing portal hypertension with endoscopic ultrasound portal pressure gradient (eus-ppg): clinical correlations and procedural outcomes Francesco Martini Received Received
  TOP-233 Sustained improvement in minimal hepatic encephalopathy and quality of life in patients with cirrhosis through two-session fresh fecal microbiota transplantation: An open-label pilot randomized controlled trial (The FLAME trial) Ankit Agarwal Received Received
  TOP-234 An optimized diagnostic strategy for MHE in cirrhotic patients based on PHES normalization and Stroop-CN: a prospective multicenter study Junliang Fu Received Received
  TOP-235 Impact of growth hormone therapy on complications, disease severity, and frailty in decompensated cirrhosis: a randomized controlled trial Parminder Kaur Received Received
  TOP-236 Neurofilament light chains and glial fibrillary acidic protein in serum for predicting post-TIPS hepatic encephalopathy Simon Johannes Gairing Received Received
  WED-237 Development and validation of a novel fibrosis digital pathology biomarker to predict portal pressure in patients with MASH cirrhosis Mathieu Petitjean Received Received
  FRI-237 Sustained off-treatment inhibition of HBV replication and HBsAg levels after long-term treatment with ABI-4334 in differentiated HepaRG cells and primary human hepatocytes Barbara Testoni Received Received
  THU-237 Effectiveness and outcomes of routine opt-out screening for hepatitis C in a UK emergency department Samuel Hey Received Received
  SAT-238 To construct a prediction model of recompensation in HBV-related decompensated cirrhosis patients combined with the inflammation index MLR Tang shanhong Received Received
  WED-238 ANT at discharge can predicts further development of overt hepatic encephalopathy after elective TIPS placement Mélisande Jorus Received Received
  THU-238 Previous hepatitis B virus infection and the risk of liver-related complications in patients after HCV cure - Data on more than 6,000 patients from the german hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  WED-239 Prognostic performance of MELD variants and CLIF-C AD in 958 patients with cirrhosis and ascites Nikolaj Torp Received Received
  FRI-239 Detecting hepatocellular carcinoma by circulating cell-free DNA in patients with chronic hepatitis B Bootsakorn Boonkaew Received Received
  THU-239 Long-term prognosis and changes in liver function after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus Yuki Tahata Received Received
  FRI-240 Hepatitis B surface antigen specific CD4 T cell response in hepatitis B vaccinated individuals Carolin Heni Received Received
  SAT-240 Evaluation of the clinical utility of wearable fitness tracking devices to diagnose frailty in patients with liver cirrhosis – A proof-of-concept study Jonna Friederike Zimmermann Received Received
  WED-240 External validation of prognostic scores for post-TIPS mortality in a contemporary, australian cohort Nirbaanjot Walia Received Received
  FRI-241 Longitudinal analysis of viral profiles in chronic HBV/HDV coinfected patients Teresa Pollicino Received Received
  WED-241 Changes in spleen stiffness as assessed via vibration-controlled transient elastography at 100Hz reflect acute hepatic venous pressure gradient response to i.v. propranolol: a european multicenter study Paul Thöne Received Received
  SAT-241 Over the years, diagnostic problems in cirrhosis continue, but its etiology changes: chronic viral hepatitis is decreasing, steatotic liver disease is increasing Zülal &304;stemihan Received Received
  THU-242 Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184 Andreas Jekle Received Received
  WED-242 The Impact of lactulose on the gut microbiome and barrier function in patients with decompensated cirrhosis Patricia Bloom Received Received
  THU-243 SOLSTICE week 24 subgroup analysis: impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran Alina Jucov Received Received
  FRI-243 VDAC1-mediated lipid droplet-mitochondria tethering promotes tumorigenesis and inhibits HBV replication in CHB patients concurrent with MASLD Zhe Dai Received Received
  SAT-244 Impact of HDV RNA levels on the risk of liver-related outcomes in patients with CHD: a european multicenter validation cohort study Adriana Palom Received Received
  FRI-244 Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies Elena Vargas-Accarino Received Received
  WED-244 Evaluation of the Baveno VII criteria for predicting liver-related events in patients with advanced chronic liver disease – a single centre retrospective study Steven Trinh Received Received
  THU-244 Tissue virological response is the main predictor of hepatitis D relapses Pavel Bogomolov Received Received
  WED-245 Personalized biomarkers scores outperform established scores in the short- and long-term prediction of hepatocellular carcinoma and decompensation Rosina Maria Critelli Received Received
  SAT-245 Treatment duration, adherence and persistence in patients with chronic hepatitis B virus infection treated with long-term nucleos(t)ide analogues in Germany Dipika Morgan Received Received
  THU-245 Safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7565020, a novel monoclonal antibody that targets the hepatitis B surface antigen: results from a phase 1 single ascending dose study in healthy volunteers and participants with chronic hep Edward J. Gane Received Received
  FRI-245 Hepatitis E virus entry requires the cholesterol transporter Niemann–Pick C1 Emely Richter Received Received
  THU-246 Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants Edward J. Gane Received Received
  FRI-246 HBV cccDNA: The molecular reservoir of hepatitis B persistence and challenges in eradication Gulce Sari Received Received
  WED-246 Long-term outcomes of patients with porto-sinusoidal vascular liver disorder. A single-centre 10 year-follow-up study sanchit sharma Received Received
  SAT-246 Long-term perspectives on treating or observing immune-tolerant chronic hepatitis B Mai Kilany Received Received
  WED-247 Targeted nutrition intervention improves frailty and quality of life in patients with liver cirrhosis Saniya Khan Received Received
  THU-247 HBsAg declines, and T cell increases, observed in CHB patients: Interim results from P1b trial of VRON-0200, a novel checkpoint modifier, following prime only, and prime and boost dosing Edward J. Gane Received Received
  FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus Gregory Camus Received Received
  SAT-247 Molecular epidemiology of chronic HDV infection in Italy: HDV genotypes and subgenotypes distribution in the HDV describe study cohort Antonella Olivero Received Received
  FRI-248 Description of tenofovir levels in south african adults in the EVOLVE study: a pilot project to support therapeutic drug monitoring in HBV infection Gloria Sukali Received Received
  THU-248 Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in healthy and chronic hepatitis B subjects Edward Gane Received Received
  WED-248 CT-based clinically significant portal hypertension: predicting complications in HCC hepatectomy Eun Sun Choi Received Received
  SAT-248 End of treatment anti-HBc IgG and HBcrAg predict severe flares after nucleos(t)ide analogue withdrawal in CHB – interim analysis from the multicenter prospective COIN-B trial Arno Furquim dAlmeida Received Received
  TOP-249 Signaling interaction between TGF-ß and EGF controls LPC proliferation and performing liver function in ALF Chenhao Tong Received Received
  TOP-250 Polyreactive immunoglobulin G is elevated in autoimmune hepatitis and acute liver failure Theresa Kirchner Received Received
  TOP-251 Efficacy and safety of Bemnifosbuvir and Ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection Alina Jucov Received Received
  TOP-252 HBsAg decline and clearance with peg-IFN add-on therapy – an individual participant data meta-analysis of prospective trials (PROSPER) Edo J. Dongelmans Received Received
  SAT-253 DM type 2 is a significant risk factor for HCC and decompensation of liver disease in HBV s Ag positive patients Assaf Issachar Received Received
  FRI-253 Large spatial variation of intrahepatic HDV RNA levels without association with HBV core or S RNA levels in patients with HDV induced cirrhosis Gustaf Rydell Received Received
  THU-253 IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance Emily P. Thi Received Received
  WED-254 Deeplearning allows prediction of portal hypertension from liver biopsies Thomas Sorz-Nechay Received Received
  SAT-254 Healthcare resource utilisation and costs associated with hepatitis delta virus infection compared with hepatitis B virus monoinfection prior to death among adults in Spain Marvin Rock Received Received
  THU-254 First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models Emily P. Thi Received Received
  FRI-254 Early immune responses define Peg-IFNa-mediated treatment outcome in chronic hepatitis D virus infection Manfred Anim Received Received
  SAT-255 Performance evaluation of the Elecsys anti-HBc II quant assay Christian Voitenleitner Received Received
  THU-255 The safety and efficacy of PD-1 antibody combined with pegylated interferon-a therapy to promote the clinical cure in nucleoside (acid) analogues-suppressed chronic hepatitis B patients Junliang Fu Received Received
  FRI-255 Discordance between peripheral hepatitis B surface antigen (HBsAg) titres and hepatic expression in chronic HBV infection James Lok Received Received
  WED-255 Three-dimensional computed tomography angiography-based computational fluid dynamics simulation for noninvasive assessment of portal hypertension in patients with cirrhosis Yang Tai Received Received
  FRI-256 Circulating miRNAs are downregulated in hepatitis delta patients that control viral replication Javier Pérez Garreta Received Received
  THU-256 The safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for up to 96 Weeks in untreated HBeAg-positive subjects with chronic hepatitis B virus infection Jinlin Hou Received Received
  WED-256 Multiparametric ultrasound for the prediction of the outcomes of endoscopic ligation of esophageal varices Valentin Calvez Received Received
  SAT-256 Role of HBV RNA in predicting nucleos(t)ide analogues initiation and risk of relapse after cessation Chen-Ta Chi Received Received
  FRI-257 Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates Jin Hong Received Received
  THU-257 Genetic prediction of causality of immune cell-mediated plasma metabolites and acute hepatitis B: a Mendelian randomization study Size Li Received Received
  SAT-257 The correlation of P62 expression in predicting outcomes of HBV-related HCC after surgical resection Chien-Wei Su Received Received
  WED-257 Long-term albumin treatment improves outcomes in patients with cirrhosis and ascites Valeria Santori Received Received
  SAT-258 Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retro-prospective observational study Jun Chen Received Received
  FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes Jill Werner Received Received
  WED-258 TIPS for portal hypertensive gastropathy bleeding reduces further decompensation and mortality Zeyu Wang Received Received
  THU-258 Patient characteristics and treatment patterns amongst hepatitis D patients: results from a real-world survey in Europe Megan Rudolph Received Received
  WED-259 Limited value of liver frailty index to predict symptom control after insertion of a transjugular intrahepatic portosystemic shunt Jonna Friederike Zimmermann Received Received
  THU-259 Up to 18 months´ functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: B-Sure third report Alexandra Walker Received Received
  FRI-259 Phenotypic characterization of untreated chronic hepatitis B infected individuals in an ethiopian cohort using fixed whole blood samples Julia MacLeod Received Received
  SAT-259 Long-term outcomes of ´Grey Zone´ (GZ) individuals living with HBeAg-negative chronic hepatitis B in a tertiary UK centre Evangelos Chalatsis Received Received
  FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy Laura Partington Received Received
  WED-260 Plasma exchange to treat hepatitis A related acute liver failure – a retrospective multicentre cohort study Asisha Janeela.M Received Received
  THU-260 IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therap Karen Sims Received Received
  SAT-260 Autoimmunity in chronic hepatitis D: results from the HDV describe study cohort Eleonora Dileo Received Received
  FRI-261 Persistent immune defects in innate-like CD8 T cells despite antiviral therapy in chronic hepatitis B Loey Mak Received Received
  SAT-261 Field evaluation of a novel hepatitis B core-related antigen rapid test (HBcrAg-RDT) for the identification of highly viremic pregnant women, the Gambia: preliminary results from a prospective diagnostic accuracy study Erwan Vo Quang Received Received
  THU-261 Monotherapy with the novel capsid assembly modulator ALG-000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection Man-Fung Yuen Received Received
  FRI-262 Isogenic studies of basal-core promoter and precore mutations in hepatitis B genotype c Leon Louis Seifert Received Received
  WED-263 Hepatitis E virus persistence in cerebrospinal fluid: a rare phenomenon observed in immunosuppressed patients beyond 18 months post-viremia clearance under Ribavirin therapy Swetha Chalissery Received Received
  SAT-263 Enhancing hepatitis delta virus detection in Spain with the Delta Double Reflex (DDR) study Federico Garcia Received Received
  FRI-263 Viral N6-methyladenosine modifications regulate hepatitis E virus infections Mara Klöhn Received Received
  WED-264 Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications Tarik Asselah Received Received
  THU-264 Safety and pharmacokinetics of bepirovirsen, delivered subcutaneously by vial, or prefilled syringe fitted with a safety syringe device in healthy adult participants, and syringe device ease of use: a randomised phase 1 trial Poonam Shah Received Received
  FRI-264 Variability of the hepatitis delta virus and the role of the interferon I in a superinfected mice model Maria Francesca Cortese Received Received
  SAT-264 New strategies to enhance molecular diagnosis of hepatitis Delta Federico Garcia Received Received
  TOP-265 Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D) Elisabetta Degasperi Received Received
  TOP-266 Association between sustained virological response and adverse liver-related outcomes in patients with decompensated HCV cirrhosis Lisa M. van Velsen Received Received
  TOP-267 Refining HCC risk prediction in non-ACLD chronic hepatitis patients after antiviral therapy: insights from a multicenter study Rachel Wen-Juei Jeng Received Received
  TOP-268 Up to 2 years´ functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: B-Sure third report Vanesa Navarro Received Received
  THU-269 Interim results of a phase I/II study to determine the safety, immunogenicity and efficacy of therapeutic hepatitis B virus synthetic long peptide vaccination Sonja Buschow Received Received
  WED-269 The annual incidence of HCV RNA positivity detected by rapid on-site RT PCR doesn´t decrease and remains relatively high over the last 3 years among drug users denis OUZAN Received Received
  SAT-269 Molecular epidemiology of hepatitis delta virus in Spain using whole-genome sequencing Federico Garcia Received Received
  FRI-269 Developing personalised treatment pathways for hepatitis B using novel assays and fine needle liver aspirates Mark Douglas Received Received
  THU-270 HBV genotype association with response to xalnesiran in nucleos(t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study Rémi Kazma Received Received
  FRI-270 T helper 17 cell differentiation and the functional cure of chronic hepatitis B: insights from proteomic analysis and microRNA expression profiling of plasma-derived exosomes Meng Zhao Received Received
  WED-270 A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes Fadi Abu Baker Received Received
  SAT-270 Burden of hepatitis D virus infection in Italy: results from the HDV describe study Gian Paolo Caviglia Received Received
  WED-271 8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension Fiona Marra Received Received
  FRI-271 Immune response patterns in HBeAg (-) chronic hepatitis B patients during NA treatment depends on the viral activity at baseline Miriam Frisch Received Received
  SAT-271 Impact of drugs for hepatocellular carcinoma development in chronic hepatitis B patients who treated with entecavir and tenofovir disoproxil as initial therapy: population-based study Hyung Joon Yim Received Received
  THU-271 Evolution of the United Kingdom´s national immunoglobulin G4-related disease multidisciplinary meeting in guiding diagnosis and management of complex cases Roshni Patel Received Received
  SAT-272 Comparing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in reducing hepatocellular carcinoma risk in chronic hepatitis B: a propensity score matching study Hyung Joon Yim Received Received
  WED-272 Real-world efficacy and safety of universal 8-week Glecaprevir/Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan Michael Huang Received Received
  FRI-273 Experimental HCV infection identifies ribosomal RNA 2´-O-methylation sites also affected across all etiologies and stages of chronic liver diseases Pélagie Huchon Received Received
  THU-273 Evaluation of the association between biomarkers and patient-reported outcomes in patients with primary biliary cholangitis Alan Bonder Received Received
  SAT-273 Characteristics and predictors for elevated alanine transferase in 3,399 treatment-naďve HBV/HDV co-infected patients, with comparison to propensity score-matched mono-HBV infected patients Habiba Kamal Received Received
  WED-273 Exploring a hepatitis C elimination model among ex-drug users in community drug rehabilitation centers insights from Guangdong, China Hong Li Received Received
  THU-274 Efficacy and safety of seladelpar in patients previously treated with fibrates or OCA Jake Wilmot Received Received
  WED-274 Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study Julia Dietz Received Received
  FRI-275 Characterization of antigen specificity of T cell responses and HBV neutralization activity in a cohort of patients who achieved HBV HBsAg loss Andrey Verendeev Received Received
  SAT-275 Likelihood level of a functional HBV-specific CD8 cell response upon discontinuation of eAg(-) chronic hepatitis B treatment correlates with long-term clinical outcome Henar Calvo Sánchez Received Received
  THU-275 Terminology, diagnosis and management of primary biliary cholangitis -autoimmune hepatitis variant syndrome (PBC-AIH): results from an international Delphi consensus process Alessio Gerussi Received Received
  WED-275 Retreatment of HCV in a large metropolis – implications for WHO elimination targets? The London experience Matthew Foxton Received Received
  THU-276 Introduction of an advanced pharmacist clinic leads to improved assessment and treatment of patients with PBC Alison Boyle Received Received
  WED-276 The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe Candido Hernandez Received Received
  SAT-276 Investigation the persistent effects following HBsAg clearance in chronic hepatitis B patients treated with Interferon therapy xiang huiling Received Received
  FRI-276 Early kinetics of HBV and HDV serum and intrahepatic markers during and after liver transplantation: impact of HBIG and baseline HBsAg levels Sara Battistella Received Received
  WED-277 Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s) Thomas Reiberger Received Received
  THU-277 Psychometric evaluation of the pruritus numeric rating scale in patients with primary biliary cholangitis with moderate-to-severe pruritus Andreas Kremer Received Received
  SAT-277 Accurate prediction of long-term hepatitis B surface antigen seroclearance with machine learning: prognostic and management implications Rex Wan-Hin Hui Received Received
  FRI-277 CD16+ ?d T cells are associated with antibody-dependent cellular cytotoxicity and viral control in chronic HBV infection Paulina Schröter Received Received
  FRI-278 Ubiquitinated hepatitis D antigen induced specific cytotoxic T lymphocyte responses inhibited HDV replication via JAK/STAT pathway in HDV infected liver organoids leer shen Received Received
  WED-278 Pharmacokinetics of bemnifosbuvir in participants with hepatic impairment Xiao-Jian Zhou Received Received
  SAT-278 A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients Ivana Carey Received Received
  THU-278 Clinical diagnostics of autoimmune hepatitis enabled by mass spectrometry-based proteomics Anne-Sofie Houlberg Jensen Received Received
  WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide Xiao-Jian Zhou Received Received
  FRI-279 Adaptive NK cells are expanded in CMV-positive patients with chronic hepatitis B or hepatitis D and remain elevated after initiation of antiviral treatment Smaranda Gliga Received Received
  SAT-279 Infants with chronic hepatitis B can achieve functional cure through a definite duration of antiviral treatment Jing Li Received Received
  THU-279 One-year efficacy and safety of tacrolimus in chronic autoimmune hepatitis Alessio Gerussi Received Received
  WED-280 Pharmacokinetics of bemnifosbuvir in participants with renal impairment Xiao-Jian Zhou Received Received
  FRI-280 Hepatitis delta virus infection hotspots in Ethiopia: a multicenter study Teklu Shiferaw Simbo Received Received
  THU-280 Efficacy, safety and long-term clinical outcomes of a low-dose versus high-dose prednisolone induction in autoimmune hepatitis: a propensity score matched analysis Arnav Aggarwal Received Received
  TOP-281 The impact of HBV genotypic diversity and temporal variations on hepatocellular carcinoma risk in chronic HBV infected patients Ding-Lian Wang Received Received
  TOP-282 Clinicial ulility of novel HBV serological marker HBcrAg and immunological markers in the second trimester of pregnancy for predicting post-delivery ALT flares Ivana Carey Received Received
  TOP-283 Transition of immune tolerant to immune active chronic hepatitis B and potential implications for monitoring and treatment Lisa M. van Velsen Received Received
  TOP-284 Accelerated HBsAg reduction rate and increased proportion of HBsAg <100 IU/mL through repeated finite Nuc therapy in HBeAg-negative chronic hepatitis B patients Rachel Wen-Juei Jeng Received Received
  THU-285 Prognostic factors in autoimmune hepatitis: a french multicenter study Anna SESSA Received Received
  FRI-285 A novel quintuplex long-amplicon droplet digital PCR assay reveals greater quantities of hepatitis B virus splice variants in people with HBV/HIV co-infection compared to HBV mono-infection Tanner Grudda Received Received
  WED-285 Real-world evidence shows comparable Bulevirtide effectiveness in hepatitis D patients with and without cirrhosis: results from the prospective nationwide D-Shield multicenter study Maria Paola Anolli Received Received
  SAT-285 Performance of the PAGE-B score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients with metabolic dysfunction Lesley Patmore Received Received
  THU-286 Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival Shannon Rossi Received Received
  SAT-286 Risk of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with or without hepatitis D virus co-infection Lesley Patmore Received Received
  WED-286 Comparative renal safety of besifovir dipivoxil maleate and tenofovir disoproxil fumarate in chronic hepatitis B patients: insights from a nationwide cohort study sang gyune kim Received Received
  THU-287 Alberta has the highest prevalence of primary biliary cholangitis in North America Bryce Tkachuk Received Received
  FRI-287 Epigenetic viral footprint of chronic HDV infection in HBV co-infected chimeric mice Valerio Taverniti Received Received
  SAT-287 Metabolic comorbidities are risk factors for adverse liver-related events in individuals with HIV-HBV on tenofovir-based antiretroviral therapy Lesley Patmore Received Received
  SAT-288 Predictive performances of PAGED-B and reREACH-B models in non-cirrhotic, treatment-naive patients with chronic hepatitis B Ho Soo Chun Received Received
  THU-288 Prognostic value of liver stiffness dynamics in patients with autoimmune hepatitis Lukas Burghart Received Received
  WED-288 HBV reactivation in HBV/HDV coinfected patients during bulevirtide monotreatment Alexander Killer Received Received
  FRI-288 Synthetic interferon exhibits potent antiviral activity against HBV with the potential for an improved safety profile Wade Blair Received Received
  WED-289 Patient centered-outcomes in HDV-treated patients with Bulevirtide Francesco Paolo Russo Received Received
  SAT-289 Scaling up treatment of chronic hepatitis B in Africa: 1-year results from a simplified public-sector treatment program in Ethiopia Lasse Olsen Rossvoll Received Received
  THU-289 Efficacy of tioguanine and mycophenolate mofetil as second-line immunosuppressive treatment in autoimmune hepatitis management Catherine Tian Received Received
  THU-290 Addressing primary biliary cholangitis symptoms during consultations: an international survey of those who see patients Caz Canavan Received Received
  FRI-290 NTCP intronic polymorphism rs17556915 had no impact on HDV RNA levels and bulevirtide response in patients treated with bulevirtide Coover Robert Received Received
  SAT-290 Staging liver fibrosis using non-invasive tests in people with chronic hepatitis B (CHB) to inform WHO 2024 guidelines: a systematic review and meta-analysis Antonio Liguori Received Received
  WED-290 Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study Eiichi Ogawa Received Received
  THU-291 Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus Cynthia Levy Received Received
  FRI-291 Targeting hepatitis E virus with an innovative CRISPR-Cas13-based therapeutic approach Yannick Brüggemann Received Received
  SAT-291 Characterizing serum HBcAg and phosphorylated HBcAg in the natural history of chronic hepatitis B infection Lung Yi Mak Received Received
  WED-291 Long risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D) Elisabetta Degasperi Received Received
  SAT-292 In HDV sub-genotypes 1, the high degree of genetic variability can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity Lorenzo Piermatteo Received Received
  THU-292 Serum levels of IL-31 and autotaxin are independently associated with pruritus severity in patients with primary sclerosing cholangitis Cynthia Levy Received Received
  WED-292 A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver trasplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta Elisabetta Degasperi Received Received
  SAT-293 High FIB-4 index predicts liver decompensation in chronic hepatitis B patients who develop clinical relapse after antiviral therapy cessation Chun-Hsun Liao Received Received
  FRI-293 Peripheral helper CD4+ T cell functionality distinguishes between acute resolving and chronic hepatitis B Peng Zhang Received Received
  THU-293 Disparities in treatment response and liver decompensation by race and ethnicity in primary biliary cholangitis: results from the ELLA-PBC cohort Lily Dara Received Received
  SAT-294 Should EASL expand its 2017 treatment criteria for chronic hepatitis B virus infection to ineligible people: analysis from a UK-based cohort Monika Prabhaker-Kaushal Received Received
  THU-294 Change in pruritus in patients with primary biliary cholangitis and moderate-to-severe pruritus: a pooled analysis from the Response and Enhance studies Sefa Basci Received Received
  WED-294 Virological response and safety of combination treatment with bulevirtide and pegylated interferon in chronic hepatitis D patients with advanced fibrosis/cirrhosis: 48 weeks interim results from SEE-D trial Soo Aleman Received Received
  FRI-295 Pharmacological modulation of hepatocyte glucocorticoid receptor alpha can toggle enclysis, the deletion of regulatory T cells by hepatocytes Yiyu Fan Received Received
  SAT-295 Functional cure of chronic HBV: natural history, determinants, and outcomes: a real-world experience from a tertiary liver center Mai Kilany Received Received
  WED-296 Impact of long-term tenofovir-based treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B using the reREACH-B score Robert Coover Received Received
  SAT-296 High rates of advanced chronic liver disease in patients with chronic hepatitis D virus infection in Uzbekistan Malika Khodjaeva Received Received
  FRI-296 Bile and plasma metabolome reveals association of TMA-TMAO pathway metabolites with gallstone disease progression Vipin Yadav Received Received
  THU-296 Evaluation of response to Ursodeoxycholic acid (UDCA) in a nationwide population with primary biliary cholangitis Ellen Werner Received Received
  TOP-297 STING activation suppresses viral replication but promotes liver inflammation and fibrosis in chronic hepatitis B concurrent with metabolic dysfunction-associated steatotic liver disease Wenhui Wu Received Received
  TOP-298 Long non-coding RNA SNHG4 is regulated by hepatitis B virus and promotes hepatocarcinogenesis Belal Ahmad Received Received
  TOP-299 HDV infection induces cellular refractoriness to IFN-?, but not IFN-? treatment Claudie EBER Received Received
  WED-300 Impact of long-term oral antiviral treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B who are hepatitis B e antigen positive using the PAGED-B score Megan Rudolph Received Received
  THU-300 Long term efficacy, effectiveness and side effects of third line therapies in autoimmune hepatitis Ilkay Ergenc Received Received
  SAT-300 The effect of antiviral therapy on the outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-) George Papatheodoridis Received Received
  THU-301 Fibrates in primary sclerosing cholangitis: a multicenter retrospective observational study Laura Cristoferi Received Received
  FRI-301 Reactive cholangiocyte-derived orosomucoid-2 (ORM2) drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming Adrien Guillot Received Received
  SAT-301 Prevalence and burden of hepatitis delta virus infection in a large cohort of hepatitis B- infected individuals in the Brazilian Amazon Maria Cassia Mendes-Correa Received Received
  SAT-302 Dynamics of HBsAg isoforms during up to 9 years in treated and untreated HBeAg-negative chronic hepatitis B patients Maria Pfefferkorn Received Received
  FRI-302 MUCIN1 positive biliary epithelial cell heterogeneity contributes to cholestatic liver injury and promotes early liver fibrosis Aishwarya Bhatnagar Received Received
  THU-302 Impact of social determinants of health on outcome of autoimmune liver diseases: insights from the european reference network on hepatological diseases (ERN RARE-LIVER) Franziska Stallbaum Received Received
  THU-303 Prevalence and impact of extrahepatic autoimmune disease in patients with primary biliary cholangitis Gemma Weijsters Received Received
  WED-303 Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. The ARISTOTELE study luca rinaldi Received Received
  SAT-303 Comprehensive analysis of the intrahepatic immune microenvironment and gene expression profiles in a large cohort of patients with untreated hepatitis B virus infection Maria Stella Franzč Received Received
  WED-304 HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D George Papatheodoridis Received Received
  THU-304 Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced primary biliary cholangitis Giulia Francesca Manfredi Received Received
  SAT-304 Insufficient implementation of pretherapeutic hepatitis B and C screening guidelines in academic and general belgian hospitals Marie Coessens Received Received
  FRI-304 Bioinformatic analysis of the spatial transcriptomes of inflamed portal tracts in human primary biliary cholangitis Atsumasa Komori Received Received
  FRI-305 Protectin DX as a novel anti-inflammatory and anti-fibrotic therapeutic candidate for the treatment of autoimmune cholangitis Audrey-Anne Lavoie Received Received
  SAT-305 Qualitative interviews to explore multicultural appropriateness and content validity of the hepatitis B quality of life (HBQOL) among highly impacted populations (chinese and vietnamese) with chronic hepatitis B (CHB) in the US Marvin Rock Received Received
  THU-305 Quantitative morphometric analysis via artificial intelligence-driven image analysis in autoimmune hepatitis: a multi-center study University Milano-Bicocca Received Received
  WED-305 Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071 Maria Paola Anolli Received Received
  SAT-306 Assessment of hepatocarcinogenesis risk using CAMP-B and PAGE-B in patients with chronic hepatitis B Masatsugu Ohara Received Received
  WED-306 The kinetic of HBsAg isoforms predicts response to BLV and pegylated interferon alfa2a in patients with chronic hepatitis delta Maria Pfefferkorn Received Received
  FRI-306 Protectin DX improves the efficiency of low dose obeticholic acid to reduce hepatic bile acids and mitigate inflammation, ER stress and fibrosis in liver cells Audrey-Anne Lavoie Received Received
  THU-306 Efficacy and safety of odevixibat in adult patients with progressive familial intrahepatic cholestasis: results from the 72-week PEDFIC2 phase III, open-label study Jones Louise Received Received
  WED-307 Good flare or bad flare? ALT variability predicts outcome after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B Marte Holmberg Received Received
  THU-307 Analysis of histopathological diagnosis and clinical diagnosis of 1,752 patients undergoing liver biopsy Ai-Rong Hu Received Received
  FRI-307 IL-27 drives activation of tissue-destructive CD8+ T cells and is functionally indispensable in immune checkpoint inhibitor-induced hepatitis Cathrin Gudd Received Received
  SAT-308 Anti-HDV prevalence in HBsAg positive patients and virological characterization of HBV/HDV co-infected individuals at the diagnostic laboratory of the university medical center Hamburg-Eppendorf between 2008 and 2024 Marc Luetgehmann Received Received
  WED-308 Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response Maurizia Brunetto Received Received
  FRI-308 Active transport via bile salt export pump (Bsep/Abcb11) is not required for cholehepatic shunting and choleretic actions of Norucholic acid (NCA/norUDCA) in mice Claudia Fuchs Received Received
  THU-308 Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis Ignasi Olivas Received Received
  SAT-309 Hepatitis B surface antigen loss after nucleot(s)ide analogue cessation in patients living with chronic hepatitis B: a model-based meta-analysis of published studies Dipika Morgan Received Received
  THU-309 Liver steatosis prevalence in primary sclerosing cholangitis Imante Lasyte Received Received
  WED-309 Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study Michael Schwarz Received Received
  WED-310 A mathematical viral load model characterises the exposure-response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologi Parag Kumar Received Received
  SAT-310 Immune profiling of peripheral and intrahepatic B cells in chronic hepatitis B Anna Pocurull Received Received
  FRI-310 Quantitative MRI metrics in the liver and pancreas for disease assessment in IgG4-related sclerosing cholangitis with autoimmune pancreatitis Yameng Deng Received Received
  THU-310 Pruritus is not a clinical feature of early-onset primary sclerosing cholangitis during late teenage years Jeremy Nayagam Received Received
  WED-311 Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta Parag Kumar Received Received
  FRI-311 Restoring gene function in cholangiocyte organoids through lentiviral transduction Enya Amundsen-Isaksen Received Received
  THU-311 Uncovering novel therapeutic targets for autoimmune hepatitis (AIH): detection via omics integration and validation in proof-of-concept clinical trial Jan Philipp Weltzsch Received Received
  SAT-311 Prevention of HBV mother to child transmission using HBV three dose and selective use of HBV BD and treatment of high viral load pregnant women in Uganda Ponsiano Ocama Received Received
  WED-312 Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with moderate hepatic impairment and in matched control participants with normal hepatic function Andrey Verendeev Received Received
  THU-312 Clinical outcomes of primary sclerosing cholangitis associated with inflammatory bowel disease after liver transplantation: a systematic review and meta-analysis Jiangrong Zhou Received Received
  FRI-312 A cfChIP-seq liquid biopsy for the diagnosis of autoimmune hepatitis Eyal Shteyer Received Received
  THU-313 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis Costello Medical Received Received
  WED-313 Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function Andrey Verendeev Received Received
  FRI-313 Epstein-Barr virus is targeted by converging T and B cell responses in primary sclerosing cholangitis Hesham ElAbd Received Received
  SAT-313 Hepatitis B virus screening, antiviral prophylaxis, and reactivation in Rituximab-treated patients: insights from a large retrospective cohort study Rawi Hazzan Received Received
  THU-314 The Mayo-risk model predicts postsurgical transplant-free survival in patients with Primary sclerosing cholangitis Johannes Chang Received Received
  SAT-314 HBV RNA ultra-deep sequencing as a tool for HBV genotyping and resistance monitoring in virologically-suppressed individuals with chronic hepatitis B infection Rémi Kazma Received Received
  WED-314 Hepatocellular carcinoma risk in patients with chronic hepatitis B: Tenofovir Disoproxil Fumarate vs Tenofovir Alafenamide from a korean nationwide study Jiwon Yang Received Received
  FRI-314 Mitochondrial dynamics and auto(mito)phagy are altered in experimental models of primary biliary cholangitis, contributing to disease pathogenesis Irune Lasa-Elosegi Received Received
  FRI-315 ATP8B1 deficiency causes steatosis and PDE4-mediated glucagon resistance in liver Jung-Chin Chang Received Received
  THU-315 Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-life setting Johannes Wiegand Received Received
  WED-315 Atherosclerotic cardiovascular risk in patients with chronic hepatitis B: Tenofovir Disoproxil fumarate vs Tenofovir Alafenamide from a korean nationwide study Jiwon Yang Received Received
  SAT-316 Sustained HBsAg loss in HIV/HBV-coinfected patients is not a rare event under HBV-active ART even if a residual risk of viral reactivation and liver disease progression still persists over time Romina Salpini Received Received
  THU-316 Evidence-based digital support in hepatology: retrieval-augmented generation´s role in autoimmune liver diseases management Ernest Saenz Received Received
  WED-316 Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study Lisa Sandmann Received Received
  WED-317 Exploring predictive factors for treatment response to Bulevirtide in Delta-positive patients Verdiana Zulian Received Received
  FRI-317 Pharmacokinetics, safety, and tolerability of seladelpar in people with renal impairment Jake Wilmot Received Received
  THU-317 The differential, but significant, burden of pruritus, fatigue, and sicca across cholestatic liver diseases Kristel Leung Received Received
  SAT-317 HCC risk in intermediate PAGE-B patients: implications for surveillance strategies Sara Battistella Received Received
  FRI-318 Evaluation of the potential impact of seladelpar on the pharmacokinetics of midazolam, tolbutamide, simvastatin, rosuvastatin, and atorvastatin Ellie Manca Received Received
  THU-318 Epidemiological trends of autoimmune hepatitis in South Korea: a population-based study from 2010 to 2023 Kyung-Ah Kim Received Received
  WED-318 Ethnicity and socioeconomic disparities in diagnostic and hepatic event incidences in patients with chronic viral hepatitis Grace Wong Received Received
  THU-319 Sebepliase alfa improves lipid metabolism and liver outcomes in pediatric patients with lysosomal acid lipase deficiency Barbara MacFee Received Received
  FRI-319 Dnmt1 deletion impairs liver regeneration and stem cell activation during cholestatic liver disease Juliana Marques Affonso Received Received
  SAT-319 High GALAD scores predict hepatocellular carcinoma in hepatitis B-related cirrhosis patients who received antiviral therapy Tung-Hung Su Received Received
  WED-319 Ten-year follow-up after 96?weeks treatment with peginterferon plus tenofovir in hepatitis D (HIDIT-II) Anika Wranke Received Received
  FRI-320 Single-cell profiling reveals increased IGHG2+ memory and activated IGHA1+ intrahepatic B cells in primary sclerosing cholangitis Lisa R. V. Brynjulfsen Received Received
  THU-320 Diagnostic distribution of patients positive for anti-mitochondrial antibodies (subtype), anti-sp100, and anti-gp210: pathological examination is necessary of PBC diagnosis: a retrospective study based on liver biopsy Hongli Liu Received Received
  FRI-321 Identifying transporters of the solute carrier (SLC) group involved in cholangiocyte defense against toxic bile acids Qinghong Li Received Received
  THU-321 Real-world assessment of standard of care trends in primary biliary cholangitis and cholestatic pruritus in Europe Lina Titievsky Received Received
  SAT-321 Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment Shue Xiong Received Received
  SAT-322 Nucleos(t)ide analogue cessation outcomes in non-cirrhotic patients with HBeAg-negative chronic hepatitis B Zeynep Melekoglu Ellik Received Received
  FRI-322 A combined immunotherapy that maintains the balance and stability of intrahepatic regulatory T cells to enhance biliary regeneration Man Chun Wong Received Received
  THU-322 The risk of psychiatric disorders in patients with autoimmune hepatitis: a nationwide registry-based follow-up study Lisbet Groenbaek Received Received
  FRI-323 Redundant yet distinct role of Vacuole membrane protein 1 and transmembrane protein 41B in regulating hepatic lipoprotein secretion and autophagy in metabolic dysfunction-associated steatohepatitis Hongmin Ni Received Received
  WED-323 Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease: long-term efficacy and safety results from a phase 2 extension study Zehrah Nanji Received Received
  SAT-323 Prognostic value of factor VIII, D-Dimer, and high mutation risk variants in re-thrombosis risk stratification for non-cirrhotic splanchnic vein thrombosis Anna Baiges Received Received
  FRI-324 Fgl2-C3aR axis mediated NETs promote intravascular coagulation and liver fibrosis in MASLD progression Xitang Li Received Received
  SAT-324 Understanding treatment efficacies of progressive familial intrahepatic cholestasis via a prospective world-wide registry, TreatFIC Alida D.E. de Groot Received Received
  THU-324 Does steatotic liver disease influence treatment response and clinical outcomes in primary biliary cholangitis? Ellina Lytvyak Received Received
  WED-324 Single-cell sequencing reveals heterogeneity differences in cholangiocyte organoids derived from biliary atresia patients compared to non-biliary atresia controls Adi Har-Zahav Received Received
  WED-325 The omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, improve the response to fibrates in human liver cell models Audrey-Anne Lavoie Received Received
  THU-325 The PSC-DM: development and validation of a clinical diagnostic model to aid the diagnosis of primary vs. secondary sclerosing cholangitis Miki Scaravaglio Received Received
  SAT-325 Quantitative biliary metrics may add to predictive ability of liver stiffness in patients with primary sclerosing cholangitis Aisha Alawi Received Received
  FRI-325 Sorafenib alleviates portal hypertension associated with metabolic dysfunction-associated liver disease by attenuating hepatic sinusoidal capillarization yingjie Ai Received Received
  SAT-326 HLA associations with specific anti-nuclear antibody reactivity in people living with primary biliary cholangitis Aisha Alawi Received Received
  WED-326 A potent tool to study progressive familiar intrahepatic cholestasis: urine – derived human induced – hepatocytes Benedetta Blarasin Received Received
  THU-326 Epidemiological and clinical differences in primary sclerosing cholangitis between men and women in Spain: a multicenter analysis of 697 patients Magdalena Salcedo Received Received
  FRI-326 Spatial transcriptomic analysis of archived primary sclerosing cholangitis livers reveals distinct molecular signatures Sayed Aseem Received Received
  THU-327 Rituximab therapy for autoimmune hepatitis cirrhosis is associated with a high rate of complete biochemical response and improvement in MELD score Riveiro Barciela Mar Received Received
  SAT-327 Advanced phenotyping of hepatic involvement in AL Amyloidosis: the D-Amy-LIPHE study Anna SESSA Received Received
  WED-327 Rare but not forgotten - comprehensive molecular and histological analysis of the primary yolk sac tumor of the liver and corresponding patient-derived cell line Darko Castven Received Received
  FRI-327 Genetic ablation of interleukin 17A augments fibrosis in a mouse model of cholestatic liver injury Takashi Kitagataya Received Received
  THU-328 Utility of splenic stiffness as a predictor for varices needing treatment in autoimmune hepatitis and primary biliary cholangitis Marlene Padilla-Lopez Received Received
  WED-328 Integrated multiomic analysis of hepatoblastoma and patient-derived organoids Darien Yeung Received Received
  FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes Raanan Greenman Received Received
  TOP-330 Prevalence and prognostic impact of sarcopenia in porto-sinusoidal vascular disorder José Ferrusquía-Acosta Received Received
  TOP-331 Standalone medical therapy versus early endovascular intervention as the first step in the management of patients with primary Budd-Chiari syndrome: a randomized controlled trial Sagnik Biswas Received Received
  TOP-332 Automated reflex testing for AAT deficiency in liver dysfunction: is it worth it? Sava Handjiev Received Received
  FRI-333 Exercise protects against semaglutide-induced muscle loss in obese Ldlr-/-.Leiden mice Eveline Gart Received Received
  THU-333 Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor Costello Medical Received Received
  SAT-333 Quality of life of patients living with vascular LIVEr diseaseS: Results of the LIVES european project aurélie plessier Received Received
  WED-333 Recreating Wolman disease in human liver organoids: a new model for pathophisiology and therapeutic exploration Davide Selvestrel Received Received
  SAT-334 Fatigue is common in adults with PBC and PSC: prospective analysis of two cohorts encompassing 1267 patients Beata Kruk Received Received
  WED-334 Prognostic factors and regulatory pathways in porto-sinusoidal vascular disorder: a longitudinal cohort and transcriptomic study Won-Mook Choi Received Received
  FRI-334 Adaptative immune activation as a biomarker of Metabolic dysfunction- associated steatotic liver disease severity Adriana Martínez-Cuazitl Received Received
  THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study Matei Mandea Received Received
  SAT-335 Genetic variant analysis in low phospholipid-associated cholelithiasis patients of the HiChol registry Carola Dröge Received Received
  WED-335 Ex vivo application of chemically derived hepatic progenitors for the treatment of maple syrup urine disease (MSUD) Elsy Soraya Salas Silva Received Received
  FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD Antonio Gil-Gómez Received Received
  THU-335 CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics Raanan Greenman Received Received
  THU-336 Direct nerve fiber recordings reveal functional alterations in cutaneous C-fibers linked to itch severity in cholestatic liver diseases Miriam Düll Received Received
  FRI-336 Genetic variation in GPAM and protection against histologic severity in metabolic dysfunction-associated steatotic liver disease Aaron Hakim Received Received
  SAT-336 Prevalence and characterization of hepatobiliary involvement in cystic fibrosis patients at a referral hospital Jordi Sánchez Received Received
  WED-336 Studying the enterohepatic circulation in progressive familial intrahepatic cholestasis type I Georg-Friedrich Vogel Received Received
  WED-337 Matrix metalloproteinase-7 and osteopontin secretion are specifically upregulated in a novel human precision-cut liver slices model of biliary atresia-associated liver fibrosis Jeske Fridrichs Received Received
  THU-337 Is the POISE really valid as a surrogate endpoint for patients with PBC treated with UDCA and PPAR agonist? – a retrospective validation study from the real-world data in Japan Atsushi Tanaka Received Received
  SAT-337 Liver disease is highly prevalent in patients with hereditary transthyretin-related amyloidosis Carlo Saitta Received Received
  THU-338 Health-related quality of life and well-being of young patients with autoimmune hepatitis during transition of care from paediatric to adult site Maciej Janik Received Received
  FRI-338 Genetic predisposition for hepatic fat accumulation impacts the uptake of fatty acids through fatty acid translocase in a human stem cell-based in vitro model Alexandra Gatzios Received Received
  SAT-338 The role of metabolic factors in alpha-1 antitrypsin deficiency Christina Schrader Received Received
  WED-338 A promising new treatment for Wilson disease: 64Cu-Methanobactin (ARBM-101) pharmacokinetics examined in animal models by whole-body PET Julie Loft Nagel Received Received
  SAT-339 Comparison of pyogenic liver abscess of biliary and non-biliary origin Cheuk Ming Chan Received Received
  THU-339 UK validation of the simple cholestatic complaints score: a patient reported outcomes measure in primary sclerosing cholangitis Nasir Hussain Received Received
  FRI-339 Identifying health-to-disease transitional biomarkers in 3D human organotypic models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) Anabel Martinez Lyons Received Received
  WED-339 Modeling rare genetic cholestasis using human hepatocyte organoids Katarina Balazova Received Received
  FRI-340 Brain dysfunction is ameliorated by alpha 2A adrenergic receptor antagonism in experimental metabolic dysfunction-associated steatotic liver disease through vasodilatory and anti-inflammatory effects Anne Catrine Daugaard Mikkelsen Received Received
  SAT-340 Liver disease and prevalence of liver transplantation in ZZ alpha-1 antitrypsin deficiency – a systematic review and meta-analysis Dimitra Georgantaki Received Received
  THU-340 Validation of the clinical global impression severity scale for primary biliary cholangitis: a clinical trials outcome tool Nasir Hussain Received Received
  WED-340 10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis Kohilan Gananandan Received Received
  FRI-341 miRNA isoforms are differentially expressed with increasing disease activity and fibrosis in metabolic dysfunction-associated steatotic liver disease Arun Sanyal Received Received
  WED-341 Kinetics of copper uptake in liver cells using the novel ligand tracer method Karina Rewitz Received Received
  THU-341 Implementation of a clinical global impression severity scale for primary biliary cirrhosis: results of a hepatologist focussed training programme Nasir Hussain Received Received
  WED-342 Artificial intelligence-driven qFibrosis® in alpha-1-antitrypsin deficiency-associated liver disease: correlation with METAVIR stage and other disease specific features Zehrah Nanji Received Received
  THU-342 Efficacy and safety of odevixibat in patients aged =10 years with Alagille syndrome: results from the 72-week ASSERT-EXT phase III, open-label extension study Nadia Ovchinsky Received Received
  FRI-342 Exploring the repurposing of Telmisartan for the treatment of MASLD: characterization of its antisteatotic mechanism of action Roger Bentanachs Received Received
  THU-343 Combination obeticholic acid (OCA) and fibrate therapy is associated with greater probability of biochemical response than switching from OCA to a fibrate in primary biliary cholangitis Nadir Abbas Received Received
  FRI-343 Anti-steatosis effect of telmisartan in a MASL-dietary rat model does not associates to changes in faecal bile acid metabolome Roger Bentanachs Received Received
  SAT-343 Population pharmacokinetic (PK) model describing the variability of trientine pharmacokinetics in Wilson disease patients in the UNITED study Verena Aliane Received Received
  WED-344 The alpha-1 Pi*MZ genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease Paul Thöne Received Received
  THU-344 Clinical characteristics of a large cohort of primary sclerosing cholangitis patients undergoing liver transplant for primary sclerosing cholangitis and biochemical predictors of recurrence Natcha Cheewasereechon Received Received
  SAT-344 Long-term outcome of sinusoidal obstruction syndrome secondary to hematopoietic stem cell transplantation Edilmar Alvarado-Tapias Received Received
  FRI-344 Sexual dimorphism of Sprague-Dawley rats in the liver inflammatory/fibrotic response to a high in sucrose and fat, choline-deficient, L-amino acid CDAA diet Roger Bentanachs Received Received
  TOP-345 A 10-year review of obstetric admissions to a quaternary liver intensive care unit: learning from morbidity and mortality Charlotte Sewell Received Received
  TOP-346 Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis EIRINI RIGOPOULOU Received Received
  TOP-347 Low vitamin B6 status associates with cholangiocarcinoma in primary sclerosing cholangitis Isma Sohail Received Received
  TOP-348 The association between metabolic comorbidities and clinical outcome in patients with primary biliary cholangitis Ellen Werner Received Received
  THU-349 Risk factors for post-liver transplantation patient and graft survival in autoimmune hepatitis: pioneering insights from a south american cohort Pedro Passos Received Received
  FRI-349 Quantifying the periportal and lobular fat distribution in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with artificial intelligence detection of portal tracts and macrovesicular steatosis Caitlin Langford Received Received
  SAT-349 Liver disease in adults with fontan circulation: a cross-sectional study from a tertiary center in western Sweden Elin Hultgren Received Received
  FRI-350 Effect of high-intensity interval, moderate continuous and voluntary training on body composition, hepatic steatosis and myosteatosis in a preclinical model of metabolic dysfunction-associated steatotic liver disease Camille Lannoy Received Received
  SAT-350 Wilson disease: presentation, clinical course and complications in a large cohort of patients attending San Paolo hospital of Milan Federica Samartin Received Received
  THU-350 Impact of non-classical phenotypes of primary biliary cholangitis on treatment response and long-term prognosis. Results from the ColHai registry Pinelopi Arvaniti Received Received
  WED-350 Missense mutation predominates in moldavian patients with Wilson´s disease Veronica Cumpata Received Received
  SAT-351 Biochemical and immunological markers show limited accuracy in predicting histological remission in paediatric autoimmune hepatitis: results from a multicenter study Eleonora Munaretto Received Received
  WED-351 Correction of the Wilson disease H1069Q point mutation by CRISPR/Cas9-mediated gene editing in induced pluripotent stem cells Viktoria Iwan Received Received
  THU-351 Advancements in autoimmune hepatitis epidemiology, treatment and complication – a 15-year retrospective study Rawi Hazzan Received Received
  WED-352 Human biliary atresia extra-hepatic cholangiocyte organoids: elevated ER and oxidative stress, altered drug metabolism, and modified cell-to-cell junction Yara Hamody Received Received
  SAT-352 Genetic and epidemiological profile of a large brazilian cohort of acute hepatic porphyria Cibele Franz Received Received
  FRI-352 Spatial multiplex analysis reveals distinct senescence patterns and cellular interactions in mouse models of MASLD and MetALD Charalampos Pavlidis Received Received
  THU-353 Comprehensive exploration of disease-specific autoantigen candidates in autoimmune hepatitis through immunocomplexome analysis Satohi Matsuo Received Received
  FRI-353 Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice Feng Chen Received Received
  SAT-353 Management of Wilson disease across europe: an international physician-oriented survey by the ERN-RARE liver group Frederik Kirk Received Received
  SAT-354 Liver and spleen stiffness measure by transient elastograghy: a promising tool for the clinical management of patients after Fontan-type surgery circulation Giovanni Petralli Received Received
  FRI-354 A dynamic human liver acinus-on-a-chip to model health-to-disease (MASLD-MASH) transitions Debbie Neill Received Received
  FRI-355 Single-cell transcriptomics reveals THR-ß agonist treatment increases macrophage proportion and inhibits complement pathway in mice with metabolic dysfunction-associated steatohepatitis Feng Xue Received Received
  SAT-355 The HepQuant DuO test finds linkage between liver blood flow, portal-systemic shunting and cardiac hemodynamics in Fontan-associated liver disease Gregory Everson Received Received
  THU-356 Extra-intestinal autoimmune conditions in patients with primary sclerosing cholangitis – does age matter? Samantha Campbell Received Received
  SAT-356 Porto-sinusoidal vascular disease: epidemiology, clinical features and treatments Hamza Benazzouz Received Received
  FRI-356 Metabolic dysfunction-associated steatohepatitis (MASH) plays central role in western diet-induced cardiac dysfunction Sandireddy Reddemma Received Received
  THU-357 The spectrum of adult cholestatic liver diseases related to ABCB4 gene mutations: genotype-phenotype correlation Sandra Ribeiro Correia Received Received
  SAT-357 Etiological reclassification of cryptogenic cirrhosis after liver transplantation : insights and impact on outcomes HEDI ARAR Received Received
  FRI-357 Liver disease activity measured with quantitative MRI is associated with major liver and cardiovascular events: a prospective cohort study Edward Jackson Received Received
  FRI-358 Anti-inflammatory effects of a chemokine receptor mimicking peptide in obesity-associated MASH and atherosclerosis in Ldlr-/- Leiden mice Eveline Gart Received Received
  SAT-358 Dynamics and prognostic implications of splanchnic volumetry in patients withportosinusoidal vascular liver disorder José Ferrusquía-Acosta Received Received
  THU-358 Epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand, a population-based study Sammy Benson-Pope Received Received
  THU-359 Atherosclerosis in primary biliary cholangitis – more common than previously thought Suzanne Elshafey Received Received
  SAT-359 Counselling young adults with liver disease on alcohol use: a survey of clinical practices across Europe Janne Suykens Received Received
  FRI-359 A 5-week treatment with the GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong reduction in liver steatosis in a diet-induced obese MASH mouse model FRANCOIS BRIAND Received Received
  FRI-360 Sex-based differences in immune response and liver damage in MASLD-associated sepsis: role of neutrophil extracellular traps MONTSERRAT MARI Received Received
  SAT-360 Screening, high risk symptomatology and outcomes of Wilson´s disease in 56,606 new referrals in a large tertiary psychiatric population James Liu Yin Received Received
  TOP-362 Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis and associated colitis Ida Schregel Received Received
  TOP-363 A novel orally bioavailable small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP) prevents HBV infection and ameliorates cholestasis in humanized mice models Stan F.J. van de Graaf Received Received
  TOP-364 Lack of CD1d on biliary epithelial cells protects from cholangitis Kathrine Sivertsen Nordhus Received Received
  WED-365 Does measuring the components of the Fibrosis-4 index (FIB-4) separately on different days affect its diagnostic and prognostic performance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)? Terry Cheuk-Fung Yip Received Received
  THU-365 Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitis Tadashi Namisaki Received Received
  SAT-365 Effectiveness of cystic fibrosis transmembrane conductance regulator modulator triple therapy in patients with advanced cystic fibrosis related liver disease Julian Yeh Received Received
  THU-366 Early assessment of treatment response in primary biliary cholangitis: key to timely management Tomá Koky Received Received
  FRI-366 Integrated analysis of the liver tissue proteome and transcriptome in metabolic dysfunction-associated steatotic liver disease (MASLD) reveals an evolving pathophysiological milieu that may support identification of novel therapeutic targets Georgia Graham Received Received
  SAT-366 Relative exchangeable copper: an accurate biomarker for the diagnosis of Wilson disease Karen Dons Received Received
  WED-366 Enhancing the non-invasive diagnosis of fibrosis in metabolic dysfunction-associated steatotic liver disease: the role of transient elastography and a two-stage machine learning diagnostic model Zhengao Xu Received Received
  THU-367 Prognosis of primary sclerosing cholangitis (PSC) in Hungary is independent of coexisting inflammatory bowel disease (IBD) and prognostic ability of the currently used PSC risk scores are limited David Tornai Received Received
  SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to investigate the efficacy and safety in Wilson disease patients Verena Aliane Received Received
  FRI-367 Pathophysiological mechanisms involved in liver steatosis in metabolic dysfunction-associated steatotohepatitis over time : a bulk RNAseq data analysis Guillaume HENIN Received Received
  WED-367 Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity and type 2 diabetes Alba Jiménez - Masip Received Received
  WED-368 Three proteins in advanced liver fibrosis: a minimalistic shallow-deep neural network approach on metabolic dysfunction–associated steatotic liver disease patients using open data Athanasios Angelakis Received Received
  SAT-368 Outcomes in Navajo neurohepatopathy patients who have undergone liver transplant Katie Cox Received Received
  FRI-368 Harnessing mouse genetic diversity to identify novel genetic determinants of MASLD to MASH transition Giorgia Benegiamo Received Received
  THU-368 Unveiling the cholangiopathy of critical COVID-19: unique imaging patterns on magnetic resonance cholangiography Valéria Borges Received Received
  FRI-369 Lysine-specific demethylase 1 modulates hepatic lipid metabolism in metabolic dysfunction-associated steatotic liver disease HARDIK MAKWANA Received Received
  WED-369 A shallow-deep neural network approach combining non-invasive tests to enhance advanced fibrosis detection in metabolic dysfunction–associated steatotic liver disease patients Athanasios Angelakis Received Received
  SAT-369 Isolated metabolic syndrome is a risk factor for splanchnic venous thrombosis and recurrence of vascular event Hélčne Larrue Received Received
  SAT-370 Disease penetrance and survival in HFE p.C282Y/p.H63D compound heterozygous and p.H63D homozygous individuals - a population-based cohort study Lorenz Michael Pammer Received Received
  WED-370 Comparative performance of controlled attenuation parameter and ultrasound-derived fat fraction in detecting hepatic steatosis in MASLD patients Andrea Falcomatŕ Received Received
  FRI-370 Hepatoprotective effects of efruxifermin treatment in GAN diet-induced obese and biopsy-confirmed mouse model of MASH Jacob Nhr-Meldgaard Received Received
  THU-370 Direct visualization of fibroblast activation protein inhibitor expression in primary sclerosing cholangitis – a novel biomarker for disease activity and inflammation? Laura Muana Wilhelm Received Received
  FRI-371 Serum lipidome heterogeneity in MASH patients identifies DNA damage as predominant hit in one subtype Idoia Fernandez Puertas Received Received
  WED-371 ALT is an effective screening tool for advanced MASLD in children with obesity and overweight Anne-Sophie Stroes Received Received
  SAT-371 Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder Lucia Giuli Received Received
  SAT-372 Spleen stiffness in porto-sinusoidal vascular disorder: link to portal hypertension and varices Géraldine Dahlqvist Received Received
  FRI-372 MASH-in-a-dish: a multicellular pre-clinical model to identify targetable metabolite crosstalk in MASH Jung-Chin Chang Received Received
  WED-372 Epigenetic biomarkers and methylome-wide association study (MWAS) for non-invasive diagnosis of at-risk MASH from plasma cell-free DNA Manal F. Abdelmalek Received Received
  THU-372 Hypertension combined with hyperlipidemia increased the risk of extrahepatic malignancy in the MASLD population Xinyue Zhao Received Received
  THU-373 Metabolic dysfunction-associated steatotic liver disease (MASLD) in italian women: is liver fibrosis independent from menopause? Agnese Salamone Received Received
  SAT-373 Epidemiology, clinical presentation and management of Wilson´s disease in Portugal – data from a national registry Maria Ins Canha Received Received
  FRI-373 Calciprotein crystallization assay as calcification biomarker in metabolic-dysfunction associated steatotic liver disease population Joyce Xu Received Received
  WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian cross-sectional study Ahmed Cordie Received Received
  FRI-374 Hepatic peroxisome proliferator-activated receptor gamma coactivator-1- alpha impacts the secretion of SerpinA3N in response to obesogenic diets in mice through induction of oxidative stress response in hepatocytes James Eng Received Received
  THU-374 Longitudinal dynamics and predictors of hepatic fibrosis and steatosis in people living with HIV: an egyptian cohort study Ahmed Cordie Received Received
  WED-374 Utilizing AI digital pathology for quantitative measurement, grading and differentiation of lobular and portal inflammation in MASH: preliminary analysis in liver histology Kutbuddin Akbary Received Received
  SAT-374 Health related quality of life in patients with porto-sinusoidal vascular disorder Marina TORRAO GOMES Received Received
  THU-375 Prevalence, clinical features and determinants of MASLD in Klinefelter syndrome: a cross-sectional study Aldo Marrone Received Received
  SAT-375 Frequency of ATP7B gene variants in brazilian patients with Wilson´s disease Maria Chiara Chindamo Received Received
  WED-375 Relevant incidental histologic diagnoses in MASLD patients enrolled in the NASH CRN Daniela Allende Received Received
  SAT-376 Children and adults with severe alpha-1 antitrypsin deficiency present a unique histological liver phenotype (Pi*ZZ genotype) Malin Fromme Received Received
  FRI-376 Training non-experts to diagnose steatohepatitis on biopsy slides Jennifer Cathcart Received Received
  THU-376 A systematic review and meta-analysis - does metabolic dysfunction-associated steatotic liver disease increase the risk of cardiovascular disease above and beyond shared risk factors? Alexander Hung Received Received
  WED-376 Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602K during a phase IIb clinical trial Alejandro E Mayorca-Guiliani Received Received
  TOP-377 The "LITMUS metabolic-dysfunction associated steatotic liver disease intention-to-treat" (LiMITT) score: a machine learning proteomic tool to select patients for therapy Anastasia Resteu Received Received
  TOP-378 Dynamics in lab-based non-invasive tests predict the development of liver-related outcomes in tertiary care Georg Semmler Received Received
  TOP-379 Untargeted lipidomic profiling in pediatric metabolic dysfunction-associated steatohepatitis: insights from youth enrolled in NASH CRN studies Helaina Huneault Received Received
  TOP-380 Baseline liver elastography and its longitudinal changes predict liver-related outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD) Antonio Liguori Received Received
  SAT-381 Rapid liver disease progression after first hepatic decompensation in individuals with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype) Malin Fromme Received Received
  THU-381 Food insecurity is associated with poorer metabolic health in adults with MASLD but is not mediated by overall diet quality or total energy intake Ani Kardashian Received Received
  FRI-381 Oncostatin M contributes to liver steatosis in experimental metabolic dysfunction - associated steatotic liver disease Jessica Nurcis Received Received
  WED-381 Identifying risk factors for "major liver-related outcomes" in patients with metabolic dysfunction-associated steatotic liver disease Anastasia Raptis Received Received
  SAT-382 Can drug metabolites predict outcome of Wilson disease? Moinak Sen Sarma Received Received
  WED-382 Thrombospondin-2, a direct serum marker of fibrogenesis, to assess treatment response in MASLD in a 6-month lifestyle intervention program Angelo Armandi Received Received
  FRI-382 The protective effect of dapagliflozin against kidney injuries by tubular mitochondrial preservation in metabolic dysfunction-associated steatohepatitis Jee-Fu Huang Received Received
  THU-382 Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective Annalisa Cespiati Received Received
  FRI-383 Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH Nicolas Eskesen Received Received
  WED-383 Change in cT1 following interventions in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis Anneli Andersson Received Received
  SAT-383 Non-invasive stratification of portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms Can Hopp Received Received
  SAT-384 Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder without portal hypertension Nicola Pugliese Received Received
  WED-384 Non-invasive identification of MASLD patients eligible for resmetirom treatment – data from a multicenter biopsy-proven MASLD cohort Katharina John Received Received
  THU-385 Association between polycystic ovary syndrome, steatotic liver disease in pregnancy, and adverse pregnancy outcomes: results from the prospective fatty liver in pregnancy cohort Cecilia Katzenstein Received Received
  SAT-385 The prevalence and risk factors of metabolic dysfunction - associated steatotic liver disease in patients with transfusion dependent thalassemia Nikolaos Fragkou Received Received
  WED-385 Prevalence and risk factors of steatotic liver disease in primary care in Slovakia Beata Shiratori Received Received
  SAT-386 The Alpha-1 foundation research registry: liver disease among alpha-1 antitrypsin deficiency patients in a United States cohort Nadine Nuchovich Received Received
  WED-386 Alpha-1 antitrypsin Pi*MZ variant and risk of disease progression in MASLD and MASH Sanna Abbasi Received Received
  FRI-386 HK3, a novel oral anti-obesity MASH drug with direct reduction of liver fibrosis Juergen Eckel Received Received
  THU-386 Both high intensity and moderate intensity exercise interventions improve steatotic liver disease: a prospective randomized trial Chun-Jen Liu Received Received
  WED-387 Improved reader alignment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with the use of a study reading plan Caitlin Langford Received Received
  SAT-387 Trajectories of serum bile acid levels and their determinants in progressive familial intrahepatic cholestasis: insights from the NAPPED consortium Pauline Huisman Received Received
  FRI-387 35 kilodalton specific-sized hyaluronan ameliorates high fat diet-induced liver injury in a murine model of moderate Laura Nagy Received Received
  FRI-388 Quantitative digital pathology and AI to characterize histological phenotypes of regression in a robust mouse model of human MASH Li Chen Received Received
  THU-388 Early-onset cancer risk in young adults with metabolic dysfunction-associated steatotic liver disease Eun Ju Cho Received Received
  WED-388 Artificial intelligence measurement of portal tracts enables quantification of portal, lobular and interface inflammation in metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis and autoimmune hepatiti Caitlin Langford Received Received
  SAT-388 Integrated PK-PD model relating serum copper concentrations, urinary copper clearance and trientine pharmacokinetics in Wilson disease: initial insights from the UNITED study Verena Aliane Received Received
  FRI-389 Histological phenotypes of regression in advanced liver fibrosis using quantitative digital pathology in a rodent model of cirrhotic human NASH with HCC Li Chen Received Received
  SAT-389 Comparison of three methodologies to measure bioavailable copper in patients with Wilson disease Peter Ott Received Received
  THU-389 The severity of MASLD is associated with chronic kidney disease in patients with type 2 diabetes and/or obesity Cyrielle Caussy Received Received
  WED-389 Cost-effectiveness of hepatic fibrosis screening in suspected MASLD cases in primary care settings DAE WON JUN Received Received
  SAT-390 First-line therapy with Zinc salts for Wilson disease patients: descriptive analysis from the spanish AEEH Wilson registry Anna Pocurull Received Received
  SAT-391 Switching from zinc salts to Trientine Tetrahydrochloride in Wilson disease: the ZICUP study Rodolphe Sobesky Received Received
  FRI-391 NEDD4 regulates TGF-beta/SMAD signaling pathway through ubiquinated decorin to ameliorate metabolic dysfunction-associated steatohepatitis Rui Jin Received Received
  WED-391 LiverPRO to diagnose and monitor liver fibrosis in patients with MASLD and obesity Katrine Prier Lindvig Received Received
  THU-391 Impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on serological milestones of chronic hepatitis B patients Hui-Chun Yang Received Received
  WED-392 Diagnostic and clinical implications of high spleen-to-liver stiffness ratio in MASLD – a prospective, comparative study Christian Sebesta Received Received
  THU-392 Changes in liver stiffness and controlled attenuation parameters of transient elastography according to weight change in metabolic dysfunction-associated liver disease Seong Kyun Na Received Received
  SAT-392 Profiling patients with Wilson´s disease using a behavioral diagnostic tool (Observia SPUR™): insights into adherence challenges and personalized care strategies Rodolphe Sobesky Received Received
  TOP-393 Liver stiffness as a predictor of major adverse cardiac events in metabolic dysfunction-associated steatotic liver disease Nirbaanjot Walia Received Received
  TOP-394 Comprehensive analysis of biomarker performance targeting "advanced fibrosis" and "at-risk" metabolic-dysfunction associated steatotic liver disease (MASH) – primary analysis of the LITMUS study cohort Yasaman Vali Received Received
  TOP-395 A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality Carey Escheik Received Received
  TOP-396 Multimorbidity, disease clusters and all-cause mortality in people with metabolic dysfunction association steatotic liver disease in UK Biobank Qi Feng Received Received
  THU-397 Clinically meaningful fatigue is associated with the presence of systemic inflammation, lower erythrocyte count and haemoglobin level, and decreased muscle strength in patients with metabolic dysfunction-associated steatotic liver disease Anna Sheptulina Received Received
  FRI-397 NMR-based metabolic signature reveals the vicious circle between fasting and feeding in homozygous carriers of the PNPLA3 I148M variant in MASLD Lina Jegodzinski Received Received
  SAT-397 Long-term clinical outcomes, efficacy, and safety of transjugular intrahepatic portosystemic shunt in Budd Chiari syndrome Shekhar Swaroop Received Received
  WED-398 Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease Clelia Asero Received Received
  THU-398 Endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease: is there a relationship? Kateryna Pivtorak Received Received
  FRI-399 Impaired hepatocyte autophagy and bile dysregulation as a novel histological and genetic signature in metabolic dysfunction-associated steatotic liver disease patients with early fibrosis Lorenzo Nevi Received Received
  SAT-399 Detection of rare mutations of Wilson´s disease during family screening Veronica Cumpata Received Received
  THU-399 The relationship between insulin resistance, thyroid gland dysfunction and bacterial overgrowth syndrome in the development of vascular complications in patients with metabolic dysfunction-associated steatotic liver disease Kateryna Pivtorak Received Received
  WED-399 Metabolic associated steatotic liver disease- related significant and advanced fibrosis´ prevalence in Brazil and the associated accuracy of FIB-4 and vibration-controlled elastography - a national register Cristiane Villela-Nogueira Received Received
  WED-400 Good diagnostic performance of Hepatoscope™ in diabetology clinics for the screening of MASLD patients with high risk of advanced liver fibrosis Cyrielle Caussy Received Received
  SAT-400 Estimating the diagnosis rate of alpha-1 antitrypsin deficiency: insights from population-based cohorts in the USA Zehrah Nanji Received Received
  THU-400 Characterization and validation of regional variation in fibrosis within traditional fibrosis stages Elaine Chng Received Received
  FRI-400 Impact of ageing on metabolic dysfunction-associated steatotic liver disease in a murine model: insights into progression, biomarkers, and therapeutic stratification Lucia Lameroli Mauriz Received Received
  WED-401 Correlation between transient elastography, clinical scores and liver histology in patients with metabolic dysfunction-associated steatotic liver disease Diederick van Doorn Received Received
  SAT-401 Liver disease progression in patients with alpha-1 antitrypsin deficiency and a Pi*ZZ genotype: a retrospective natural history study Zehrah Nanji Received Received
  THU-401 Liver stiffness and MACE development: an intricate relationship Agnese Salamone Received Received
  FRI-401 Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients Lucrezia Petrucci Received Received
  SAT-402 Combination of pharmacological and surgical interruption of the enterohepatic circulation can treat cholestasis and pruritus in patients with progressive familial intrahepatic cholestasis types 1 and 2 who proved unresponsive to either treatment alone Willem Lexmond Received Received
  FRI-402 The Nlrp3 inflammasome affects Kupffer cell phenotype, proliferation and triglyceride accumulation in the liver Lukas Geisler Received Received
  THU-402 Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in non-cirrhotic MASLD patients Madalina Indre Received Received
  SAT-403 Rare variants in ABCB4 in intrahepatic cholestasis of pregnancy in the national genomic research library Xi Yang Received Received
  FRI-403 Spatial lipidomics applied to human liver across the spectrum of metabolic dysfunction-associated steatotic liver disease using mass spectrometry imaging Monika Selvakumar Received Received
  WED-403 Evaluation of liver fibrosis by FIB4, liver stiffness (Fibroscan, ShearWave), LiverRisk score and EASL 2-step approach in a cohort of 1169 patients (STEATOLIB) followed for MASLD denis OUZAN Received Received
  FRI-404 Leucine regulates mitochondrial function in an in vitro model of MASLD Lizbeth Magnolia Martínez Aguilar Received Received
  WED-404 Fibroblast activity (PRO-C3) and liver stiffness correlate with spatial distribution of collagens in MASLD and ALD: insights from digital pathology Diana Julie Leeming Received Received
  THU-404 Genome-wide association study of noninvasive scores of fibrotic MASLD in an italian population Francesco Malvestiti Received Received
  SAT-404 Accuracy of non-invasive tools in excluding advanced fibrosis in Wilson disease: results from the Wilson disease registry and Barcelona cohorts Zoe Marińo Received Received
  FRI-405 Pharmacological decreases in reductive stress ameliorate lipotoxicity in hepatocytes Mari J. Jokinen Received Received
  WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness Diana Julie Leeming Received Received
  THU-405 Impact of ultra processed foods on metabolic dysfunction-associated steatotic liver disease: limitations of the NOVA classification Franziska Beck Received Received
  SAT-405 Efficacy of lower carbohydrate diets for reducing liver fat and improving metabolic dysfunction: a systematic review and meta-analysis Aslihan Ozdemir Received Received
  WED-406 FICE-4C nomogram can help anticipating liver related complications in non-cirrhotic MASLD patients Paloma Carrillo Received Received
  FRI-406 A quantitative systems pharmacology model identifies mechanisms attenuated by knockdown of HSD17B13 expression and associated with a reduction in hepatocellular ballooning Mario Giorgi Received Received
  THU-406 Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – data from the german SLD-registry Yvonne Serfert Received Received
  FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD Martina Colognesi Received Received
  SAT-407 Assessing early changes and responses to resmetirom therapy using real world single center data Allysa Saggese Received Received
  THU-407 Assessing muscle function in non-cirrhotic patients with steatotic liver disease : a cross-sectional study Guillaume Henin Received Received
  THU-408 The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease Grazia Pennisi Received Received
  FRI-408 MASLD-associated changes across the gut-liver-brain axis are not ameliorated by a low-fat diet intervention in an aged mouse model Matthew Siddle Received Received
  WED-408 Can we use coronary-CT scan for screening of metabolic-associated steatotic liver disease? Letitia Toma Received Received
  SAT-408 Effectiveness of bariatric surgery versus glucagon-like peptide-1 receptor agonists for prevention of adverse cardiovascular outcomes among patients with metabolic dysfunction-associated steatotic liver disease, diabetes, and obesity Saleh Alqahtani Received Received
  TOP-409 Carriage of rare pathogenic APOB variants predispose to severe metabolic-associatetd steatotic liver disease and hepatocellular carcinoma Giulia Periti Received Received
  TOP-410 When is a liver biopsy necessary? Predictive factors of autoimmune hepatitis in patients with metabolic dysfunction-associated steatotic liver disease and positive autoantibodies LEIRE SANCHO SAN MARTÍN Received Received
  TOP-411 Disease state transitions across the spectrum of steatotic liver disease significantly affect long-term incidence of cirrhosis among a national cohort of veterans in the United States Mai Sedki Received Received
  TOP-412 Long-term mortality in steatotic liver disease is greatest in those with a combination of metabolic dysfunction and excessive alcohol consumption Carey Escheik Received Received
  THU-413 Metabolic-dysfunction associated steatotic liver disease in inflammatory bowel disease: prevalence and progression Grazia Pennisi Received Received
  WED-413 Does hyperferritinemia predict ferroptosis in metabolic dysfunction associated steatotic liver disease? A real-world experience Ritu Singh Received Received
  SAT-413 Cardiovascular disease risk, liver outcomes, and statin use among adults with metabolic dysfunction-associated steatotic liver disease Saleh Alqahtani Received Received
  FRI-413 Hepatoprotective effects of fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH Jacob Nhr-Meldgaard Received Received
  WED-414 Non-invasive assessment of fibrotic metabolic dysfunction-associated steatohepatitis by multisensorial electronic technologies Francesca Terracciani Received Received
  SAT-414 Can non-diabetic patients with metabolic dysfunction associated steatotic liver disease benefit from glucagon-like peptide-1 analogs? A multicenter cohort study Ritu Singh Received Received
  FRI-414 Reproducible hepatoprotective effects and clinical translatability of long-term semaglutide treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH Jacob Nhr-Meldgaard Received Received
  THU-414 Rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma: a comparative analysis of clinical features and outcomes Gupse Adali Received Received
  SAT-415 Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence Ritu Singh Received Received
  WED-415 The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with metabolic dysfunction-associated steatotic liver disease Fabrizio Amato Received Received
  FRI-415 The mGluR5 blockade by MPEP inhibits PKC and triggers AMPK activation reducing hepatic steatosis in vitro Michelangelo Trucchi Received Received
  THU-415 Comparison of clinical characteristics and outcome of HCC patients with and without MASLD underwent surgical resection – experience from an asian tertiary center Chia Jung Ho Received Received
  FRI-416 Patatin-like phosphatase domain-containing 3 (PNPLA3) genotype and dietary fat modify the liver adiposity Milla-Maria Tauriainen Received Received
  THU-416 Risk assessment for carotid atherosclerosis in asymptomatic patients with metabolic dysfunction-associated steatotic liver disease Hana Park Received Received
  SAT-416 The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis Lu Li Received Received
  WED-416 Establishing a training protocol for liver stiffness measurement by transient elastography in metabolic dysfunction-associated steatotic liver disease screening Faisal Abaalkhail Received Received
  WED-417 Multiparametric ultrasound-based algorithm SteatoScore 2.0 versus monoparametric controlled attenuation parameter in clinical practice: a comparison study in a monocentric MASLD cohort Giovanni Petralli Received Received
  SAT-417 Sex disparities in response to low-carb, high-fat diet in MASLD Ellen Elise Petersen Received Received
  THU-417 Influence of cardiometabolic risk factors and alcohol consumption on liver stiffness in MASLD patients: a multicenter study in Colombia Ismael de Jesus Yepes Barreto Received Received
  FRI-417 The HSD17B13 rs72613567:A variant is associated with reduced hepatic glycolipid content in non-obese individuals Nils Haep Received Received
  WED-418 One-year changes in ALT and LSM, not in CAP, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease Grazia Pennisi Received Received
  FRI-418 Plasma proteomics identifies pathways to target in metabolic dysfunction-associated steatotic liver disease Niharika Jakhar Received Received
  THU-418 The effect of a fast-food meal on endothelial function in people with metabolic dysfunction-associated steatotic fatty liver desease James OBeirne Received Received
  SAT-418 Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry Yvonne Serfert Received Received
  WED-419 The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to risk stratify for the presence of advanced MASLD fibrosis Hamish Miller Received Received
  SAT-419 A postbiotics and metabiotics reduces the hepatic steatosis indices and aminotransferase activity in MASLD patients: a randomized clinical trial (DELI_MASLD study) Yeva Ilkiv Received Received
  THU-419 Differences in quality of life and coping strategies between patients with metabolic dysfunction-associated steatotic liver disease and liver transplant recipients. A comparison with the general spanish population Jesús Funuyet-Salas Received Received
  FRI-419 Therapeutic potential of targeting processing-bodies in metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma Noémie Gellée Received Received
  WED-420 Prescreening with a novel machine learning model (LiverPRO) may improve trial enrollment efficiency in metabolic dysfunction-associated steatohepatitis (MASH): a retrospective analysis of the SYNERGY-NASH trial Mark Hartman Received Received
  THU-420 10 years progression of metabolic risk factors, diet quality and degree of steatosis and fibrosis in a general population cohort - ECOR liver study Joana Estrabocha Received Received
  SAT-420 Natural explant with dihydromiricetin in metabolic associated steatotic liver disease (?ASLD): a double-blind, placebo controlled, randomized clinical trial George Papatheodoridis Received Received
  FRI-420 Low frequency, mild gradient intermittent hypoxia still induces liver fibrogenesis in mice fed a high-fed diet Shogo Ohkoshi Received Received
  THU-421 10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort Joana Estrabocha Received Received
  SAT-421 The reversal of MASH cirrhosis. Pooled analysis from RCTs Henrik Hee Seung Yang Received Received
  FRI-421 Differential fatty acid metabolism in the liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease Saana Palomurto Received Received
  WED-421 Novel metabolomics-based non-invasive test for pediatric metabolic dysfunction-associated steatohepatitis using data from youth enrolled in NASH CRN studies Miriam Vos Received Received
  THU-422 Hepatic mitochondrial reductive stress predicts major adverse liver-related outcomes and is modifiable by common medications and diet Juho V. Asteljoki Received Received
  FRI-422 Taurine reprograms hepatocyte metabolism and its plasma levels are inversely associated with the progression of MASLD Pavitra Kumar Received Received
  SAT-422 Effect of hepatic impairment on the pharmacokinetics of Miricorilant: results from a phase 1, open-label, adaptive-design study Joseph M. Custodio Received Received
  WED-422 The diagnostic ability for hepatic steatosis by attenuation imaging using MRI-PDFF as reference standard ; a prospective multicenter study in Japan Takashi Nishimura Received Received
  SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3): rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM ) Jörn M. Schattenberg Received Received
  WED-423 Risk factors for hepatic steatosis- a study of deceased liver donors Jaimie Chang Received Received
  THU-423 All-cause and disease-specific mortality in young adults with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study Jeayeon Park Received Received
  SAT-424 Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis Jörn M. Schattenberg Received Received
  WED-424 Fibroscan-based screening to determine the prevalence and severity of steatotic liver disease in type 1 diabetes – an australian quantentary centre experience Raj Ashok Received Received
  THU-424 Patient preferences for metabolic-dysfunction associated steatotic liver disease: moving towards patient centred care Katie Williams Received Received
  FRI-425 Thrombospondin-2 reflects improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy RAMBABU SURABATTULA Received Received
  SAT-425 Evaluating the efficacy of a carnitine orotate and biphenyl dimethyl dicarboxylate complex in the pathogenetic treatment of metabolic-associated fatty liver disease: midterm data Aliya Kaisina Received Received
  WED-425 Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice Javier Ampuero Received Received
  THU-425 Clinical and genetic predictors of steatotic liver disease in lean individuals: a cohort study of risk factors and fibrosis prediction Angela Sato Espinoza Received Received
  TOP-426 Lipidomics crosstalk with hepatic stellate cells and macrophages in people with metabolic dysfunction-associated steatotic liver disease Dan Wang Received Received
  TOP-428 Bispecific small interfering RNA targeting YAP1/WWTR1 as a novel therapeutic agent for metabolic dysfunction-associated steatohepatitis Masayuki Sugimoto Received Received
  WED-429 The utility of noninvasive tests - LIVERFASt, FIB4 and vibration-controlled transient elastography (VCTE, Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients Mona MUNTEANU Received Received
  FRI-429 Generation of patient-derived liver organoids from needle biopsies for precision disease modeling of metabolic-associated steatotic liver disease Raquel Ferrer-Lorente Received Received
  THU-429 Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study Laurens A. van Kleef Received Received
  SAT-430 Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints Kha Le Received Received
  FRI-430 Hepatic estrogen receptor alpha drives liver metabolic adaptation during pregnancy Sara Della Torre Received Received
  WED-430 Best buys to diagnose and treat metabolic dysfunction-associated steatohepatitis among people living with diabetes type 2: a multi-country generalized cost-effectiveness analysis Jeffrey Lazarus Received Received
  THU-430 Weight loss was associated with risk reduction of MASLD, at-risk MASH and fibrosis with ongoing effects beyond the current recommendations Laurens A. van Kleef Received Received
  THU-431 Influence of cardiometabolic risk factors on HCC risk in patients with metabolic dysfunction-associated steatotic liver disease Ho Soo Chun Received Received
  FRI-431 A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and metabolic associated steatohepatitis (MASH) Yuanping Shi Received Received
  SAT-431 Effectiveness of a smartphone app in promoting weight loss in patients with metabolic dysfunction-associated steatotic liver disease: a pilot randomized controlled trial Lung Yi Mak Received Received
  WED-432 Noninvasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease Jimmy Che-To Lai Received Received
  THU-432 Impact of metabolic dysfunction-associated steatotic liver disease on post-surgical outcomes in HBV-related hepatocellular carcinoma Younghyeon Ahn Received Received
  SAT-432 Effects of Berberine Ursodeoxcholate (HTD1801) in chinese patients with T2DM and presumed MASLD Kjersti Swearingen Received Received
  SAT-433 Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support (the "CoCoNut" protocol) significantly improves metabolic and clinical outcomes of MASLD patients Mario Romeo Received Received
  WED-433 Translating genetic information into clinical practice: Improved decision-making in advanced fibrosis assessment Dong Yun Kim Received Received
  THU-433 The impact of cardiopulmonary fitness on metabolic dysfunction-associated steatotic liver disease in a combined lifestyle intervention for adolescents with obesity Maarten Buytaert Received Received
  SAT-434 Efficacy of pharmacotherapy in improvement of liver fibrosis and steatohepatitis in patients with metabolic dysfunction associated steatotic liver disease (MASLD): a network meta-analysis Shubham Mehta Received Received
  THU-434 Liver phenotypes in a multicentric PCOS cohort: prospective analysis including steatotic liver disease-associated genetic variants Marcin Krawczyk Received Received
  WED-434 Use of noninvasive tests (NITs) to diagnose and follow non-alcoholic steatohepatitis (NASH) with liver fibrosis patients treated with resmetirom Jörn M. Schattenberg Received Received
  FRI-434 Investigating the pharmacological potential of a new investigational drug- AD64 for treating metabolic dysfunction-associated steatohepatitis induced by a hepatopathogenic diet in rats Shiran Shetty Received Received
  FRI-435 Increased nuclear localization of small heterodimer partner despite incresed serum BA profile in patients with metabolic dysfunction-associated steatohepatitis Shih-Chieh Chien Received Received
  SAT-435 A comparative analysis of metabolic dysfunction-associated steatotic liver disease and Mediterranean diet across different races Meng-Lun Hsieh Received Received
  THU-435 Obesity-related cognitive problems are not related to liver disease severity and remain unchanged after metabolic restoration Mette Enok Munk Lauridsen Received Received
  THU-436 Histologic severity on liver biopsy is identical between normal weight and overweight adults with metabolic dysfunction associated steatotic liver disease: is it time to revise the definition of lean MASLD? Kaela Miller Received Received
  FRI-436 Inhibition of hepatic bile salt uptake using the anti-HDV drug Bulevirtide attenuates inflammation in mouse models for colitis and diet-induced steatohepatitis Thuc-Anh Nguyen Received Received
  SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study Asahiro Morishita Received Received
  WED-436 Identifying risk factors linked to metabolic-associated steatotic hepatitis in people living with HIV in Newark, New Jersey Paul Bellafiore Received Received
  FRI-437 Liver sinusoidal endothelial cells affect lipid metabolism in hepatocytes and form lipid droplets under steatotic conditions Ting Chen Received Received
  SAT-437 Denifanstat improves multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk Wen-Wei Tsai Received Received
  WED-437 suPAR levels independently discriminate patients with at-risk MASLD Julian Pohl Received Received
  THU-437 Association of alpha-1 antitrypsin Pi*Z allele and disease severity in metabolic dysfunction-associated steatotic liver disease Kaela Miller Received Received
  THU-438 Altered C-fiber function and neuropathic changes in metabolic syndrome and MASLD indicate early peripheral nerve dysfunction Miriam Düll Received Received
  WED-438 Systematic review of care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD) Kirsi van Eekhout Received Received
  FRI-438 Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice Takumi Sugawara Received Received
  SAT-438 General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States Naim Alkhouri Received Received
  WED-439 Comparison of FibroScan© and iLivTouch© for liver stiffness and steatosis assessment in patients with MASLD Kamela Gjini Received Received
  THU-439 Impact of a multidisciplinary clinic for metabolic dysfunction-associated steatotic liver disease on cardiovascular risk and liver health Mirko Zoncapč Received Received
  SAT-439 The impact of metabolic surgery on metabolic dysfunction-associated steatotic liver disease Hiromasa Namba Received Received
  FRI-439 Shallow-deep neural networks reveal extracellular vesicles as robust biomarkers for liver steatosis stages S0 vs. S1-S3 in metabolic dysfunction-associated steatotic liver disease patients Eleni Trifylli Received Received
  WED-440 Effect of liver damage on telomere length in people with diabetic kidney disease Viktoriia Yerokhovych Received Received
  FRI-440 The role of extracellular ATP (ATPe) in the progression of metabolic dysfunction – associated steatotic liver disease (MASLD) Vanessa García-Fernández Received Received
  SAT-440 Effects of Berberine Ursodeoxcholate (HTD1801) in patients with at-risk MASH and T2DM Kjersti Swearingen Received Received
  THU-440 The paradox of low hepatic fat content in steatotic liver disease: insights from an MRI-PDFF study ATSUSHI NAKAMURA Received Received
  TOP-441 CD8+ T cells are pro-inflammatory, cytotoxic, and clonally expanded in the early stages of fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) Raju Kumar Received Received
  TOP-442 Somatic mutation in early stage metabolic-dysfunction associated steatotic liver disease (MASLD) Georgeina L Jarman Received Received
  TOP-443 Paneth cells regulate intestinal lymphangiogenesis and lipid metabolism in metabolic dysfunction-associated steatotic liver disease Sheida Moghadamrad Received Received
  TOP-444 Lifestyle intervention with a mediterranean diet and structured exercise promotes improved liver steatosis, steatohepatitis, and fibrosis, and allows for patient stratification. EHmet+DIA study Carmen Lara Romero Received Received
  SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide: longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fi Mazen Noureddin Received Received
  FRI-445 Deep learning analysis reveals the impact of steatosis size and density on the progression of non-alcohol-related liver disease in severe obesity Vicente Cambra Cortés Received Received
  WED-445 A comparison of the prognostic value of 12 body composition markers for MASLD, at-risk MASH and Increased liver stiffness in a general population setting Laurens A. van Kleef Received Received
  THU-445 Subgroup definition and monitoring of liver fibrosis evolution in patients with MASH bridging fibrosis based on objective measurements of septa parameters using digital pathology with artificial intelligence analyses Elaine Chng Received Received
  SAT-446 Survodutide activates cAMP signaling and reduces steatosis and fibrosis through its glucagon component in human liver spheroids Philip Vonschallen Received Received
  THU-446 Risk stratification of liver-related complications through unsupervised partitioning clustering of alanine aminotransferase (ALT) levels and trajectories in patients with type 2 diabetes (T2D) Nana Peng Received Received
  WED-446 Reliable quantitative multiparametric hepatic steatosis assessment by Steatoscore2.0 using routine liver ultrasound images Laura De Rosa Received Received
  FRI-446 Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus with MASLD as a mediator Won Kim Received Received
  WED-447 The ultrasound multiparametric method Steatoscore2.0 measures liver steatosis with high inter- and intra- operator reproducibility Laura De Rosa Received Received
  THU-447 Impact of metabolic dysfunction-associated steatotic liver disease on fatigue and pruritus in primary sclerosing cholangitis: a U.S. single-center cross-sectional study Natalia Rojas-Amaris Received Received
  FRI-447 Preclinical studies of a novel hydrolysis-based prodrug for treating metabolic dysfunction associated steatohepatitis Xiaowu Chen Received Received
  SAT-448 A 10-week, randomized, double blind, placebo-controlled exploratory proof of concept study of Utreglutide (GL0034) in individuals with overweight and obesity Rajamannar Thennati Received Received
  THU-448 Impact of anthoprometric and body composition on response to lifestyle intervention in patients living with MASLD Paloma Carrillo Received Received
  WED-448 Steatotic liver disease in patients with irritable bowel syndrome- a new category? Evidence based on response to therapy Laura Iliescu Received Received
  WED-449 Exploring the evolution of circulating protein biomarkers in liver transplantation setting for MASH, ALD, and MetALD Laura Martínez-Arenas Received Received
  SAT-449 Saroglitazar vs. vitamin E in metabolic-dysfunction associated fatty liver disease related compensated chronic liver disease- a cohort study Rakhi Maiwall Received Received
  THU-449 Steatosis in cirrhosis: a prognostic marker for liver related outcomes in metabolic-dysfunction associated steatotic liver disease Yiying Pei Received Received
  WED-450 The use of controlled attenuation parameter for the assessment of treatment response in patients with metabolic dysfunction-associated steatotic liver disease undergoing a lifestyle intervention program Lorenza Vaira Received Received
  FRI-450 ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice Xuan Luong Received Received
  SAT-450 ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a H Rohit Loomba Received Received
  THU-450 Cryptogenic cirrhosis in Brazil: much beyond burned-out metabolic associated steatohepatitis Paulo Bittencourt Received Received
  SAT-451 ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD Rohit Loomba Received Received
  FRI-451 Comparative analysis of NAD+ boosters reveals the role of liver-nerve axis in metabolic health Yasmine Liu Received Received
  THU-451 Long-term outcomes of metabolic dysfunction associated steatotic liver disease (MASLD) patients in a prospective, german real-world cohort Monika Rau Received Received
  WED-451 Comparison of the pathophysiology of "metabolic" and "genetic" MASLD: a multiOmics cohort study Mario Masarone Received Received
  THU-452 Intravenous infusions of fatty acids and ethanol induce hepatic mitochondrial reductive stress in humans Riikka Sane Received Received
  FRI-452 Bispecific small interfering RNA targeting YAP1/WWTR1 reduces low-density lipoprotein-cholesterol via proprotein convertase subtilisin/kexin type 9 transcriptional regulation in metabolic dysfunction-associated steatotic liver diseases Yuki Yamada Received Received
  WED-452 Development of novel supervised machine learning models to predict the population at risk of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in a spanish mediterranean population Marta Cedenilla Received Received
  WED-453 Referral algorithm from primary care based on the risk calculation for significant fibrosis Marta Hernández Conde Received Received
  THU-453 Evaluation of liver steatosis and advanced fibrosis assessed by transient elastography in general population: a prospective study from north-eastern Romania Robert Nastasa Received Received
  FRI-453 Proteomics reveals the effect of liraglutide in enhancing fatty acid metabolism and reducing fibrosis in metabolic dysfunction-associated steatotic liver disease Yang Jingyi Received Received
  SAT-453 MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH) Shaheen Tomah Received Received
  FRI-454 BTB and CNC homology 1 aggravates metabolic dysfunction-associated steatohepatitis by activating calreticulin Zhiping Wan Received Received
  THU-454 Coagulation imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes: key role of factor VIII Rosa Lombardi Received Received
  SAT-454 Therapeutic Effects of GLP-1 agonist versus SGLT2-i on patients with T2D and MASLD Ermina Stratina Received Received
  WED-454 Decoding fibrosis: transcriptomic and clinical insights via AI-derived collagen clusters in MASLD Marta Wojciechowska Received Received
  THU-455 Real-world assessment of clinical burden and healthcare resource utilisation among patients with metabolic dysfunction-associated steatohepatitis with additional cardiovascular, renal and metabolic comorbidities in France, Italy, Germany and Canada Riku Ota Received Received
  SAT-455 A single centre, comparative study of Saroglitazar combined with vitamin E versus Saroglitazar alone in managing steatotic liver disease and/or metabolic dysfunction among liver transplant recipients Swapnil Dhampalwar Received Received
  WED-455 Sampling variability of liver fibrosis assessed by digital pathology in pre-cirrhotic patients with MASH Mathieu Petitjean Received Received
  FRI-455 The impact of donor and recipient HSD17B13, PNPLA3 and TM6SF2 genotype on post-transplant fibrosis, steatosis and survival in liver transplant recipients Maria Rosina Troppmair Received Received
  THU-456 The impact of chronic hepatitis B on fibrosis progression in metabolic dysfunction-associated steatotic liver disease &27861;&23071; &33454; Received Received
  WED-456 Intra-abdominal fat thickness measured by ultrasound correlates with CAP (Controlled Attenuation Parameter) measured by FibroScan® in a cohort of patients followed for MASLD/MASH at an urban liver centre: Impact of utilization in clinical practice Magdy Elkhashab Received Received
  SAT-456 Current evidence on dietary interventions in people with metabolic-dysfunction associated fatty liver disease and MetALD – a systematic review and meta-analysis of randomized controlled trials Ute Stern Received Received
  TOP-457 Statin, but not aspirin use, is inversely associated with steatotic liver disease and liver fibrosis: results from two large population based studies Jesse Pustjens Received Received
  TOP-458 qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study Jörn Schattenberg Received Received
  TOP-459 MetALD has a higher rate of extrahepatic cancer and cardiovascular events compared to other subtypes of steatotic liver disease Katrina Pekarska Received Received
  TOP-460 Urinary proteomics identifies complement as potential biomarkers in severe alcohol-associated hepatitis patients Laura Nagy Received Received
  FRI-461 Impact of pre-transplant infection and multi-drug resistant organisms colonization on in-hospital post-transplant survival in subjects with pre-transplant liver failure massimo puoti Received Received
  WED-461 Potential issues with practical implementation of EASL-EASD-EASO clinical practice guidelines on management of metabolic-associated steatotic liver disease in a Swedish healthcare setting Merle Roeren Received Received
  SAT-461 The early impact of bariatric surgery on liver fibrosis and steatosis in MASLD patients Valentina Cossiga Received Received
  THU-461 Genetic risk score correlates with Cytokine expression and risk of HCC and cirrhosis in MASLD patients from Latin America Siyu Fu Received Received
  WED-462 Determinants of liver stiffness improvements and worsening in metabolic dysfunction associated steatotic liver disease: insights from two cohorts Mirko Zoncapč Received Received
  SAT-462 First-in-human single and multiple ascending dose study of AZD2389, a potent inhibitor of fibroblast activation protein, in healthy participants to evaluate safety, tolerability, pharmacokinetics and target engagement Samuel Daniels Received Received
  FRI-462 Benefits of calcineurin inhibitor sparing regimen in a biopsy-guided personalized immunosuppression program after liver transplantation Alisa Kielkowski Received Received
  THU-463 Coexistence of fatty acid desaturase 2 (FADS2) and PNPLA3 risk alleles contributes to fibrosis progression in MASLD Shunsuke Ikejima Received Received
  WED-463 Three-tier testing pathways are required in metabolic dysfunction-associated steatotic liver disease for improved detection of advanced fibrosis Mirko Zoncapč Received Received
  FRI-463 Effect of donor and recipient CYP3A5 genotypes on the pharmacokinetics of tacrolimus after liver transplantation Ana Pascual-Dapena Received Received
  SAT-463 A prospective study on hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital: role of FIB-4 and elastometry. FIBRADDICT study Armand ABERGEL Received Received
  SAT-464 Prospective evaluation of undiagnosed MetALD prevalence in MASLD patients using the ani score Carlos Alventosa-Mateu Received Received
  THU-464 Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting Sabine Kahl Received Received
  WED-464 Gaps in screening and management of metabolic dysfunction-associated steatotic liver disease: a retrospective audit of patients at cardiometabolic risk in a secondary care setting Monica Cucco Received Received
  FRI-464 How immunosuppression influences cancer survival in liver transplant recipients: insights from a tertiary care center Carmen Alonso Martin Received Received
  FRI-465 Sexual health after liver transplantation is significantly impacted and varies by gender Sarah Lieber Received Received
  THU-465 Long term outcomes of liver transplantation for patients with metabolic dysfunction and alcohol associated/related liver disease (MetALD) versus alcohol associated liver disease (ALD) Swapnil Dhampalwar Received Received
  SAT-465 Performance of MELD 3.0 in predicting 90- and 180-day mortality in alcoholic hepatitis Ana Suárez-Saro Fernández Received Received
  WED-465 Association of hepatic steatosis biomarkers with hepatic steatosis prevalence and risk of developing MASLD fibrosis in patients with type 2 diabetes mellitus in eastern Croatia: a pilot study Martina Smolic Received Received
  WED-466 Serum biomolecules improve liver enzyme-based prediction scores of significant liver fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis Nateneal Beyene Received Received
  SAT-466 Plasma exchange as a rescue therapy for patients with severe alcohol-associated hepatitis ANAND KULKARNI Received Received
  THU-466 Development of a machine learning model for predicting cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study from UK Biobank Tae Seop Lim Received Received
  FRI-467 Incidence and risk factors for incisional hernias following liver transplantation: a retrospective single-centre european study Callum Riley Received Received
  THU-467 MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learning Valentin Calvez Received Received
  SAT-467 Fibroblast activation assessed by PRO-C3 and PRO-C6 is associated to accumulation of key bile acids - A hallmark of fibrosis initiation and mortality in alcohol-related liver disease Andressa de Zawadzki Received Received
  WED-467 Low sensitivity of the 2024 EASL screening criteria for identifying MASLD fibrosis in the NHANES cohort Nicolas Goossens Received Received
  SAT-468 Hot & cold fibrosis: fibro-inflammatory biomarkers as prognostic tools in alcohol-related liver disease Andressa de Zawadzki Received Received
  FRI-468 Chronic rejection outcomes in pediatric post liver transplantation-single center experience-King Faisal specialist hospital & research center,Riyadh, Saudi Arabia Dalal Albogami Received Received
  WED-468 Non-invasive markers to predict biopsy response in people with metabolic dysfunction-associated steatohepatitis and fibrosis: exploratory analysis of a phase 2 trial of glucagon receptor/glucagon-like peptide-1 receptor dual agonist, survodutide Mazen Noureddin Received Received
  THU-468 Adverse outcomes and HBsAg seroclearance of chronic hepatitis B complicated with metabolic dysfunction-associated steatotic liver disease: a cohort study Ai-Rong Hu Received Received
  SAT-469 Maintaining a low to moderate alcohol consumption over time in MASLD patients increases the risk of fibrosis progression over moderate drinkers and MetALD patients Ares Villagrasa Received Received
  FRI-469 Sodium and lactate levels during hypothermic oxygenated machine perfusion as predictive biomarkers for early allograft dysfunction in liver transplantation David Pereyra Received Received
  THU-469 Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data Won Kim Received Received
  THU-470 Liver-related events are uncommon in patients meeting AASLD criteria for Resmetirom and are not seen in those with a liver stiffness measurement < 10 kPa Hua Xuan Yeow Received Received
  FRI-470 Retrospective study on simultaneous liver kidney transplantation: renal outcome and prevalence of acute cellular rejection Dorien Pint Received Received
  WED-470 AI improves non-invasive diagnosis and screening of advanced MASLD Paul Calčs Received Received
  WED-471 Noninvasive fibrosis indices are less effective in predicting significant fibrosis in younger adults with metabolic dysfunction-associated steatotic liver disease Ahlim Lee Received Received
  SAT-471 Bacterial infections in patients with severe alcoholic hepatitis: drivers of organ failure and mortality Laura Buttler Received Received
  FRI-472 Factors associated with retransplantation-free survival in patients receiving TIPS after liver transplantation : results of a french multicenter retrospective study Delphine Weil-Verhoeven Received Received
  SAT-472 Misclassification of alcohol use disorder in MASLD and MetALD: prevalence, clinical characteristics, and outcomes DAE WON JUN Received Received
  TOP-473 Histological features predict response to corticosteroids and short-term survival in severe alcohol-associated hepatitis Rudolf Stauber Received Received
  TOP-474 Bio-molecular characterization of albumin identifies predictors of disease severity and early mortality in severe alcohol associated hepatitis SUSHMITA PANDEY Received Received
  FRI-475 The effect of dual hypothermic oxygenated machine perfusion on the incidence of post-transplant diabetes mellitus in recipients of livers donated after circulatory death Efrayim H. Küükerbil Received Received
  SAT-475 Unemployment and social isolation predict relapse in patients with alcohol related cirrhosis Christopher Oldroyd Received Received
  WED-476 Misclassification in non-invasive tests for liver fibrosis is expected: an example predicting liver stiffness in an international cohort Rickard Strandberg Received Received
  SAT-476 Liver death trajectories differ in patients with alcohol consumption and/or metabolic syndrome: a 13-year nationwide study Claire Delacte Received Received
  THU-476 Rising trends in preventable premature MASLD-related deaths: disparities across urban and rural U.S. counties (2011–2021) Carey Escheik Received Received
  FRI-476 Current status of endoscopic treatment for anastomotic biliary stricture after living donor liver transplantation at our institution Eisuke Ozawa Received Received
  WED-477 Validating non-invasive tests for diagnostic prediction of fibrosis in patients with biopsy-proven MASLD: CORE, LiverRisk, and FIB-4 Rickard Strandberg Received Received
  THU-477 Serum bile acid is associated with clinically significant pruritus in patients with metabolic dysfunction-associated steatotic liver disease Carey Escheik Received Received
  SAT-477 Feasibility and effectiveness of a liver health check clinic in community alcohol services Daniel Gutmann Received Received
  FRI-477 Recurrence of primary sclerosing cholangitis after liver transplantation: a single centre experience Emil Bik Received Received
  SAT-478 Routine, pre-emptive anti-craving treatment to prevent alcohol relapse after liver transplantation Pedro de Borba Engster Received Received
  WED-478 Novel multiparametric MRI imaging predicts histologic response in resmetirom versus placebo in the multicentre, international, Maestro NASH phase 3 trial Rohit Loomba Received Received
  FRI-478 Outcome and predictors of major adverse cardiovascular events after liver transplantation: a single center experience Eugenia Vittoria Pesatori Received Received
  THU-478 Metabolic dysfunction-associated steatotic liver disease (MASLD) screening according to EASL guideline is cost-effective Carey Escheik Received Received
  FRI-479 AI-driven prediction of fibrosis progression in liver transplant recipients using a temporal deep learning framework Xiang Xuan Eunice Tan Received Received
  WED-479 Assessment of the metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to denifanstat in the FASCINATE-2 trial Wen-Wei Tsai Received Received
  THU-479 Plasma exosome antigens as prognostic biomarkers in alcohol-associated hepatitis Anna Brujats Received Received
  WED-480 Denifanstat-mediated reduction of plasma glycine- and taurine-conjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in phase 2b FASCINATE-2 study Wen-Wei Tsai Received Received
  FRI-480 Changes in sarcopenia and adipose tissue alterations do not predict post-transplant outcomes in patients with cirrhosis and hepatocellular carcinoma undergoing liver transplantation Francesca DArcangelo Received Received
  FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma Giuliana Amaddeo Received Received
  WED-481 Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: low number-needed-to screen in multiple lines of care Stan Driessen Received Received
  SAT-481 Performance of six biomarkers compared to histological fibrosis stage as surrogate markers of clinical endpoints in drug trials of patients with MetALD and ALD - a dual biopsy study Ellen Lyngbeck Jensen Received Received
  THU-481 Gut microbiota derived immunological signature in metabolic alcohol associated liver disease Jung A Eom Received Received
  FRI-482 Coronary atherosclerosis progression in patients with cirrhosis: effect of liver transplantation and association with early post-LT kidney dysfunction Giulia Pagano Received Received
  THU-482 Outcomes in a real-world patient group started on Acamprosate for alcohol use disorder (AUD) with co-existent advanced fibrosis: adherence, efficacy and clinical impact over 24 months Helen White Received Received
  WED-482 Leveraging natural language processing (CogStack) to analyse FibroScan data: a seven-year exploration (2016–2023) of socioeconomic disparities, ethnic variations, and fibrosis trends Saima Ajaz Received Received
  SAT-482 Prospective study of phosphatidylethanol as a quantitative, objective biomarker to detect under-reported alcohol use in steatotic liver disease Federica Tavaglione Received Received
  SAT-483 Younger, sicker, higher mortality; the burden of alcohol related liver disease in Ireland Clare Foley Received Received
  FRI-483 Adherence to the mediterranean diet and physical activity levels among liver transplant recipients in Greece: relationship to the metabolic syndrome Kleoniki Chatzistavridou Received Received
  WED-483 Development of a deep learning-based model for predicting liver-related events in steatotic liver disease using specific health checkup data Shunichi Wakabayashi Received Received
  SAT-484 Impact of alcohol binge duration and metabolic features on liver stiffness in steatotic liver disease Frances Lee Received Received
  THU-484 Digital pathology biomarkers describe fibrosis severity and disease activity in the FAT-MASH murine model and response to preventative treatment with mannose Mathieu Petitjean Received Received
  WED-484 The culprits behind methotrexate-proposed hepatotoxicity are modifiable risk factors Sinan Sharba Received Received
  FRI-484 Machine learning in predicting 3-month mortality for liver transplant candidates with HCC: a paradigm shift Ilias Kounis Received Received
  FRI-485 Development of an explainable machine learning model for predicting waitlist mortality in liver transplant candidates Ilias Kounis Received Received
  SAT-485 Comorbidities at diagnosis of alcohol-related liver cirrhosis compared to the general population: a population-based case-control study of 11,989 patients Gustav Jakobsson Received Received
  THU-485 Prevalence, genetic risks, and cardiovascular outcomes of Met-ALD in a longitudinal multiethnic U.S. cohort Jie Yao Received Received
  WED-485 US markers and necroinflammation, steatosis, and fibrosis in metabolic dysfunction-associated steatotic liver disease: the iLEAD study Katsutoshi Sugimoto Received Received
  SAT-486 Fecal microbiota transplantation is associated with improvement in survival compared to standard of care in severe alcoholic hepatitis: systematic review and meta-analysis Jakub Hoferica Received Received
  FRI-486 NT-proBNP predicts the development of acute-on-chronic liver failure and mortality in patients with cirrhosis listed for liver transplantation Juan Manuel Diaz Received Received
  THU-486 The anticoagulant Edoxaban improves portal hypertension and liver injury in progressive liver disease Katharina Bonitz Received Received
  WED-486 First construction and validation of new circulating markers (NITs) to assess the risk of early-fibrosis (eF) occurrence in outpatients with type-2 diabetes (T2D) and elevated transaminases Peta Valentina Received Received
  FRI-487 Treatment of grafts not meeting criteria for transplantation with nor-ursodeoxycholic acid during normothermic machine perfusion reduces apoptosis and biliary injury markers Jule Dingfelder Received Received
  WED-487 The blood-based SteatoTest-2 score identifies a previously invisible early steatosis phenotype Peta Valentina Received Received
  SAT-487 Disease severity is more important than age and underlying cirrhosis at predicting mortality from alcohol related hepatitis Huw Purssell Received Received
  THU-487 Liver-targeted mRNA therapeutics through fibroblast growth factor 21 and apolipoprotein A1 delivery in experimental acute pancreatitis Maite G Fernandez-Barrena Received Received
  THU-488 A new translational dietary rat model allows studying MetALD natural history and assesing the efficacy of various therapeutic interventions María Martínez-Gómez Received Received
  WED-488 Weight loss-related changes in MRI-derived measures of body composition and liver health: a large-scale analysis from the UK biobank Magdalena Nowak Received Received
  SAT-488 Alcohol as a mediator of genetic and metabolic risk for fibrosis and steatosis in SLD Jan Embacher Received Received
  FRI-488 Concomitant sarcopenia and myosteatosis in patients with cirrhosis is associated with longer recovery and mortality after liver transplantation Ellina Lytvyak Received Received
  SAT-489 Monitoring hepatic function at 90 days of abstinence predicts recompensation and reduced liver-related mortality in patients with decompensated alcohol-related cirrhosis Jan Embacher Received Received
  WED-489 Similar prevalence of MASLD and liver fibrosis when screening high-risk patients identified in primary care versus outpatient clinics in secondary care Vivian de Jong Received Received
  THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease Laura Nagy Received Received
  FRI-489 Coronary angiography in the preoperative work-up for liver transplantation (LT): a multicenter italian cohort study Margherita Saracco Received Received
  FRI-490 Reintegration into working life for liver transplant recipients: cross-disciplinary evaluation of risk factors for unemployment Margherita Saracco Received Received
  WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunction-associated steatotic liver disease and metabolic parameters Valentina Flagiello Received Received
  SAT-490 ALD is diagnosed at more advanced stages of fibrosis as compared to MetALD and MASLD in the general population Jordi Gratacós Ginčs Received Received
  THU-490 Cytokine release assay QuantiFERON Monitor predicts 90-day mortality in patients with severe alcohol-related hepatitis Paula Boeira Received Received
  SAT-491 ELIBIO MRI-based Digital liver biopsy correlates with elastography and blood test in patients with chronic liver diseases (CLD) Renaud Winzenrieth Received Received
  THU-491 Metabolomic and transcriptomic insights into gender-specific PFAS effects on liver disease Shashank Gupta Received Received
  FRI-491 Outcomes of ABO-incompatible deceased donor liver transplantation in adults with acute liver failure: a study from a Costa Rican hospital Maria Lynch-Mejia Received Received
  WED-491 Longitudinal validation of the AGA, AASLD and EASL care pathways for metabolic dysfunction-associated steatotic liver disease (masld) in a prospective cohort of individuals with type 2 diabetes Veeral Ajmera Received Received
  WED-492 Liver fibrosis is a strong predictor of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease independent from metabolic syndrome weiwei xu Received Received
  THU-492 Altered high density lipoprotein 3 and associated proteins signatures contribute to immune dysfunction in alcohol associated liver cirrhosis Shivani Gautam Received Received
  FRI-492 Torque Teno virus as a biomarker of immune status and attenuated immune response to vaccination in liver transplant recipients Ezequiel Mauro Received Received
  SAT-492 Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD) Takefumi Kimura Received Received
  FRI-493 Conversion from standard-release to prolonged-release tacrolimus mitigates calcineurin-induced nephrotoxicity in patients after liver transplantation Maximilian Joseph Brol Received Received
  THU-493 Single-cell RNA sequencing and lipidomics identify synergistic effects of alcohol and PNPLA3 I148M on hepatic pathology Stephen Hoang Received Received
  SAT-493 A call to action - shortfalls and variation in care for inpatients with alcohol related liver disease in the UK: results of the ALERT UK national audit Laura Burke Received Received
  WED-493 Evaluating noninvasive tests for significant fibrosis in a population-based MASLD cohort: insights from NHANES 2017–2020 Winston Dunn Received Received
  SAT-494 Validating the association between alcohol-related hepatitis and alcohol-related cirrhosis: a population-based study Lucy Wilson Received Received
  WED-494 Development and validation of two NIS2+®-based models for the detection of MASH resolution and fibrosis improvement Yacine Hajji Received Received
  FRI-494 Graft rejection and biliary complications affect liver stiffness measurements in the first year after liver transplantation Michele Sagasta Received Received
  SAT-495 Stratification of liver fibrosis in individuals at-risk of metabolic dysfunction and alcohol-associated liver disease (MetALD) Luis Antonio Diaz Received Received
  THU-495 The role of aryl hydrocarbon receptor across different cellular targets in pectin´s improvement of alcohol-associated liver disease Wanchao Hu Received Received
  FRI-495 Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation Maike Rebecca Pollmanns Received Received
  WED-495 Liver stiffness measurement as a tool for identifying risk of hepatic-related hospitalizations: insights from a large real-world cohort YAEL MILGROM Received Received
  FRI-496 Impact of donor-recipient age disparity on survival and recurrence in liver transplantation for hepatocellular carcinoma NADA ELDOMIATY Received Received
  SAT-496 Steatosis independent of fibrosis predict hepatic decompensation and mortality in patients with MetALD and ALD Mette Andersen Received Received
  THU-496 Allied health professionals are essential for facilitating initial evaluation and optimisation of patients for liver transplantation Abigail Greenwell Received Received
  WED-497 Steatotic liver disease as a mortality risk enhancer in the presence of metabolic syndrome weiwei xu Received Received
  SAT-497 Predictors of alcohol relapse in patients with alcohol-associated liver disease after liver transplant evaluation Prasun Jalal Received Received
  THU-497 The challenge of adherence in Wilson disease: a prospective study Zoe Marińo Received Received
  FRI-498 Prognostic impact of multi-resistant bacteria gut colonization in patients undergoing liver transplantation Marina Orti-Cuerva Received Received
  THU-498 Demonstration of the success of a nurse led service surveying for hepatocellular carcinoma and other cirrhosis associated complications Amy Thatcher Received Received
  WED-498 Hepatic collagen percent by morphometry correlates with non-invasive tests in metabolic dysfunction associated steatotic liver disease Carey Escheik Received Received
  SAT-498 Cause-specific mortality across the spectrum of steatotic liver disease: a nationwide cohort study Pedro Ochoa-Allemant Received Received
  FRI-499 Hepatic artery atherosclerosis is a risk factor for biliary strictures after liver transplantation Paloma Elma Alańon Martinez Received Received
  THU-499 Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial Annika Olsson Received Received
  SAT-499 Will individuals with alcohol use disorder participate in screening for chronic liver disease? Pernille Dahlin Received Received
  WED-499 Validation of small transient elastography device for liver fibrosis and steatosis detection in a population-based study Anna Soria Received Received
  WED-500 Evaluation of novel point-of-care ultrasound for hepatitis "PUSH" for healthcare workers managing hepatitis B infection in Zambia Costanza Bertoni Received Received
  FRI-500 Association between pre-transplant body mass index and survival after liver transplantation in an adult recipient cohort from Johannesburg, South Africa Preyanka Pillay Received Received
  THU-500 Community liver health checks are a valuable tool to support early diagnosis of liver disease Bethia Featherstone Received Received
  WED-501 Prognostication of liver disease patients via ARFI-based liver stiffness measurement using the WFUMB "Rule-of-4" algorithm Christian Sebesta Received Received
  FRI-501 Extensive portal vein thrombosis in patients with cirrhosis undergoing liver transplantation : results of a national multicenter retrospective study Romain BARUSSEAU Received Received
  SAT-501 Steatosis predicts poor abstinence rates in patients with alcohol use disorder Queralt Herms Rubió Received Received
  THU-501 Malnutrition, sarcopenia and inadequate dietary intake before liver transplant: a time for action Brooke Chapman Received Received
  THU-502 Non-weight-based ribavirin dosing for hepatitis E in immunosuppressed patients: a single-centre experience Fatema Jessa Received Received
  FRI-502 An audit to assess adherence to local guidelines for prophylaxis and monitoring of herpes simplex virus (HSV) in patients following orthotopic liver transplant in a tertiary transplant centre Rachel McGaw Received Received
  SAT-502 Prevalence and predictors of early re-hospitalization or death among a national cohort of veterans hospitalized for alcohol-associated hepatitis in the United States Robert Wong Received Received
  WED-503 Clinical decision tree for non-invasive diagnosis of graft steatosis in liver transplant patients Dominik Lüttgen Received Received
  SAT-503 Cardiac performance is impaired in patients with proven alcohol related hepatitis and and predicts 3-month mortality in this patient population Valainathan Shantha Received Received
  THU-503 Internal consistency and diagnostic validity of SARC-F questionnaire in chronic liver disease patients with sarcopenia on liver transplant wait list GANESH SANKARRAJAN Received Received
  WED-504 Multi-omic machine learning for risk prediction of cholangiocarcinoma in population-based cohorts Felix Van Haag Received Received
  FRI-504 Nephrocheck as a predicitve tool for post-operative acute kidney injury following liver transplant for chronic liver disease Rosemary Worrall Received Received
  THU-504 Negative consequences of screening for steatotic liver disease Helle Lindholm Schnefeld Received Received
  SAT-504 Rising proportion of young adults and women on the U.S. liver transplant waitlist for end-stage liver disease attributed to rising alcohol-associated liver disease following the COVID-19 pandemic Shyam Patel Received Received
  TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States Xiaolong Qi Received Received
  TOP-506 Outcomes for patients listed for liver transplantation with low MELD-Na scores: high frequency of MELD-Na score increases, liver transplantation, death and removal from waitlist Alan Hutchison Received Received
  TOP-507 Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent Greg Everson Received Received
  TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus Milan Sonneveld Received Received
  THU-509 Improving clinical efficiency of Hepatology clinics by optimising patient adherence with blood test monitoring Jennifer Finn Received Received
  WED-509 Decoding the dynamics: minimal detectable difference in non-invasive tests may exceed proposed thresholds for meaningful changes Georg Semmler Received Received
  FRI-509 Assessing the safety and efficacy of advanced therapies to treat inflammatory bowel disease in patients with a liver transplant Samantha Campbell Received Received
  SAT-509 Affinity-tuning chimeric antigen receptors could improve the therapeutic efficacy of regulatory t cells in liver transplantation Ada Kurt Received Received
  THU-510 Impact of hepatitis delta infection on quality of life: results from the Nora-hepatitis B study Judit Romero-Vico Received Received
  FRI-510 Acute pancreatitis in emergency liver transplantation for acute liver failure: prevalence, predictors and consequences Samuel Tribich Received Received
  WED-510 Repeated transient elastography measurements for the assessment of liver fibrosis Helena Katchman Received Received
  SAT-510 Reconstruction of native biliary networks in decellularized rat liver scaffolds with human intrahepatic cholangiocyte organoids Javier Martínez-García Received Received
  THU-511 Evaluation of the utility of the Nora-hepatitis B mobile application: a comparative study between chronic infection and HBeAg-negative chronic hepatitis Judit Romero-Vico Received Received
  SAT-511 Extracellular nicotinamide adenine dinucleotide as an independent prognostic marker for long-term survival after liver transplantation Can Kamali Received Received
  FRI-511 QEL-001 LIBERATE study expansion cohort, CAR (Chimeric Antigen Receptor) T regulatory (Treg) cells engraftment and expansion following rATG (rabbit anti-thymocyte globulin) conditioning in post liver transplantation Alberto Sanchez-Fueyo Received Received
  WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance Jan Embacher Received Received
  WED-512 Validation of Baveno VII criteria for non-invasive diagnosis of clinically significant portal hypertension: systematic review and individual patient data meta-analysis Juan Bańares Received Received
  THU-512 Long-term real-world outcomes of obeticholic acid treatment for primary biliary cholangitis: insights from a pharmacy-led single-centre study Kate Greener Received Received
  SAT-512 HepatoPredict has a good prognostic value in patients with hepatocellular carcinoma independently of biopsied nodule Joana Cardoso Received Received
  FRI-512 TAVI in liver transplant candidates: a retrospective analysis from a high-volume transplant center Marta Sánchez-Ric Received Received
  WED-513 Role of liver and spleen stiffness in predicting hepatic decompensation following transarterial chemoembolization in patients with hepatocellular carcinoma Kessarin Thanapirom Received Received
  THU-513 Should all patients referred for liver transplantation undergo a review in a dedicated multidisciplinary assessment clinic prior to formal liver transplant work up? Katie McCollum Received Received
  SAT-514 High-risk PNPLA3 rs738409 genotype is associated with higher CCL2 concentrations in liver transplant candidates with alcohol - related liver disease Tomislav Kelava Received Received
  THU-514 Patient-perceived quality of care – effectiveness of the quality liver nursing care model Maria Hjorth Received Received
  FRI-514 Dynamic changes of spleen stiffness in liver transplanted patients:preliminary findings from a single-center study SOFIA RIDOLFO Received Received
  WED-514 Prediction of esophageal varices in fontan associated liver disease (FALD) Victoria Kusztos Received Received
  SAT-515 "The feasibility of cell-free DNA for monitoring liver graft rejection: a pilot study perspective" Joanna Raszeja-Wyszomirska Received Received
  THU-515 Impact of consensus guidelines on hepatitis B reactivation risk assessment and management in immunosuppressive therapy Naz Kanani Alviri Received Received
  WED-515 Phase angle by BIA is useful for screening for malnutrition in patients with cirrhosis Masafumi Haraguchi Received Received
  FRI-515 Evolving trends and the role of mitigating performance status decline on the liver transplant waitlist Tomohiro Tanaka Received Received
  SAT-516 3D engineered endothelial cell implants protect liver explant viability ex vivo and reduce liver inflammation Mireia Medrano-Bosch Received Received
  WED-516 Bile acids drive fibroblast activation, fibrogenesis, interstitial matrix fibrosis and outcomes in PSC Andressa de Zawadzki Received Received
  THU-516 Nurse-led clinic for patients with decompensated liver cirrhosis Palle Bager Received Received
  SAT-517 Three-dimensional cell cultures for biliary disease therapies Mattia Pasqua Received Received
  WED-517 Weight dependent, weight independent and non-pharmacological effects on fibroblast activity in metabolic dysfunction associated steatotic liver disease (MASLD) Morten Karsdal Received Received
  THU-517 iCARE: Insights on competency advancement and recommendations for nurses managing HBV/HDV with bulevirtide – findings from a european advisory board Patrizia Künzler-Heule Received Received
  WED-518 Comparing ultrasound and magnetic resonance imaging for hepatocellular carcinoma screening in high-risk populations: a systematic review and meta-analysis of prospective cohorts Pedro Passos Received Received
  FRI-518 Depression is highly prevalent amongst patients listed for liver transplant and unrelated to liver disease severity Victoria Kronsten Received Received
  THU-518 Multi-displinary team initiation of GLP-1/GIP agonist Tirzepatide in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): single-centre UK study Rachel Halley Received Received
  SAT-518 The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course Maike Rebecca Pollmanns Received Received
  SAT-519 Kallikrein-Kinin system activation in hepatic ischemia/Reperfusion injury: a key driver of Edema and thrombosis Rajni Yadav Received Received
  FRI-519 The post-operative recurrence rate is significantly higher in patients with HBV-HCC compared to those with HCV-HCC Tsung-Han Wu Received Received
  THU-519 Prescribing for pain and symptom management in hospital patients with advanced liver disease: a single centre, retrospective clinical audit Sarah Phillips Received Received
  THU-520 Improving the outcomes of patients with cirrhosis in a community clinic through the utilization of advanced practice providers and standardized tailored management protocol Tarek Hassanein Received Received
  WED-520 Prognostic utility of serum ammonia in cirrhosis: a systematic review and meta-analysis Yevedzo Ntuli Received Received
  FRI-520 Rising global burden of liver transplants attributable to metabolic-associated steatotic hepatitis: trends from 68 countries (2009–2023) Carey Escheik Received Received
  SAT-520 Effective in vivo transplantation of revascularized porcine liver scaffolds in pigs for extended function over one month Sandra Meliton Barbancho Received Received
  TOP-522 Health-related quality of life, events of decompensation and mortality – effectiveness of the quality liver nursing care model Maria Hjorth Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
16:44
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

EASL Congress 2025

 

7-10 May Amsterdam
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 07/05/2025 TO 10/05/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.EASL2025.2025 




PosterSessionOnline
Logo Draft
 
Logo Cert